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Abstract 
 
THE ROLE OF TUMOR SUPPRESSOR GENES P53 AND NF1 IN NEURAL 
STEM CELLS AND BRAIN TUMOR DEVELOPMENT 
By 
 
Yuan Wang 
 
 
 
Chair: Yuan Zhu 
 
Glioblastoma multiforme (GBM) is the most frequent and infiltrative neoplasm among 
human primary brain tumors. Highly resistant to conventional radiation and 
chemotherapy, GBM is one of the most deadly human cancers with a median survival of 
12 months that has remained unimproved over the past two decades. Recent studies have 
identified that tumor suppressor genes TP53 and Neurofibromatosis Type 1 (NF1) are 
two of the most frequently mutated genes in human GBM. However, how deficiency in 
these tumor suppressor genes transforms normal brain cells into malignancy is not yet 
understood. Further, the cell of origin for glioma remains largely unknown. 
 
This thesis work utilizes transgenic mouse models to understand the role of p53 and Nf1 
in normal neural stem/progenitor cell function and how inactivation of these genes 
transforms neural stem/progenitor cells and leads to neurological diseases. In the p53 
model, p53 deficiency is sufficient for glioma formation by allowing the accumulation of 
cooperative oncogenic alterations. In addition, the accumulation of mutant p53 protein 
can be used to trace the early lesions in the brain, which occur first in neural stem cells in 
 xi 
 
the subventricular zone (SVZ) stem cell niche. Subsequent expansion of mutant p53-
expressing transit-amplifying progenitor-like cells in the SVZ-associated areas initiates 
glioma formation. This study establishes a critical role of p53 deficiency in 
gliomagenesis, and provides insight into the cell-of-origin for glioma. In the Nf1 mouse 
model, Nf1 deficiency alone is insufficient for glioma formation and only appears to 
confer a transient growth advantage to neural progenitor cells during development, which 
does not persist into adulthood. The critical role of Nf1 is to regulate neuron/glia fate 
determination of neural progenitor cells. Bi-allelic Nf1 inactivation causes ectopic Olig2 
expression specifically in transit-amplifying progenitors, causing increased gliogenesis at 
the expense of neurogenesis. In addition, Nf1-deficient brains exhibit enlarged corpus 
callosum, a structural defect recently linked to NF1-associated learning disabilities. These 
NF1-associated developmental defects can be reversed by treatment with a MEK 
inhibitor during neonatal stages. Together, this study not only provides insights into fate-
determination of SVZ progenitor cells, but also identifies a potential therapeutic window 
for treating NF1-associated brain abnormalities. 
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Chapter I Introduction 
 
Glioblastoma (grade IV malignant astrocytic glioma), also known as glioblastoma 
multiforme (GBM), is the most frequent and malignant neoplasm among human primary 
brain tumors. GBM is highly infiltrative to surrounding normal brain tissues, a trait that 
prevents complete surgical resection. Furthermore, GBM is invariably resistant to 
conventional radiation and chemotherapy. As a consequence, GBM is one of the most 
deadly human cancers with a median survival of 12 months that has remained 
unimproved over the past two decades (Zhu and Parada 2002; Furnari et al. 2007; Louis 
2007). It is therefore important to develop novel therapies based on a greater 
understanding of the cellular and molecular mechanisms underlying gliomagenesis. As 
reflected by its name (multiforme), GBM contains diverse cell populations with extreme 
morphological, genomic and transcriptional heterogeneity (Jung et al. 1999; Maher et al. 
2001; Furnari et al. 2007; The Cancer Genome Atlas Research Network, 2008). This 
unique feature of GBM raises one of the most difficult questions regarding GBM 
pathogenesis: how a normal brain cell acquires genetic mutations that lead to generation 
of a cancer with such diverse cell populations exhibiting the characteristics of stem cells, 
progenitor cells and differentiated cells. The most straightforward hypothesis for this 
question is that the cell-of-origin of GBM is a multipotent neural stem cell, as stem cells 
do not need to acquire the capacities of self-renewal (replicating themselves) and 
multipotency (generating multilineage cells). However, it is worth noting that it is also 
possible for progenitor cells or fully differentiated brain cells to gain stem cell 
characteristics as a result of acquired mutations. One of the important recent advances in 
cancer research is the development of the cancer stem cell hypothesis, which is based on 
the observations that a subset of tumor cells exhibit stem cell characteristics, self-renewal 
and mulitpotency, and more importantly, possess higher tumorgenic capacities (Bonnet 
and Dick 1997; Reya et al. 2001; Wicha et al. 2006; Stiles and Rowitch 2008). The major 
objective of my thesis is to understand the mechanisms by which normal brain cells 
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acquires genetic mutations and become GBM cells with stem cell characteristics. A few 
years ago, my thesis adviser, Dr. Yuan Zhu, developed a series of genetically engineered 
mouse (GEM) models with mutations in p53 and Neurofibromatosis type 1 (Nf1) tumor 
suppressor genes. These p53/Nf1 GEM models developed malignant astrocytic gliomas 
with nearly complete penetrance (Zhu et al. 2005b). More importantly, malignant 
astrocytic gliomas in the p53/Nf1 GEM models appear to arise from and cluster around 
the subventricular zone (SVZ) stem cell niche, where multipotent neural stem cells and 
other neural progenitor cells reside (Zhu et al. 2005b). Based on these observations, we 
propose the hypothesis that p53 and Nf1 tumor suppressor genes cooperatively transform 
cells in the SVZ stem cell lineages in adult brain. In other words, this hypothesis suggests 
that SVZ cells are a cell-of-origin of malignant astrocytic gliomas driven by p53 and Nf1 
mutations. To test this hypothesis, my thesis has focused on determining the role of p53 
and Nf1 in the regulation of SVZ stem cell function in the developing and adult brain. In 
this Chapter, I will provide important background information regarding glioma biology, 
cancer stem cell hypothesis and cell-of-origin of glioma, GBM core pathways, p53 and 
NF1 tumor suppressor genes, as well as neural stem cell biology.  
 
1.1 Glioma and its classification  
 
In vertebrates, the embryonic neural tube gives rise to three major cell types in the central 
nervous system (CNS): neurons, astrocytes and oligodendrocytes. The latter two are 
collectively called glial cells. Tumors that arise in the CNS are classified mainly based on 
the predominant cell types, determined by morphological and histological criteria. 
Tumors that exhibit glial cell features are therefore termed glioma which account for the 
majority of adult neurological tumors (Zhu and Parada 2002; Furnari et al. 2007; Louis 
2007). Gliomas can be further subclassified into astrocytoma, oligodendroglioma and 
oligoastrocytoma (also known as mixed gliomas), which are based on the proportion of 
tumor cells resembling astrocytes, oligodendrocytes or both, respectively (Maher et al. 
2001; Zhu and Parada 2002; Furnari et al. 2007; Louis 2007). 
 
The World Health Organization classifies gliomas into grade I-V based on the 
malignancy and histopathological criteria (Zhu and Parada 2002; Furnari et al. 2007; 
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Louis 2007). Grade I gliomas are generally benign, whereas Grade II-V are malignant 
and infiltrative. Among all types of gliomas, astrocytomas are the most common CNS 
neoplasms, which account for more than 60% of all primary brain tumors. Grade IV 
malignant astrocytic glioma (glioblastoma), also known as glioblastoma multiforme 
(GBM), is the most frequent and infiltrative neoplasm among human primary brain 
tumors. There are two subtypes of glioblastoma. Primary glioblastoma arises de novo 
with no evidence of pre-existing lesions whereas secondary glioblastoma develops 
progressively from lower-grade gliomas. Despite their differences in the clinical courses 
and molecular lesions, primary and secondary GBMs exhibit the same histopathological 
and clinical features. The median survival for glioblastoma patients is less than one year, 
which has not improved over the past two decades (Maher et al. 2001; Zhu and Parada 
2002; Furnari et al. 2007; Louis 2007). This presents a major challenge to clinical 
oncologists and cancer researchers and calls for a greater understanding of the cellular 
and molecular basis for gliomagenesis. 
 
1.2 Strategies for glioma mouse modeling  
 
Much of our current understanding of glioma comes from the study of glioma mouse 
modeling. There are four major strategies to induce glioma formation in mice: chemical 
mutagen-induced models, xenograft or allograft transplantation models, tissue specific 
genetic models and retroviral infection models. Each of these strategies has its strength 
and limitations. Treatment with mutagens such as DNA alkylating agents could randomly 
generate point mutations and induce glioma in mice histologically similar to human 
glioma (Barth 1998), however, it is hard to define which genetic alteration or which cell 
type is responsible for glioma development. Xenograft or allograft transplantation models 
have been widely used in preclinical trials for glioma treatment (Plate et al. 1993; Kondo 
et al. 1998). In these models, cultured human or rodent glioma cell lines are injected into 
the brain of nude mice. These cells give rise to glioma in mice at a predictable rate with 
high tumor penetrance. However, the treatment response in mice could not be directly 
applied in humans since tumor microenvironment could be drastically different in mice 
compared to humans. Also these transplantation models do not recapitulate the 
tumorigenesis process and provide little information about the de novo development of 
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glioma. Both mutagen induced models and transplantation models are modeling glioma 
formation with undefined genetic alterations. With the advancement in our understanding 
of the molecular genetics of glioma, it is applicable to model glioma through 
recapitulation of the genetic events during gliomagenesis by germline or tissue specific 
genetic modifications (Reilly et al. 2000; Zhu et al. 2005a; Alcantara Llaguno et al. 
2009). Gain-of-function or loss-of-function germline modifications can be achieved by 
transgenic or gene targeting techniques. Gain of function mutations could be mimicked 
by overexpression of oncogenes, and loss of function mutations could be achieved by 
targeted deletion of tumor suppressors. This strategy tests the transformation competence 
of the activation of certain signaling pathways and allows the assessment of cooperative 
effects between different oncogenes and tumor suppressor genes. However, germline 
mutations could potentially lead to developmental defects and embryonic lethality. Tissue 
specific glioma models circumvent this caveat by targeting restricted population of cells 
with the Cre/LoxP system (Sauer 1998). This strategy could also provide significant 
insight into which cell type(s) is most susceptible for malignant transformation. The 
limitation of germline/tissue specific glioma models lies in the fact that it only mimics 
one possible genetic setting for gliomagenesis and may only represent a subset of gliomas 
driven by specific genetic mutations. The last strategy for glioma modeling is regional 
specific genetic modification using retroviral vectors (Holland et al. 2000; Alcantara 
Llaguno et al. 2009; Jacques et al. 2010). This strategy introduces genetic modifications 
through retroviral infection and targets the cells within a specific region of the brain (e.g. 
SVZ). This technique can be used to assess the relative tumorigenic capacity of cells 
from different regions of the brain. 
 
1.3 Cancer stem cell hypothesis and cell-of-origin for brain tumor 
 
The extreme heterogeneity within the tumor, along with the highly proliferative nature of 
cancer cells leads to a straightforward hypothesis that cancer might arise from a rare 
population of cells with stem cell properties: self-renewal and multipotency. This concept 
was first proposed about 150 years ago (Cohnheim 1867; Durante 1874; Cohnheim 1875; 
Wicha et al. 2006). Over 40 years ago, it was further specified that tissue-specific stem 
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cells may be the cell-of-origin of cancer (Till and Mc 1961; Wicha et al. 2006). In vitro 
“clonogenic assays” supported this notion by showing that a subpopulation of tumor cells 
isolated from tumor specimens has higher proliferative capacity in colony formation 
assays (Reya et al. 2001). However, this hypothesis has not been directly tested until 
recently due to the technical difficulties to directly measure and compare the self-renewal 
capacity of different sub-population of cancer cells.  
 
Recent advances in stem cell biology and the development of new animal models allows 
the direct test of the validity of this hypothesis. Various studies have revealed that within 
tumors there are a subset of tumor cells which exhibit stem cell characteristics: self-
renewal and mulitpotency (Bonnet and Dick 1997; Holyoake et al. 1999; Cobaleda et al. 
2000; Al-Hajj et al. 2003; Hope et al. 2003; Singh et al. 2003) These stem-like cells, also 
referred to as cancer stem cells (CSCs), tumor-initiating cells or tumor-propagating cells, 
show higher tumor-initiating capacity in transplantation assays than non-CSCs and are 
more resistant to radiation therapy (Bao et al. 2006). These observations lead to the 
central hypothesis of cancer stem cell theory: in contrary to traditional belief that all 
cancer cells share the same tumorigenic capacity, solid and liquid tumors are composed 
of 1) a relatively small population of slowly cycling cells that undergo self-renewal to 
sustain and expand the tumors and 2) a larger population of cells that are fate-committed 
and have finite division capacity, forming a hierarchy of cells that is reminiscent of the 
relationship between stem cells and differentiated cells. Based on the cancer stem cell 
hypothesis, the reason why cancer therapies frequently fail is because they are targeting 
the wrong cell types. While radiation and chemotherapy could effectively eliminate large 
numbers of actively proliferating cancer cells, the slowly-proliferating cancer stem cells 
remain and could re-propagate the tumors (Wicha et al. 2006; Stiles and Rowitch 2008).  
 
CSCs were first identified in liquid tumor leukemia (Bonnet and Dick 1997; Holyoake et 
al. 1999; Cobaleda et al. 2000; Hope et al. 2003), and later in solid tumors including brain 
tumors (Al-Hajj et al. 2003; Singh et al. 2003). Singh et al. reported that a group of cells 
that express the cell surface marker CD133 may represent brain tumor stem cells (Singh 
et al. 2003). These CD133
+
 cells express neural stem cell markers and have the unique 
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capacity to form tumors when transplanted into immunodeficient mice and are capable of 
forming multipotent neurospheres in culture (Singh et al. 2004). Additional studies 
suggest that CD133
+ 
glioma cells are more radioresistant and angiogenic than CD133
–
 
tumor cells, which further supports the cancer stem cell hypothesis (Bao et al. 2006). The 
potential caveats for these studies include that CD133
+
 cells may not represent the entire 
population of glioma stem cells. Some gliomas contain self-renewing, multipotent cells 
that are CD133
- 
(Beier et al. 2007). Furthermore, CD133 also labels non-CSCs such as 
ependymal cells (Pfenninger et al. 2007). Finally, in xenograft models the recipient 
mouse brain may represent a selective microenvironment that favors the survival of 
certain cell types and the number of cells that are capable of initiating tumors is 
underestimated. The last argument has been supported by studies in melanoma xenograft 
models in which a much larger proportion of melanoma cells exhibit tumorigenic 
capacity in optimized host environment. Quintana et al found that while only 1 in a 
million melanoma cells form tumors in immunocompromised NOD/SCID mice, when 
co-injected with matrigel (a gelatinous protein mixture secreted by mouse sarcoma cells 
which mimics the complex extracellular environment), 1 in 4 melanoma cells can form 
tumors in NOD/SCID IL2Rγnull mice which lack T, B, and natural killer cells and bypass 
xenogeneic immune responses(Quintana et al. 2008). Whether this happens in brain 
tumor xenograft models is still under investigation.  
 
CSC hypothesis provides a novel framework to address the mechanism underlying 
gliomagenesis. By identifying and characterizing the CSC population in glioblastomas, 
novel therapies may be developed to eradicate this population of cells. Similarly, the 
identification of the tumor initiating cells may provide earlier diagnosis and/or 
prophylactic therapies to susceptible patients. Despite the controversies regarding the 
frequency of CSCs among human cancers, the striking similarity between brain tumor 
stem cells (BTSCs) and normal neural stem cells raises an interesting question whether 
these BTSCs, or brain tumors in general, are derived from neural stem cells. However, 
the stem cell characteristics of BTSCs cannot serve as direct evidence for its 
developmental origin, because theoretically, more differentiated cells could acquire 
oncogenic mutations and dedifferentiate into stem-like cells.  At least three types of cells 
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could in principle serve as the cell-of-origin for malignant glioma: (1) mature 
dedifferentiated cells, (2) lineage-restricted neural progenitors that are normally 
unipotent, and (3) multipotent neural progenitors.   
 
Recent studies provided several lines of evidences to suggest multipotent neural 
progenitors are the cell-of-origin. The first line of evidence comes from signaling 
analysis in neural stem cells and brain cancers. Activation of similar signaling pathways 
has been identified in both neural progenitors and cancer cells. Notch signaling, which 
promotes formation of radial glial and survival of neural stem cells (Gaiano et al. 2000; 
Androutsellis-Theotokis et al. 2006), is constitutively activated in high grade gliomas and 
glioma cell lines and is required for the maintenance of CD133
+
 cells in GBM (Purow et 
al. 2005; Fan et al. 2010). Mitogenic signals that promote neural progenitor cell 
proliferation through EGF, FGF, PDGF and LIF, and their respective receptors, are 
commonly identified in gliomas (Kesari et al. 2005; Stiles and Rowitch 2008). The 
phosphatidylinositol-3-OH kinase (PI3K) signaling pathway, which is responsible for 
metabolism and survival, is also activated in high grade gliomas (Samuels et al. 2004). 
All these signaling analyses indicate that neural progenitors and tumors share common 
regulatory mechanisms. The second line of evidence comes from glioma mouse models. 
If multipotent neural progenitors are the cell-of-origin for gliomas, the predication will be 
that neural progenitors are competent for malignant transformation by mutations found in 
human GBMs. In 2005, Zhu et al. developed an in vivo glioma mouse model by targeting 
two tumor suppressors p53 and Nf1 (Zhu et al. 2005b). In this model, they used a Cre 
transgene driven by human glial fibrillary acidic protein (hGFAP) promoter to introduce 
p53 and Nf1 mutations into developing radial glia, and found high brain tumor penetrance 
among these mice. Under this genetic targeting strategy, all the radial-glia-derived 
progeny, including adult neural stem/progenitors and well differentiated neurons and glia 
carry the same p53/Nf1 mutations. Nevertheless, based on Magnetic Resonance Imaging 
(MRI) analysis and histological studies, p53/Nf1 gliomas appear to initiate and cluster 
around the SVZ stem cell niche, supporting the notion that SVZ neural progenitors are 
the cell-of-origin for brain tumors. The competence of SVZ progenitors to undergo 
malignant transformation was further demonstrated by Alcantara Llaguno et al. in 2009. 
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They employed adenovirus-mediated Cre expression in the adult SVZ, along with a 
tamoxifen (TM)-inducible Cre system, to specifically target p53/Nf1/Pten mutations into 
adult neural SVZ stem and progenitor cells. The targeted deletion of these tumor 
suppressors in the SVZ resulted in efficient gliomagenesis, while targeted deletion in the 
cortex where mature cell reside did not (Alcantara Llaguno et al. 2009). Together these 
observations suggest that a population of cells residing in the SVZ is the cell-of-origin for 
gliomas. 
 
Although signaling analysis and glioma mouse models favor multipotent neural 
progenitors as the cell-of-origin, definitive evidence is lacking. The signaling comparison 
is flawed due to the fact that tumor cells have accumulated numerous mutations and the 
signaling profiles cannot be directly linked to the cell-of-origin. The study in mouse 
models cannot distinguish between various types of neural SVZ stem and progenitor 
populations, because based on current Cre/LoxP conditional knockout system, targeting 
the stem cells will inevitably target all the progeny derived from stem cells. In addition, 
there is no reliable marker to detect the earliest glioma cells in the brain, and the lack of 
lineage-tracing makes it extremely difficult to conclude which type(s) of cells are the 
cell-of-origin.  
 
1.4 Glioma core pathways and the role of tumor suppressors in gliomagenesis 
 
If neural stem/progenitor cells are the cell-of-origin for brain tumors, the immediate 
question is how normal cells undergo malignant transformation to become tumor-
initiating cells. Recent large-scale cancer genome analysis [e.g. The Cancer Genome 
Atlas (TCGA)] has systematically identified genes and pathways that are altered in 
human GBM and provided significant insights into the molecular mechanism of 
gliomagenesis. In particular, they identified three core pathways that must be deregulated 
for primary GBMs to form: retinoblastoma protein RB, p53, and RTK/Ras/PI3K 
pathways. Rb signaling is responsible for preventing excessive cell growth by inhibiting 
cell cycle progression, and is altered in 78% of human glioblastomas (The Cancer 
Genome Atlas Research Network, 2008). In the p53 glioma core pathway, tumor 
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suppressor p53 is the key player, which is often referred to as “the guardian of genome” 
due to its critical role in regulating cell cycle progression and inducing apoptosis 
(programmed cell death) or senescence (cell aging, loss of replication capacity) in 
response to cellular stress (i.e. DNA damage and oncogenic mutations) (Vogelstein et al. 
2000). In humans, p53 is encoded by the TP53 gene. 87% of human glioblastoma have 
mutations in the p53 pathway, and between 30 to 40% of primary glioblastomas have 
mutations in the TP53 gene (The Cancer Genome Atlas Research Network, 2008). 
Consistently, individuals with Li-Fraumeni syndrome, a familiar cancer syndrome caused 
by the presence of a germ-line mutation in the TP53 gene, are predisposed to 
development of astrocytic gliomas (Louis 2007). In secondary GBM, TP53 mutations are 
among the earliest genetic mutations. Importantly, the frequencies of TP53 mutations are 
equally high among grade II (59%), grade III (53%), and grade IV malignant gliomas 
(65%), suggesting that TP53 mutations play a critical role in the early stage of 
gliomagenesis (Ohgaki et al. 2004).  
 
RTK/Ras/PI3K signaling, which is required for cell growth and metabolism, are 
hyperactivated in glioma cells and genetic alterations in this pathway occur in 88% of 
human GBMs (The Cancer Genome Atlas Research Network, 2008). Neurofibromin, 
which contains a functional domain homologous to Ras GTPase activating protein (GAP) 
family members, negatively regulates RTK/Ras signaling pathways by accelerating the 
conversion of active Ras-GTP to inactive Ras-GDP (Ballester et al. 1990; Xu et al. 1990). 
Neurofibromin is encoded by the NF1 gene, which is named after a familiar cancer 
syndrome, Von Recklinghausen’s neurofibromatosis type 1 (NF1).  Each year, 1 out of 
3000 newborns suffer from NF1 disease. NF1 patients are predisposed to developing 
benign and malignant tumors in central and peripheral nervous system (Listernick et al. 
1999). Consistently, cancer genome atlas found that 15% to 20% of human primary 
GBMs harbor NF1 mutations (The Cancer Genome Atlas Research Network, 2008). It is 
worth noting that NF1 patients also develop non-tumor related phenotypes, including 
macrocephaly, astrogliosis and cognitive deficits (Hyman et al. 2005). In terms of 
cognitive deficits, NF1 belongs to a group of neurological disorders termed neuro-cardio-
facial-cutaneous-syndromes (NCFC), caused by germline mutations in the Ras/ERK 
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signaling pathway (Bentires-Alj et al. 2006; Denayer and Legius 2007). (More 
information about NF1 and NCFC will be discussed in Chapter III introduction section). 
Therefore, investigating the role of Nf1 in neural cells will not only advance our 
understanding of brain tumor development, but also provide insights into these non-tumor 
related brain pathology.  
 
Of note, TP53 and NF1 are among the top five mutated genes in human GBMs (The 
Cancer Genome Atlas Research Network, 2008). These signaling pathways are tightly 
regulated in normal brain cells but apparently deregulated in tumors. How these signaling 
alterations singly and cooperatively contribute to gliomagenesis remains to be 
determined.  
 
1.5 The significance of studying tumor suppressor function in neural stem cells 
 
Identification of brain tumor cell-of-origin will not only facilitate early diagnosis of the 
tumors, but also provide a potential therapeutic target to treat the deadly disease at its 
infancy. Since early stage tumor cells are generally considered genetically more stable 
and may share the same oncogenic mutations, targeting these tumor-initiating cells will 
be easier than targeting end-stage tumor cells which have already accumulated numerous 
mutations and exhibit disruptions in various signaling pathways (Jung et al. 1999; Maher 
et al. 2001; Furnari et al. 2007; The Cancer Genome Atlas Research Network, 2008). 
However, given the technical difficulties in defining cell-of-origin of brain cancers as 
discussed in section 1.3, I took an indirect approach to study the hypothesis of whether 
neural stem cell are a cell-of-origin of malignant astrocytic gliomas. Specifically, if this 
hypothesis is correct, I expect that the critical tumor suppressor genes that are frequently 
inactivated in human glioblastoma (e.g. TP53 and NF1) must play an important role in 
regulating normal neural stem cell function. More specifically, my thesis attempted to 
address a more testable hypothesis that p53 and Nf1 play a critical role in regulating self-
renewal, proliferation, survival and differentiation of neural stem cells. This will not only 
provide insights into gliomagenesis but also address fundamental questions of neural 
stem cell biology. 
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To investigate how p53 and Nf1 regulate neural stem cell function, it is essential to 
understand the developmental origin of neural stem cells and how they give rise to multi-
lineage progeny in the brain. I will dedicate the second half of my introduction chapter to 
a brief review of different aspects of neural stem cell biology.   
 
1.6 Methodology for labeling and characterization of neural stem/progenitor cells  
 
In mammals, neural stem cells are a unique population of self-renewing, multipotent cells 
that are capable of generating nerve cells (neurons) and glial cells (the supporting 
elements) in the CNS throughout life. The advancement in neural stem cell biology is 
achieved through technical innovations to study neural stem cell function and 
neurogenesis/gliogenesis in vitro and in vivo.  Major techniques widely used in the field 
are summarized below:  
 
Nucleotide analog labeling:  In vivo analysis of neural progenitor cell proliferation and 
differentiation is first achieved by using nucleotide analogs to label mitotic cells. In the 
1950s, exogenous nucleotide [H
3
]-thymidine was introduced to mark dividing cells, 
which incorporates into newly synthesized DNA during the S-phase of cell cycle and can 
be passed down to the progeny of the mitotic cells. [H
3
]-thymidine could be later 
visualized through autoradiographic detection (Sidman et al. 1959). The generation of 
new neurons was first reported using [H
3
]-thymidine labeling in three-day old mouse 
brains (Smart 1961). In the 1980s, bromodeoxyuridine (BrdU), a synthetic thymidine 
analog, was introduced as another S-phase marker of the cell cycle (Gratzner 1982). 
Since BrdU could be easily detected by immunohistochemistry and colocalized with 
other cell markers by immunofluorescence, BrdU has become the most commonly used 
method in the field for phenotypic and quantitative analysis of neural progenitors and 
their progeny. Short-term pulse labeling with nuclear analogs is used to analyze cell 
proliferation. Since the amount of analogs incorporated from a single injection is diluted 
during each cell cycle and may become undetectable after three or more cell divisions, in 
a long-term pulse-chase experiment, only cells that exit cell cycle shortly after the pulse 
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can retain the nucleotide analog labeling. Therefore, long-term pulse-chase with nuclear 
analogs can be used to label newly differentiated cells or slowing dividing cells, such as 
neural stem cells. The major limitation of this approach is that it cannot be used to label 
live cells, because the visualization of [H
3
]-thymidine requires autoradiography and the 
detection of BrdU requires tissue fixation and DNA denaturation.  
 
Retroviral/lentiviral labeling: Another approach to label mitotic cells is retroviral 
labeling. For retroviruses which lack nuclear import mechanisms, integration of viral 
DNA into host cell DNA can only occur in cells that undergo mitosis and break down 
their nuclear membrane (Lewis and Emerman 1994). Therefore, expression of transgenes 
carried by retroviruses may only occur in mitotic cells and their progeny.  Expression of a 
live reporter, such as green fluorescence protein (GFP), allows live cell imaging to 
analyze neural progenitor cell proliferation and differentiation. In contrast to retroviruses, 
lentiviruses can perform viral integration into host genome at any time of the cell cycle 
and could be used to label relatively quiescent cells such as neural stem cells (Zufferey et 
al. 1998). Both retroviral and lentiviral labeling are based on genetic modifications and 
are thus applicable for long-term lineage tracing. In addition, retroviral/lentiviral 
infection could also be used to deliver Cre-recombinase or small interfering RNA 
(siRNA) to specifically knockout/knockdown genes in a restricted population of cells. 
The drawback of this techinique is that it requires invasive stereotaxic injection into 
specific brain regions and triggers inflammatory responses which may complicate the 
interpretation of the results.  
 
Specific marker expression: The most straightforward approach to label neural 
progenitors and their progeny in vivo is to introduce transgenic reporters under the 
control of specific promoters that only express in desired cell population(s). For example, 
in Nestin-GFP transgenic mice, all the Nestin-expressing neural stem/progenitor cells can 
be visualized by their GFP expression (Yamaguchi et al. 2000). However, this approach 
only transiently labels cells that express specific markers. As the cells differentiate and 
lose the immature markers, it is impossible to track the same population of cells. Thus, 
this approach by itself cannot be used for lineage tracing.  
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Neurosphere assay: Neural stem cells are routinely studied in vitro using a method 
commonly referred to as the neurosphere assay, which was first developed by Reynolds 
and Weiss (Reynolds and Weiss 1992). Neural progenitor cells isolated from ventricular 
zone (VZ)/SVZ could be cultured in self-renewal medium (which contains growth factors 
like EGF and FGF) and form sphere-like heterogeneous cellular entities (primary 
neurospheres) in non-adherent culture systems. Primary neurospheres are almost entirely 
formed from colonial expansion of individual neural stem cells and transit-amplifying 
progenitor cells. Thus, the number of the total neurospheres formed reflects the frequency 
of neural stem/progenitor cells, and the size of neurospheres is determined by 
proliferation/survival status of these neural progenitors. Primary neurospheres could be 
physically dissociated into individual cells and cultured in self-renewal medium to form 
secondary neurospheres. The frequency of secondary neurospheres represents the self-
renewal capacity of neural progenitors. Neurosphere assay could also be used to analyze 
multi-lineage differentiation of neural progenitors. Upon growth factor withdrawal, cells 
within neurospheres differentiate into neurons, oligodendrocytes and astrocytes, which 
can be marked by specific markers Tuj1, O4 and GFAP, respectively, through 
immunocytochemistry. The relative ratio of each differentiated progeny allows the 
assessment of the differentiation potential and fate specification of neural progenitors 
(Pacey et al. 2006).  
 
While neurosphere assay is an ideal method for isolation, expansion and characterization 
of neural stem and progenitor cells, it does not distinguish between neural stem and 
progenitor cells (Reynolds and Rietze 2005). To discriminate these two cell populations, 
Louis et al recently developed a collagen-based assay, called the Neural Colony-Forming 
Cell Assay (NCFCA), for the quantification of neural stem cells (Louis et al. 2008). In 
the NCFCA, colonies ≥2 mm in diameter are derived from cells that meet all the 
functional criteria of neural stem cells, while colonies < 2mm are derived from 
progenitors. This technique could thereby facilitate specific analysis of neural stem cell 
function. 
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1.7 Neural stem cells: the developmental origin and their progeny 
 
With these technical innovations, since the initial isolation of neural stem cells from 
rodent CNS in late 1980s and early 1990s (Temple 1989; Reynolds and Weiss 1992), 
characterization of neural stem cells and neural-stem-cell-derived progenitors in murine 
models has greatly advanced our understanding of normal brain development.  
 
Developing neural stem cells  
In mice, the developmental origins of neural stem cells are neuroepithelial cells derived 
from the ectoderm. Around embryonic day 9 (E9) and E10, neuroepithelial cells acquire 
glial features and generate radial glia, which function as the developing neural stem cells. 
Radial glial cells reside in the ventricular zone (VZ), a region immediately adjacent to the 
lateral ventricle (Kriegstein and Alvarez-Buylla 2009). This microenvironment where 
stem cells reside is often referred to as the neural stem cell niche. During embryonic CNS 
development, generation of neurons (neurogenesis) precedes the generation of glia 
(gliogenesis) (Miller and Gauthier 2007). Cortical neurogenesis takes place from E10 to 
E18 in mice.  Radial glial cells, which express brain lipid-binding protein (BLBP) and 
Nestin, can undergo asymmetric division to directly give rise to neuron in the cortex. 
Alternatively, they can indirectly generate neurons through lineage-committed, transit-
amplifying neural progenitors, also known as neuron-restricted intermediate progenitor 
cells (nIPCs). Radial glial processes function as a scaffold to guide neuronal migration 
during cortical neurogenesis. Oligodendrocytes are also derived from radial glial cells 
through glial-restricted intermediate progenitor cells (gIPCs) during late embryonic 
development. At perinatal stage, the majority of radial glial cells detach from the 
ventricle and transform into astrocytes, while the remainder continue to generate neurons 
and oligodendrocytes through their respective nIPCs and gIPCs (Kriegstein and Alvarez-
Buylla 2009). The peak of gliogenesis occurs in the first few weeks of neonatal 
development (Miller and Gauthier 2007). The developmental origin of neural stem cells 
is illustrated in Figure 1.  
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Adult neural stem cells  
Neurogenesis in the adult brain was traditionally considered non-existent. Ramon y Cajal 
suggested that neurons are generated exclusively during prenatal development based on a 
premise that the addition of new neurons would disrupt the existing neuronal network. 
This conclusion governed the field for  most of the past century due to the fact that there 
was no good lineage tracing technique to prove the existence of adult neurogenesis 
(Gross 2000). Only recently has it been accepted that new neurons are constantly 
generated in discrete regions of adult brain. Adult neural stem cells were first isolated in 
1992 from the adult rodent CNS (Reynolds and Weiss 1992) and later from humans in 
1999 (Kukekov et al. 1999). In the adult brain, multipotent neural stem and progenitor 
cells are spatially restricted in two stem cell niches: the subventricular zone (SVZ) of the 
lateral ventricle and the subgranular layer (SGL) of the hippocampal dentate gyrus 
(Merkle and Alvarez-Buylla 2006). SVZ neural stem cells, also called type B cells, are 
astrocytic cells derived from neonatal radial glial cells. Type B cells give rise to transit-
amplifying intermediate progenitor cells (intermediate progenitor cells, IPCs or type C 
cells), which are highly proliferative and generate neural progenitor cells (neuroblasts, 
type A cells) and oligodendrocytes precursor cells (OPCs). Neuroblasts migrate 
tangentially along rostral migratory stream (RMS), a tubular structure ensheathed by glial 
cells, until they reach the olfactory bulb (OB) and differentiate into mature interneurons, 
including GABAnergic granule neurons and dopaminergic periglomerular neurons. 
OPCs, on the other hand, migrate radially into the overlying corpus callosum and become 
oligodendrocytes (Ming and Song 2005; Merkle and Alvarez-Buylla 2006). Notably, 
gliogenesis in the adult brain is significantly reduced compared to the developing brain 
and the majority of SVZ progenitor cells (~95%) are later committed to the neuronal fate 
(Marshall et al. 2003; Merkle and Alvarez-Buylla 2006).  
 
Based on ultra-structural analyses, Doetsch et al has calculated the relative ratio of 
different cell populations in the adult SVZ (Doetsch et al. 1997). Among them, about 
23% are type B cells, 11% are type C cells and 33% are type A cells. There is no single 
specific marker available to identify SVZ neural stem cells or type B cells. While they 
express Nestin like embryonic radial glial cells, they also express glial fibrillary acidic 
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protein (GFAP) and glutamate aspartate transporter (GLAST), markers that are 
frequently associated with astrocytes (Doetsch et al. 1997).  Meanwhile, Nestin is not a 
specific marker for SVZ neural stem cells since it is also expressed in SVZ type C and A 
cells. Therefore, SVZ neural stem cells are commonly referred to as GFAP
+
/Nestin
+ 
cells. 
The best known marker for Type C cells is Ascl1, a basic helix-loop-helix (bHLH) 
transcription factor that promotes proliferation, although it is also expressed in a subset of 
type A cells(Parras et al. 2004; Kohwi et al. 2005). As type C cells commit to neuronal or 
glial lineage, they start to express transcription factors Dlx2 or Olig2, respectively. 
Neuronal-committed SVZ A cells can be marked by immature neuronal markers 
polysialylated neural cell adhesion molecule (PSA-NCAM), class III -tubulin (Tuj1) 
and doublecortin (DCX), while glial-committed OPCs acquire NG2 expression 
(Kriegstein and Alvarez-Buylla 2009). The lineage relationship of adult SVZ progenitors 
and their marker expression profile is summarized in Figure 2 B and C. 
 
The functional importance of adult neurogenesis was first demonstrated by studies in 
songbirds (Ming and Song 2005). The first evidence that adult-born neurons can integrate 
into existing neuronal network and form functional circuits came from 
electrophysiological studies of new neurons in adult songbird (Fan et al. 2005). During 
the past decade, accumulating evidence correlates adult neurogenesis to behavior both in 
songbirds and in mammals. For instance, in the hippocampus, increased SGZ 
neurogenesis in rodents is associated with enhanced spatial learning and long term 
potentiation (LTP) (Farmer et al. 2004), and decreased SGZ neurogenesis led to defects 
in behavior tests and a reduction of LTP in the dentate gyrus (Shors et al. 2001; Shors et 
al. 2002). In the olfactory bulb, enriched odor exposure increases the number of newborn 
neurons and improves odor memory (Rochefort et al. 2002), while reduced olfactory bulb 
neurogenesis in genetically modified mice exhibited impaired odor discrimination 
(Gheusi et al. 2000; Enwere et al. 2004).  
 
1.8  Fate specification of VZ/SVZ neural stem/progenitor cells 
 
The brain is a complicated organ that requires precise and tightly regulated events during 
development for proper function. The “neuron first, glia second” developmental order has 
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evolved for efficient patterning (Miller and Gauthier 2007). Neuronal circuitry must be 
formed first to determine the proper number and position of glial cells for the circuitry. 
This also explains why neurogenesis is so limited in adult brain, where neuron-glial 
network has been established during embryonic and neonatal development. For 
neurogenesis itself, it requires proper neuronal subtype specification to give rise to 
diverse populations of neurons in the brain at different developmental stages. In this 
section, I will review the current findings about the fate specification of VZ/SVZ neural 
stem/progenitor cells. 
 
Neruon-glia fate determination  
Much progress has been made in the understanding of the underlying mechanism that 
governs the neurogenic-gliogenic-neurogenic switch of VZ/SVZ stem cells over the 
course of embryonic, neonatal and adult stages. During the neurogenic period, bHLH 
transcription factors neurogenin 1 (ngn1) and neurogenin 2 (ngn2) promote neurogenesis 
and repress gliogenesis (Ross et al. 2003). Distal-less homeobox-containing (Dlx) 
transcription factors Dlx1 and Dlx2 repress oligodendrocyte precursor cell formation by 
inhibiting oligodendroglial cell fate acquisition in neuroglial common progenitors 
(Petryniak et al. 2007). Besides inhibition through pro-neuronal transcription factors, 
gliogenesis is also repressed in early neuroglial progenitors through epigenetic silencing 
of signaling pathways required for glia fate specification. For instance, in early neural 
precursors, DNA methylation leads to repression of astrocyte-specific genes, inactivation 
of the gp130/JAK/STAT pathway and inhibition of astrogenesis (Fan et al. 2005).  
 
In the gliogenic period, gp130/JAK/STAT signaling plays a central role in initiating 
astrogenesis (Nakashima et al. 1999). Cytokines including ciliary neurotrophic factor 
(CNTF), leukemia inhibitor factor (LIF), and cardiotrophin-1 (CT-1) activate cytokine 
receptor gp130, which recruits and phosphorylates the tyrosine kinase JAK. Activated 
JAK then phosphorylates and activates the transcription factors STATs to regulate 
downstream gene expression. Early OPC development depends on Sonic hedgehog (Shh) 
signaling (Alberta et al. 2001). Among the downstream targets of Shh, bHLH proteins 
Olig1 and Olig2 are essential for OPC specification and maturation throughout the central 
 18 
 
nervous system (Lu et al. 2002; Zhou and Anderson 2002). Kessaris et al. demonstrated 
that the upregulation of Olig2 through Shh is dependent on Ras/ERK signaling (Kessaris 
et al. 2004). In addition to Shh, fibroblast growth factor 2 (FGF2) can also promote Olig2 
expression in neocortical progenitor cells and induce oligodendrogenesis (Chandran et al. 
2003). Hyperactivation of other receptor tyrosine kinase (RTK) pathways (i.e. epidermal 
growth factor receptor EGFR, platelet-derived growth factor receptor PDGFR) can lead 
to overproduction of Olig2
+
 cells (Jackson et al. 2006; Ivkovic et al. 2008), which may 
potentially function through the Ras/ERK signaling cascade. 
 
Neuronal subtype specification and the heterogeneity of VZ/SVZ progenitors 
Although embryonic VZ appears to be a uniform layer of proliferating progenitors, 
recently studies have demonstrated that it is composed of radial glial cells that are 
heterogeneous in terms of the neuronal subtypes they will produce. Based on their unique 
transcription factor expression profile, embryonic VZ could be subdivided into four 
major subregions: Septum, cortex, lateral ganglionic eminence (LGE), and medial 
ganglionic eminence (MGE). Combinatorial expression of transcription factors Pax6, 
Emx1, Gsh1, Gsh2, Er81, Sp8, Nkx2.1, Dlx1, Dlx2, Olig2, Ngn2 and Ascl1 is implicated 
in neuronal subtype specification of radial glial cells and IPCs in different subregions of 
the VZ (Campbell 2003; Puelles and Rubenstein 2003; Guillemot 2007).  
 
Similar regional heterogeneity has also been observed in neonatal/adult SVZ. Merkle et 
al demonstrated that different types of olfactory bulb neurons are generated from 
different sublocations of the SVZ though adenoviral regional labeling of neonatal radial 
glial cells and adult SVZ type B cells (Merkle et al. 2004; Merkle et al. 2007). There are 
two principal types of adult-born olfactory neurons, periglomerular cells and granule 
cells. Periglomerular cells can be subdivided into three populations of cells that express 
unique markers: calretinin (CalR), calbindin (CalB) and tyrosine hydroxylase (TH). 
Granule cells include deep, superficial, and CalR
+
 cells. Each subtype has distinct 
function in the olfactory bulb (Shepherd 2004; Ming and Song 2005). In their study, 
Merkle et al reveals that dorsal SVZ gives rise to TH
+
 periglomerular cells and a 
subpopulation of the CalR
+
 periglomerular cells, while the majority of CalB+ 
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periglomerular cells are derived from ventrolateral SVZ. For granule cell specification, 
dorsal SVZ progenitors primarily generate superficial GCs, while ventral SVZ 
progenitors gives rise to deep GCs. The majority of CalR+ periglomerular cells and 
granule cells are derived from the medial wall of the lateral ventricle facing the septum. 
Transcriptional control of neuronal subtype specification includes the expression of Pax6 
(dopaminergic periglomerular neurons and a subpopulation of superficial granule cells) 
and SP8 (CalR
+
 cells) (Hack et al. 2005; Kohwi et al. 2005; Waclaw et al. 2006). These 
studies demonstrated that neural stem/progenitor cells in embryonic and neonatal/adult 
VZ/SVZ are heterogeneous and are regionally specified to generate a diverse 
subpopulation of neurons.  
 
1.9 Summary and overall layout of this thesis 
 
In summary, neural stem cells play a critical in normal brain development, and 
deregulation of mechanisms that maintain neural stem cell homeostasis through 
inactivation of tumor suppressors could lead to brain tumor development. Therefore, 
investigating the role of tumor suppressors in neural stem cells could not only provide us 
insights in basic developmental biology, but also advance our understanding of disease 
mechanisms. The objective of my thesis work is to understand the role of p53 and Nf1 in 
normal neural stem/progenitor cell function and how inactivation of these tumor 
suppressor genes may transform neural stem/progenitor cells and potentially lead to brain 
tumor development. In Chapter II, I will present the p53 glioma mouse model, which 
demonstrates the central role of p53 in gliomagenesis and provides new evidence that 
implicates neural stem/progenitor cells as the cell-of-origin for p53-associated glioma. In 
Chapter III, I will present the Nf1 mouse model and show how loss of Nf1 impacts on the 
fate-specification of neural progenitors and how this could relate to cognitive deficits in 
NF1 patients. Chapter IV will be the summary and discussion of the entire thesis.  
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Figure 1. The developmental origin of neural stem cells. 
 (See text for details, adapted fromKriegstein and Alvarez-Buylla, 2009).  
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Figure 2. The lineage relationship and marker expression of adult SVZ neural progenitor 
cells. (See text for details).  
 
 
 
 
 
 23 
 
1.10 References 
 
The Cancer Genome Atlas Research Network. 2008. Comprehensive genomic 
characterization defines human glioblastoma genes and core pathways. Nature 
455: 1061-1068. 
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. 2003. Prospective 
identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 
3983-3988. 
Alberta JA, Park SK, Mora J, Yuk D, Pawlitzky I, Iannarelli P, Vartanian T, Stiles CD, 
Rowitch DH. 2001. Sonic hedgehog is required during an early phase of 
oligodendrocyte development in mammalian brain. Mol Cell Neurosci 18: 434-
441. 
Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, Burns DK, Alvarez-Buylla A, 
Parada LF. 2009. Malignant astrocytomas originate from neural stem/progenitor 
cells in a somatic tumor suppressor mouse model. Cancer Cell 15: 45-56. 
Androutsellis-Theotokis A, Leker RR, Soldner F, Hoeppner DJ, Ravin R, Poser SW, 
Rueger MA, Bae SK, Kittappa R, McKay RD. 2006. Notch signalling regulates 
stem cell numbers in vitro and in vivo. Nature 442: 823-826. 
Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M, Collins F. 1990. 
The NF1 locus encodes a protein functionally related to mammalian GAP and 
yeast IRA proteins. Cell 63: 851-859. 
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, 
Rich JN. 2006. Glioma stem cells promote radioresistance by preferential 
activation of the DNA damage response. Nature 444: 756-760. 
Barth RF. 1998. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, 
F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 36: 91-102. 
Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, 
Brawanski A, Bogdahn U, Beier CP. 2007. CD133(+) and CD133(-) 
glioblastoma-derived cancer stem cells show differential growth characteristics 
and molecular profiles. Cancer Res 67: 4010-4015. 
Bentires-Alj M, Kontaridis MI, Neel BG. 2006. Stops along the RAS pathway in human 
genetic disease. Nat Med 12: 283-285. 
Bonnet D, Dick JE. 1997. Human acute myeloid leukemia is organized as a hierarchy that 
originates from a primitive hematopoietic cell. Nat Med 3: 730-737. 
Campbell K. 2003. Dorsal-ventral patterning in the mammalian telencephalon. Curr Opin 
Neurobiol 13: 50-56. 
Chandran S, Kato H, Gerreli D, Compston A, Svendsen CN, Allen ND. 2003. FGF-
dependent generation of oligodendrocytes by a hedgehog-independent pathway. 
Development 130: 6599-6609. 
Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, Flores T, Garcia-Sanz R, Gonzalez M, 
Sanchez-Garcia I. 2000. A primitive hematopoietic cell is the target for the 
leukemic transformation in human philadelphia-positive acute lymphoblastic 
leukemia. Blood 95: 1007-1013. 
Cohnheim J. 1867. Ueber entzundung und eiterung. Path Anat Physiol Klin Med 40: 1-
79. 
 24 
 
Cohnheim J. 1875. Congenitales, quergestreiftes Muskelsarkon der Nireren. Virchows 
Arch 1875: 64. 
Denayer E, Legius E. 2007. What's new in the neuro-cardio-facial-cutaneous syndromes? 
Eur J Pediatr 166: 1091-1098. 
Doetsch F, Garcia-Verdugo JM, Alvarez-Buylla A. 1997. Cellular composition and three-
dimensional organization of the subventricular germinal zone in the adult 
mammalian brain. J Neurosci 17: 5046-5061. 
Durante F. 1874. Nesso fisio-pathologico tra la struttura dei nei materni e la genesi di 
alcuni tumori maligni. Arch Memor Observ Chir Pract 11: 217-226. 
Enwere E, Shingo T, Gregg C, Fujikawa H, Ohta S, Weiss S. 2004. Aging results in 
reduced epidermal growth factor receptor signaling, diminished olfactory 
neurogenesis, and deficits in fine olfactory discrimination. J Neurosci 24: 8354-
8365. 
Fan G, Martinowich K, Chin MH, He F, Fouse SD, Hutnick L, Hattori D, Ge W, Shen Y, 
Wu H et al. 2005. DNA methylation controls the timing of astrogliogenesis 
through regulation of JAK-STAT signaling. Development 132: 3345-3356. 
Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, Koh C, Zhang J, Li YM, 
Maciaczyk J et al. 2010. NOTCH pathway blockade depletes CD133-positive 
glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. 
Stem Cells 28: 5-16. 
Farmer J, Zhao X, van Praag H, Wodtke K, Gage FH, Christie BR. 2004. Effects of 
voluntary exercise on synaptic plasticity and gene expression in the dentate gyrus 
of adult male Sprague-Dawley rats in vivo. Neuroscience 124: 71-79. 
Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon 
KL, Louis DN, Brennan C et al. 2007. Malignant astrocytic glioma: genetics, 
biology, and paths to treatment. Genes Dev 21: 2683-2710. 
Gaiano N, Nye JS, Fishell G. 2000. Radial glial identity is promoted by Notch1 signaling 
in the murine forebrain. Neuron 26: 395-404. 
Gheusi G, Cremer H, McLean H, Chazal G, Vincent JD, Lledo PM. 2000. Importance of 
newly generated neurons in the adult olfactory bulb for odor discrimination. Proc 
Natl Acad Sci U S A 97: 1823-1828. 
Gratzner HG. 1982. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new 
reagent for detection of DNA replication. Science (New York, NY 218: 474-475. 
Gross CG. 2000. Neurogenesis in the adult brain: death of a dogma. Nat Rev Neurosci 1: 
67-73. 
Guillemot F. 2007. Cell fate specification in the mammalian telencephalon. Prog 
Neurobiol 83: 37-52. 
Hack MA, Saghatelyan A, de Chevigny A, Pfeifer A, Ashery-Padan R, Lledo PM, Gotz 
M. 2005. Neuronal fate determinants of adult olfactory bulb neurogenesis. Nat 
Neurosci 8: 865-872. 
Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. 2000. Combined 
activation of Ras and Akt in neural progenitors induces glioblastoma formation in 
mice. Nat Genet 25: 55-57. 
Holyoake T, Jiang X, Eaves C, Eaves A. 1999. Isolation of a highly quiescent 
subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94: 
2056-2064. 
 25 
 
Hope KJ, Jin L, Dick JE. 2003. Human acute myeloid leukemia stem cells. Arch Med Res 
34: 507-514. 
Hyman SL, Shores A, North KN. 2005. The nature and frequency of cognitive deficits in 
children with neurofibromatosis type 1. Neurology 65: 1037-1044. 
Ivkovic S, Canoll P, Goldman JE. 2008. Constitutive EGFR signaling in oligodendrocyte 
progenitors leads to diffuse hyperplasia in postnatal white matter. J Neurosci 28: 
914-922. 
Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, Roy M, Quinones-Hinojosa A, 
VandenBerg S, Alvarez-Buylla A. 2006. PDGFR alpha-positive B cells are neural 
stem cells in the adult SVZ that form glioma-like growths in response to increased 
PDGF signaling. Neuron 51: 187-199. 
Jacques TS, Swales A, Brzozowski MJ, Henriquez NV, Linehan JM, Mirzadeh Z, C OM, 
Naumann H, Alvarez-Buylla A, Brandner S. 2010. Combinations of genetic 
mutations in the adult neural stem cell compartment determine brain tumour 
phenotypes. EMBO J 29: 222-235. 
Jung V, Romeike BF, Henn W, Feiden W, Moringlane JR, Zang KD, Urbschat S. 1999. 
Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-
specific CGH on microdissected tumor cells. J Neuropathol Exp Neurol 58: 993-
999. 
Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. 2005. Targeted molecular 
therapy of malignant gliomas. Curr Neurol Neurosci Rep 5: 186-197. 
Kessaris N, Jamen F, Rubin LL, Richardson WD. 2004. Cooperation between sonic 
hedgehog and fibroblast growth factor/MAPK signalling pathways in neocortical 
precursors. Development 131: 1289-1298. 
Kohwi M, Osumi N, Rubenstein JL, Alvarez-Buylla A. 2005. Pax6 is required for making 
specific subpopulations of granule and periglomerular neurons in the olfactory 
bulb. J Neurosci 25: 6997-7003. 
Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK. 1998. Targeted therapy of human 
malignant glioma in a mouse model by 2-5A antisense directed against telomerase 
RNA. Oncogene 16: 3323-3330. 
Kriegstein A, Alvarez-Buylla A. 2009. The glial nature of embryonic and adult neural 
stem cells. Annu Rev Neurosci 32: 149-184. 
Kukekov VG, Laywell ED, Suslov O, Davies K, Scheffler B, Thomas LB, O'Brien TF, 
Kusakabe M, Steindler DA. 1999. Multipotent stem/progenitor cells with similar 
properties arise from two neurogenic regions of adult human brain. Exp Neurol 
156: 333-344. 
Lewis P, Emerman M. 1994. Passage through mitosis is required for oncoretroviruses but 
not for the human immunodeficiency virus. JVirol 68: 510-516. 
Listernick R, Charrow J, Gutmann DH. 1999. Intracranial gliomas in neurofibromatosis 
type 1. Am J Med Genet 89: 38-44. 
Louis DN, Ohgaki, H., Wiestler, O.D., and Cavenee, W.K. . 2007. WHO Classification of 
Tumors of the Central Nervous System. 
Louis SA, Rietze RL, Deleyrolle L, Wagey RE, Thomas TE, Eaves AC, Reynolds BA. 
2008. Enumeration of neural stem and progenitor cells in the neural colony-
forming cell assay. Stem Cells 26: 988-996. 
 26 
 
Lu QR, Sun T, Zhu Z, Ma N, Garcia M, Stiles CD, Rowitch DH. 2002. Common 
developmental requirement for Olig function indicates a motor 
neuron/oligodendrocyte connection. Cell 109: 75-86. 
Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho 
RA. 2001. Malignant glioma: genetics and biology of a grave matter. Genes Dev 
15: 1311-1333. 
Marshall CA, Suzuki SO, Goldman JE. 2003. Gliogenic and neurogenic progenitors of 
the subventricular zone: who are they, where did they come from, and where are 
they going? Glia 43: 52-61. 
Merkle FT, Alvarez-Buylla A. 2006. Neural stem cells in mammalian development. Curr 
Opin Cell Biol 18: 704-709. 
Merkle FT, Mirzadeh Z, Alvarez-Buylla A. 2007. Mosaic organization of neural stem 
cells in the adult brain. Science (New York, NY 317: 381-384. 
Merkle FT, Tramontin AD, Garcia-Verdugo JM, Alvarez-Buylla A. 2004. Radial glia give 
rise to adult neural stem cells in the subventricular zone. Proc Natl Acad Sci U S 
A 101: 17528-17532. 
Miller FD, Gauthier AS. 2007. Timing is everything: making neurons versus glia in the 
developing cortex. Neuron 54: 357-369. 
Ming GL, Song H. 2005. Adult neurogenesis in the mammalian central nervous system. 
Annu Rev Neurosci 28: 223-250. 
Nakashima K, Wiese S, Yanagisawa M, Arakawa H, Kimura N, Hisatsune T, Yoshida K, 
Kishimoto T, Sendtner M, Taga T. 1999. Developmental requirement of gp130 
signaling in neuronal survival and astrocyte differentiation. J Neurosci 19: 5429-
5434. 
Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, 
Schuler D, Probst-Hensch NM, Maiorka PC et al. 2004. Genetic pathways to 
glioblastoma: a population-based study. Cancer Res 64: 6892-6899. 
Pacey L, Stead S, Gleave J, Tomczyk K, Doering L. 2006. Neural stem cell culture: 
Neurosphere generation, microscopical analysis and cryopreservation. Nature 
Protocols Online  
Parras CM, Galli R, Britz O, Soares S, Galichet C, Battiste J, Johnson JE, Nakafuku M, 
Vescovi A, Guillemot F. 2004. Mash1 specifies neurons and oligodendrocytes in 
the postnatal brain. EMBO J 23: 4495-4505. 
Petryniak MA, Potter GB, Rowitch DH, Rubenstein JL. 2007. Dlx1 and Dlx2 control 
neuronal versus oligodendroglial cell fate acquisition in the developing forebrain. 
Neuron 55: 417-433. 
Pfenninger CV, Roschupkina T, Hertwig F, Kottwitz D, Englund E, Bengzon J, Jacobsen 
SE, Nuber UA. 2007. CD133 is not present on neurogenic astrocytes in the adult 
subventricular zone, but on embryonic neural stem cells, ependymal cells, and 
glioblastoma cells. Cancer Res 67: 5727-5736. 
Plate KH, Breier G, Millauer B, Ullrich A, Risau W. 1993. Up-regulation of vascular 
endothelial growth factor and its cognate receptors in a rat glioma model of tumor 
angiogenesis. Cancer Res 53: 5822-5827. 
Puelles L, Rubenstein JL. 2003. Forebrain gene expression domains and the evolving 
prosomeric model. Trends Neurosci 26: 469-476. 
 27 
 
Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, Sundaresan T, Pastorino S, 
Park JK, Mikolaenko I et al. 2005. Expression of Notch-1 and its ligands, Delta-
like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer 
Res 65: 2353-2363. 
Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. 2008. 
Efficient tumour formation by single human melanoma cells. Nature 456: 593-
598. 
Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. 2000. Nf1;Trp53 mutant 
mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 26: 
109-113. 
Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem 
cells. Nature 414: 105-111. 
Reynolds BA, Rietze RL. 2005. Neural stem cells and neurospheres--re-evaluating the 
relationship. Nat Methods 2: 333-336. 
Reynolds BA, Weiss S. 1992. Generation of neurons and astrocytes from isolated cells of 
the adult mammalian central nervous system. Science (New York, NY 255: 1707-
1710. 
Rochefort C, Gheusi G, Vincent JD, Lledo PM. 2002. Enriched odor exposure increases 
the number of newborn neurons in the adult olfactory bulb and improves odor 
memory. J Neurosci 22: 2679-2689. 
Ross SE, Greenberg ME, Stiles CD. 2003. Basic helix-loop-helix factors in cortical 
development. Neuron 39: 13-25. 
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell 
SM, Riggins GJ et al. 2004. High frequency of mutations of the PIK3CA gene in 
human cancers. Science (New York, NY 304: 554. 
Sauer B. 1998. Inducible gene targeting in mice using the Cre/lox system. Methods 14: 
381-392. 
Shepherd GM. 2004. The synaptic organization of the brain. Oxford University Press, 
Oxford ; New York. 
Shors TJ, Miesegaes G, Beylin A, Zhao M, Rydel T, Gould E. 2001. Neurogenesis in the 
adult is involved in the formation of trace memories. Nature 410: 372-376. 
Shors TJ, Townsend DA, Zhao M, Kozorovitskiy Y, Gould E. 2002. Neurogenesis may 
relate to some but not all types of hippocampal-dependent learning. Hippocampus 
12: 578-584. 
Sidman RL, Miale IL, Feder N. 1959. Cell proliferation and migration in the primitive 
ependymal zone: an autoradiographic study of histogenesis in the nervous system. 
Exp Neurol 1: 322-333. 
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. 2003. 
Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-
5828. 
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, 
Cusimano MD, Dirks PB. 2004. Identification of human brain tumour initiating 
cells. Nature 432: 396-401. 
Smart I. 1961. The subependymal layer of the mouse brain and its cell production as 
shown by autography after [H3]-thymidine injection. J Comp Neurol 116: 325-
347. 
 28 
 
Stiles CD, Rowitch DH. 2008. Glioma stem cells: a midterm exam. Neuron 58: 832-846. 
Temple S. 1989. Division and differentiation of isolated CNS blast cells in microculture. 
Nature 340: 471-473. 
Till JE, Mc CE. 1961. A direct measurement of the radiation sensitivity of normal mouse 
bone marrow cells. Radiat Res 14: 213-222. 
Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408: 307-310. 
Waclaw RR, Allen ZJ, 2nd, Bell SM, Erdelyi F, Szabo G, Potter SS, Campbell K. 2006. 
The zinc finger transcription factor Sp8 regulates the generation and diversity of 
olfactory bulb interneurons. Neuron 49: 503-516. 
Wicha MS, Liu S, Dontu G. 2006. Cancer stem cells: an old idea--a paradigm shift. 
Cancer Res 66: 1883-1890; discussion 1895-1886. 
Xu GF, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, White R, Weiss R, Tamanoi F. 
1990. The catalytic domain of the neurofibromatosis type 1 gene product 
stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 63: 
835-841. 
Yamaguchi M, Saito H, Suzuki M, Mori K. 2000. Visualization of neurogenesis in the 
central nervous system using nestin promoter-GFP transgenic mice. Neuroreport 
11: 1991-1996. 
Zhou Q, Anderson DJ. 2002. The bHLH transcription factors OLIG2 and OLIG1 couple 
neuronal and glial subtype specification. Cell 109: 61-73. 
Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, Messing A, Parada LF. 2005a. 
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss 
induces malignant astrocytoma. Cancer Cell 8: 119-130. 
Zhu Y, Harada T, Liu L, Lush ME, Guignard F, Harada C, Burns DK, Bajenaru ML, 
Gutmann DH, Parada LF. 2005b. Inactivation of NF1 in CNS causes increased 
glial progenitor proliferation and optic glioma formation. Development 132: 5577-
5588. 
Zhu Y, Parada LF. 2002. The molecular and genetic basis of neurological tumours. Nat 
Rev Cancer 2: 616-626. 
Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D. 1998. Self-
inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 
72: 9873-9880. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 29 
 
 
Chapter II Expression of mutant p53 marks the transition from neural 
progenitor to malignant glioma  
 
This part of my thesis is mainly a joint effort from former lab post-doc Dr. Jiong Yang 
and me.  Dr. Yang collected the tumor samples and mainly focused on the end-stage 
analysis. I focused on the characterization of early stage p53
+ 
cells in the brain and the 
investigation of the lineage relationship between neural stem/progenitor cells and early 
glioma cells. Drs.Yuan Zhu and Paul E. McKeever performed the histological analysis. 
 
2.1 Introduction 
 
Glioblastoma (Grade IV malignant astrocytic glioma), also known as glioblastoma 
multiforme (GBM), is the most frequent and aggressive neoplasm among human primary 
brain tumors (Furnari et al., 2007; Louis et al., 2007). There are two subtypes of GBM. 
Primary GBM arises de novo with no evidence of pre-existing lesions whereas secondary 
GBM develops from lower-grade, albeit malignant, i.e., Grade II or III gliomas. Despite 
distinctive clinical courses and differing molecular lesions, primary and secondary GBMs 
share the same histopathological and clinical features, most notably a high propensity to 
diffusely infiltrate normal brain parenchyma and resistance to virtually all current 
therapies. Consequently, GBM is one of the most deadly human cancers with a median 
survival that has remained at 12 months for over the past two decades (Furnari et al., 
2007; Louis et al., 2007).  
 
Recent studies have identified genes and core pathways that are altered in human GBM 
(Ohgaki et al., 2004; Parsons et al., 2008; TCGA Research Network, 2008). Mutations in 
the components of the P53 tumor suppressor pathway have been identified in the majority 
of human primary GBM, approximately 30 to 40% of which have mutations in the TP53 
gene (Parsons et al., 2008; TCGA Research Network, 2008). Furthermore, frequencies of 
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TP53 mutations are similar among lower-grade malignant gliomas and secondary GBMs, 
suggesting an important role of TP53 gene defects in early stages of glioma development 
(Ohgaki et al., 2004). Consistently, individuals with Li-Fraumeni syndrome, who carry 
germline P53 mutations, are predisposed to development of astrocytic gliomas (Louis et 
al., 2007). However, the mechanisms by which TP53 deficiency transforms normal brain 
cells remain poorly understood.  
 
One critical challenge to understand the GBM pathogenesis is to identify the cell-of-
origin of this disease. The cell-of-origin in most human cancers remains unknown as 
human tumor samples are typically acquired and analyzed at the terminal stages of the 
disease and thus do not provide a window to study this important question. Recent studies 
demonstrated that a number of brain cancers, including GBM, are driven and sustained 
by a subset of stem cell-like cells that exhibit the cellular characteristics of normal stem 
cells, including self-renewal and multipotency (Galli et al., 2004; Hemmati et al., 2003; 
Singh et al., 2004). However, whether a normal stem cell, a progenitor cell, or even a 
fully differentiated cell is the cell-of-origin for glioma stem cells remains largely 
unknown (Sanai et al., 2005; Stiles and Rowitch, 2008). In the adult brain, multipotent 
neural stem and progenitor cells are spatially restricted in two stem cell niches: the 
subventricular zone (SVZ) of the lateral ventricle and the subgranular zone (SGZ) of the 
hippocampal dentate gyrus (Merkle and Alvarez-Buylla, 2006). Genetic studies using 
murine glioma models and imaging analysis from a clinical study provide evidence that 
some GBMs may arise from the SVZ stem cell niche (Alcantara Llaguno et al., 2009; 
Lim et al., 2007; Zhu et al., 2005a). At the cellular level, neural stem cells in the adult 
SVZ (type B cells or SVZ-B) give rise to a highly proliferative cell population, transit-
amplifying progenitor cells (SVZ-C cells), which then differentiate into two lineage-
restricted progenitor cells, neuroblasts (SVZ-A cells) and oligodendrocyte precursor cells 
(SVZ-OPC) (Hack et al., 2005; Menn et al., 2006). Because of a lack of reliable markers 
for glioma cells, particularly at early stages of tumor development, the role of the various 
SVZ cell populations in gliomagenesis remains undefined.  
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In this study, we develop a murine glioma model in which an in-frame p53 deletion 
mutation is specifically targeted into the nervous system and use it to investigate the role 
of neural stem cells and transit-amplifying progenitors in P53-mediated gliomagenesis.  
 
2.2 Material and methods 
 
2.2.1 Histology and tumor analysis 
 
Mice were aged until signs of distress appeared. Then, mice were perfused with 4% 
paraformaldehyde (PFA) and brains were dissected, followed by overnight post-fixation 
in 4% PFA at 4 ºC. Brains were divided into two hemispheres along the midline and each 
hemisphere was processed for either paraffin-embedded or cryostat sections. Serial 
sections were sagittally prepared at 5 m for paraffin sections or 14 m for cryostat 
sections. Every eleventh slide was stained by H&E. Stained sections were independently 
examined under a light microscope by Yuan Zhu and Paul E. McKeever. Tumor grading 
was determined by Yuan Zhu and Paul E. McKeever based upon the WHO grading 
system for malignant astrocytic glioma and medulloblastoma (Louis et al., 2007). 
Adjacent sections were subjected to immunohistochemical analysis (see below).  
 
2.2.2 Histological grading of malignant astrocytic gliomas in CKO1, CKO2 and 
CKO3 mice 
 
Histopathology of neoplasms that developed in these mice had to meet diagnostic criteria 
of the World Health Organization (WHO) for classification of tumors of the CNS (Louis 
et al., 2007). Tumors with neoplastic astrocytes were classified as astrocytic gliomas. 
Astrocytic features include extension of cellular processes from neoplastic cells. These 
vary from long and thick to thin and short. They are highlighted with H&E and GFAP 
stains. Variable nuclear shapes, particularly elongated, bent and dark staining nuclei 
characterize neoplastic astrocytes. Their perinuclear cytoplasm is highly variable: from 
imperceptible to substantial and appearing to push the nucleus to the perimeter of the cell. 
Astrocytic glioma is a classification that includes astrocytoma, anaplastic astrocytoma, 
glioblastoma, and oligoastrocytoma. To be among the first three tumors, neoplastic 
astrocytes must predominate. To be either an anaplastic astrocytoma (WHO grade III on a 
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scale of four) or glioblastoma (WHO grade V), the tumor must have mitoses. It must be 
crowded with malignant cells, cells with coarse nuclear chromatin, angulated and 
pleomorphic nuclei, or nucleolar abnormalities. To be classified as a glioblastoma and 
given the highest grade of malignancy, the additional feature of either necrosis or 
microvascular proliferation must be present. Microvascular proliferation is hypotrophy 
and hyperplasia of cells in the walls of tumor vessels.  
 
2.2.3 LacZ/ -gal staining 
 
The R26R-LacZ transgene was introduced to the CKO1 and CKO2 mice.  Mice with 
genotypes of hGFAP-cre+;p53
flox/KO
;R26R-LacZ+ (CKO1) and hGFAP-
cre+;p53
flox/flox
;R26R-LacZ+ (CKO2) were generated. Brains were collected from mutant 
mice at ages of postnatal day (P0.5), P21, and 6 months. Tumor tissues were isolated 
from mutant mice with high-grade brain tumors. Dissected tissues were post-fixed in 
PFA for 2 hours and transferred to 30% sucrose for overnight dehydration. Frozen 
sections cut at 10 μ were prepared and subjected to X-gal staining for 1 hour to overnight 
depending on the signal intensity. X-gal stained sections were then subjected to nuclear 
fast red for counterstaining.  Co-localization of -gal expressing cells with other lineage 
markers was obtained by double immunofluorescence.  
 
2.2.4 Immunohistochemistry/ Immunofluorescence 
 
Paraffin sections were deparaffinized through Xylene, 100% ethanol, 95% ethanol, 50% 
ethanol and 30% ethanol and rehydrated in distilled water. Antigen retrieval was 
performed with Retrieve-all antigen retrieval solution from Signet. Cryosections do not 
require deparaffinization or antigen retrieval steps and were directly fixed in 4% PFA for 
15 minutes. Sections were then permeablized by 0.3% Triton-X (Sigma) solution for 20 
minutes and blocked for 1 hour with 1.5% normal goat/horse/donkey serum (Sigma) 
depending on the secondary antibody to be used (e.g. use goat serum for blocking if the 
secondary antibody is from goat). Slides were put in humidified chamber and incubated 
in primary antibodies dissolved in the blocking solution at 4
o
C overnight. The 
visualization of primary antibodies was performed with either a horseradish peroxidase 
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system using a diaminobenzidine-based (DAB) peroxidase substrate (Vectastain ABC kit, 
Vector) or immunofluorescence by using Cy2 (or Alexa 488), Cy3 (or Alexa 555) and 
Cy5 (Alexa 647)-conjugated secondary antibodies at 1:200 dilution for 1 hour incubation 
(Cy2/Cy3/Cy5, Jackson Immunoresearch; Alexa 488/555/647, Invitrogen). Slides were 
washed in between the steps with 1X PBS.  The dilutions of primary antibodies used in 
this study were: p53 (1:500, rabbit, Novo Castra), BrdU (1:1000, rat, Abcam), Ki-67 
(1:500, mouse, BD Pharmingen), CD133 (1:500, rat, eBiosciences), PDGFR  (1:1000, 
rat, eBiosciences), Olig2 (Rabbit, 1:20000, a kind gift from Dr. C. Stiles; guinea pig, 
1:10000, a kind gift from Dr. B. Novitch), GFAP (1:2000, mouse, BD Pharmingen), 
MAP2 (1:200, mouse, Sigma), Nestin (1:100, mouse, Chemicon), PSA-NCAM (1:1000, 
mouse, Chemicon), NG2 (1:200, mouse, Millipore), ), -gal (1:1000, rabbit, 5 prime-3 
prime) , -gal (1:1000, goat, AbD Serotec), and CD31 (1:200, mouse, Dako). CD133 or 
PDGFRα staining was performed on cryostat sections, and an Invitrogen 
biotin/streptavidin system was used for signal amplification. Sections were examined 
under either a light or a fluorescence microscope (Olympus).  
 
2.2.5 BrdU Assay 
 
The CKO1/CKO2 mutant and control littermates were pulsed with BrdU five times a day 
at 2-hour intervals. The dose of BrdU was 50μg/g (gram, body weight). Mice were 
perfused with 4% PFA 2 hours after the last pulse. Brains were dissected and processed 
for either paraffin-embedded or cryostat sections. The staining for BrdU followed the 
regular immunofluorescence or immunohistochemistry protocol described above, except 
that after the Triton-X permeablization step, sliders were incubated in 2N HCl for 30 
minutes followed by 0.1 M sodium borate for 20 minutes to denature the DNA. 
 
2.3 Results 
 
2.3.1 p53 deficiency is sufficient to induce glioma formation 
 
To investigate the role of p53 in gliomagenesis, we used hGFAP-cre to introduce p53 
mutation specifically into the central nervous system. As aforementioned, because radial 
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glial cells are the primary multipotent neural stem/progenitor cell populations in the 
developing brain, hGFAP-cre-mediated gene deletion will be transmitted to all the 
progeny of radial glial cells, including neurons, glia, and adult neural stem cells (Merkle 
and Alvarez-Buylla 2006). The p53 conditional allele (p53flox) used for this study is 
unlike other p53 conditional alleles. Cre-mediated recombination of this p53flox allele 
results in an in-frame deletion of exons 5 and 6, which encode a significant portion of the 
p53 DNA binding domain (Cho et al. 1994; Kitayner et al. 2006). Consistently, it has 
been previously shown that this p53 in-frame deletion mutant (hereafter, p53
ΔE5-6
) lacks 
transcriptional function (Lin et al. 2004). Thus, the p53
ΔE5-6 
allele represents a DNA 
binding domain-deficient loss-of-function allele. Moreover, the resultant protein of the 
p53
ΔE5-6 
allele is not degraded or overexpressed and mimics the levels of wildtype p53. 
As such, this truncated protein can be used as a surrogate marker for determining the 
levels of p53 in cells, which is often elevated in human tumors. 
 
To study tumorigenic activity of the p53
ΔE5-6 
mutation in the brain, we first crossed the 
hGFAP-cre line with the p53
flox 
mouse to generate hGFAP-cre+;p53
flox/+ 
mice. Ten 
hGFAP-cre+;p53
flox/+ 
mice were monitored over 12 months. These mice were healthy and 
behaved indistinguishably from the wild-type littermates. Moreover, there was no 
evidence of tumor formation in the brain of these aged mice. We then generated hGFAP-
cre+;p53
flox/KO 
(hereafter referred to as conditional knockout 1 or CKO1) and hGFAP-
cre+;p53
flox/flox 
(CKO2) mouse strains (Figure 3A). As previously shown, inactivation of 
p53 followed by Nf1 loss efficiently induces malignant gliomas with complete penetrance 
(Zhu et al. 2005a). Thus a heterozygous Nf1 mutation was introduced to the p53
ΔE5-6 
mutant mice and generated a third mutant strain with the genotype of hGFAP-
cre+;p53
flox/flox
;Nf1
KO/+ 
(CKO3). In CKO3 brains, p53-deficient cells are expected to 
inactivate the wild-type Nf1 allele to undergo p53/Nf1-mediated gliomagenesis, whereas 
p53-deficient cells in the CKO1/2 brains could potentially cooperate with diverse 
oncogenic alterations to promote glioma formation (Figure 3A).  
 
Both CKO1 and CKO2 mice were healthy, fertile, and indistinguishable from their 
control littermates within the first 6 months after birth (Figure 3B). However, 85% of 
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CKO1 (22/26) and 84% of CKO2 (43/51) mice analyzed in this study developed 
neurological symptoms including tremor, seizure, ataxia, or lack of balance requiring 
sacrifice between the ages of 6 and 14 months (Figure 3B). Each of the CKO1 and CKO2 
mice with neurological deficits exhibited enlarged brains with evidence of high-grade 
brain tumors. The remaining CKO1 and CKO2 mice were sacrificed because of the 
presence of tumors outside the central nervous system (CNS). These non-CNS tumors 
were diagnosed as soft-tissue sarcomas, likely arising due to hGFAP-cre expression in 
cells outside the CNS (data not shown). A portion of the CKO1 (1/4) and CKO2 (2/8) 
mice with non-CNS sarcomas also exhibited enlarged brains with high-grade tumors. 
Together, nearly 90% of both CKO1 (23/26) and CKO2 (45/51) mutant mice developed 
high-grade brain tumors (Figure 3A), most of which (20/23 of CKO1 and 40/45 of 
CKO2) were histopathologically characterized as malignant gliomas with astrocytic 
characteristics and the remainder of which were medulloblastomas (Figure 3C). Because 
CKO1 and CKO2 mice exhibited essentially the same brain tumor phenotypes, they will 
be presented together as the p53
ΔE5-6
 mutant mice. Compared to CKO1 and CKO2, 
CKO3 mice develop tumors at much faster rate, consistent with previous findings that 
Nf1 mutation could accelerate glioma formation in a p53-deficient background (Zhu et al. 
2005a). Together, CKO1, CKO2 and CKO3 represent highly penetrant p53-dependent 
models of GBM.  
 
2.3.2 CD133
+
 malignant astrocytic glioma and GBM 
 
Malignant astrocytic gliomas observed in the advanced-stage p53
E5-6
 mice diffusely 
infiltrated the forebrain and expressed glioma markers GFAP, Nestin, and Olig2, albeit 
with a high degree of heterogeneity within individual tumors and between different 
tumors (Figures 4A, 4B). Importantly, approximately 40% of the p53
E5-6
 high-grade 
astrocytic gliomas exhibited the characteristics of human GBM, including the presence of 
necrosis, pseudopalisading tumor cells, and microvascular proliferation (Figure 4A). It is 
worth noting that regardless of the presence or absence of detectable necrosis, these 
malignant gliomas exhibited similarly high degrees of nuclear atypia (Figures 4B), 
resembling human primary GBM. These tumors also exhibited the defining features of 
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human high-grade diffuse gliomas: high levels of mitotic figures and presence of 
secondary structures of Scherer (Figures 4C). Furthermore, similar to human 
counterparts, a subpopulation of p53
E5-6
 tumor cells expressed a glioma stem cell 
marker, CD133 (also known as prominin1), and the CD133
+ 
glioma cells were often 
located around blood vessels and expressed p53, Nestin, and Olig2 (Figure 5) (Calabrese 
et al., 2007; Singh et al., 2004). Taken together, the p53
E5-6
 mouse model accurately 
recapitulates both the genetics and pathology of human high-grade astrocytic gliomas. 
 
2.3.3 p53-deficiency does not provide any growth advantage in adult SVZ 
 
To investigate the mechanism underlying p53-mediated gliomagenesis, we examined the 
brain of young adult mutant mice. At 2 months of age, no significant difference was 
identified between the control and p53
ΔE5-6 
brains (n = 6 for each genotype), which is 
consistent with the notion that p53 is dispensable for normal brain development 
(Donehower et al. 1992; Jacks et al. 1994). Although previous studies demonstrated that a 
germline p53 null mutation results in mild hyperplasia in the SVZ of the adult brain (Gil-
Perotin et al. 2006; Meletis et al. 2006), we found no abnormality in the p53
ΔE5-6 
mutant 
SVZ stem cell niche with respect to the number or the density of the total SVZ cells 
(Figure 6). Furthermore, no significant difference in the number, the density, or the 
percentage of BrdU-positive proliferating cells was identified between the control and 
mutant brains including the SVZ region at 2 months (Figures 6M–3Q). Together, these 
results indicate that the p53
ΔE5-6 
mutation does not confer a measurable growth advantage 
to brain cells including SVZ stem and progenitor cells in young adult mice.  
 
2.3.4 Nf1 inactivation promotes p53-mediated malignant glioma formation  
 
The fact that p53-deficiency does not provide any growth advantage to brains suggest 
that additional cooperative oncogenic alterations must occur to transform p53-deficient 
brain cells, and introduction of these oncogenic mutations to p53-deficent background 
could accelerate glioma formation. Consistently, despite that Nf1 inactivation or 
activation of PI3K and MAPK signaling pathways appears not essential for p53-mediated 
gliomagenesis, all the CKO3 mice (hereafter, p53
E5-6
;Nf1
-/-
) analyzed (n = 36) developed 
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malignant astrocytic gliomas with significantly shorter latency compared to the p53
E5-6
 
mutant mice (Figure 3B,C). Nearly 70% of malignant gliomas observed in p53
E5-6
;Nf1
-/-
 
mice exhibited histopathological features of human GBM, such as necrosis. These results 
demonstrate that Nf1 inactivation, as one of cooperative oncogenic alterations, albeit not 
essential, can rapidly promote p53
E5-6
-mediated gliomagenesis.  
 
2.3.5 Mutant p53
ΔE5-6 
expression marks p53-deficient brain tumor cells 
 
In human cancers, p53 mutations are mostly missense point mutations and in-frame 
deletion mutations in the DNA-binding domain (IARC TP53 DATABASE). Unlike other 
tumor suppressors that are typically down-regulated in tumor cells, the majority of human 
tumors with p53 mutations express high levels of the mutant p53 protein (Soussi and 
Wiman 2007). Our p53
ΔE5-6 
tumors phenocopies human tumors in this respect (Figure 
7A-F). The p53 nuclear immunostaining was very specific for p53
ΔE5-6 
brain tumor cells, 
as no labeling was observed in the normal brain cells, including those carrying one or two 
p53
ΔE5-6 
alleles, or in the p53 null malignant astrocytic gliomas (the tumor model in Zhu 
et al., 2005a paper). In addition, we used the Rosa-LacZ reporter to confirm that p53-
expressing cells have undergone Cre-mediated recombination. Indeed, all the p53
ΔE5-6 
brain tumors analyzed extensively expressed high levels of -gal (Figure 7G a and a’). 
Furthermore, almost all of the p53
ΔE5-6
-positive brain tumor cells exhibited high levels of 
-gal expression (Figures 7G b and b’). It is worth noting that three of five p53ΔE5-6 brain 
tumors analyzed contained a subpopulation of tumor cells with no or low -gal staining, 
which often exhibited high levels of GFAP and hGFAP-cre expression (Figure 7H and 
data not shown). This is consistent with the previous observations that the R26R-LacZ is 
not expressed in most GFAP-expressing mature astrocytes, despite their expression of 
hGFAP-cre (Malatesta et al. 2003). In summary, p53 is stabilized in end-stage gliomas 
and can be used as a marker for tumor cells. 
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2.3.6 Expression of mutant p53
ΔE5-6 
proteins marks the earliest-stage glioma cells 
 
The stabilization of mutant p53 exclusively in advanced stage glioma cells leads to an 
interesting question whether we can use the stabilization of this mutant p53 to mark 
glioma cells in the early stage of tumorigenesis. The first step is to identify early stage 
glioma precursors. In the normal adult brain, particularly after 4 months of age, virtually 
all the proliferating cells are restricted to the SVZ or RMS (Figure 8A). This extremely 
low proliferation background permits the use of BrdU immunostaining as a sensitive 
assay to identify glioma precursors. Based on the time course of tumor development in 
p53
ΔE5-6 
mice (Figure 3B), we studied the brains of 10 mutant mice at ages of 4 to 4.5 
months and found that all of them exhibited abnormal proliferation in the portion of the 
corpus callosum immediately adjacent to the SVZ or RMS (Figures 8B and 8C). 
Specifically, four of these ten p53
ΔE5-6
 brains had small clusters of abnormal proliferating 
cells, three of which were identified in the corpus callosum immediately adjacent to the 
SVZ (Figures 8B’ and 8C’) and one was observed in the olfactory bulb (OB) (see Figure 
13D). By analyzing the serial sections of these four brains, we confirmed that the 
identified proliferating clusters were the only proliferating cell clusters present in these 
brains. Thus, these results indicate that the proliferating clusters constitute the initially 
expanding glioma precursors. Consistently, many cells in the proliferating cell clusters 
exhibited a high degree of nuclear atypia (Figures 8D and 8F, arrows), a property 
reminiscent of malignant glioma cells. In addition to the cells in the adult neurogenic 
niches, glioma precursors were the only cells in mutant brains that expressed Nestin, 
which is never found in the normal corpus callosum (Figures 8E and 8G, top panels). 
Together, we conclude that glioma precursors in most mutant brains were Nestin-
expressing (Nestin
+
) cells located in the corpus callosum immediately adjacent to the 
SVZ. 
 
We went on to determine whether these glioma precursor cells could be marked by 
mutant p53 expression. We found that about 90% of the proliferating cells revealed by 
BrdU staining in the corpus callosum expressed a detectable level of mutant p53
ΔE5-6 
proteins whereas no cells exhibited such expression in the similar areas of normal brains 
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(Figures 8E and 8G, bottom panels). Double-immunofluorescence labeling revealed that 
Nestin and mutant p53
ΔE5-6
 proteins were almost always co-expressed in these cells 
(Figures 8H and 8H’). Furthermore, the p53ΔE5-6-positive cells expressed Olig2, but not 
GFAP, CD133, or markers for lineage-restricted progenitors such as PSA-NCAM (a 
SVZ-A cell marker) or NG2 (a SVZ-OPC cell marker) (Figures 8I, I’, K, and K’ and data 
not shown). We further confirmed that all the Nestin+ cells in the proliferating clusters 
co-expressed Olig2 (Nestin
+
/Olig2
+
, Figure 8J), demonstrating that glioma precursors are 
distinct from Nestin
-
/Olig2
+ 
normal glial progenitors or oligodendrocytes in the corpus 
callosum (Figures 8J and 8J’, arrowheads). Taken together, these results demonstrate that 
the expression of mutant p53
ΔE5-6 
proteins specifically marks glioma precursors, which 
immunohistochemically resemble a subpopulation of transit-amplifying SVZ-C 
progenitor cells (hereafter, SVZ-C*) with the lineage marker expression pattern of 
Nestin
+
/GFAP
-
/Olig2
+
/CD133
-
.  
 
To validate that the initially expanded p53
E5-6
-positive SVZ-C*-like cells are glioma 
precursors, we analyzed 19 grossly healthy p53
E5-6
 mice at older ages (6 to 9 months) 
along with 3 mutant mice with non-CNS sarcomas at 10 to 12 months of age. Of these 22 
grossly normal p53
E5-6
 brains, 15 exhibited no microscopically visible tumor mass. 
Compared to the mutant brains at younger ages, all the brains with no microscopically 
visible tumor (n = 14) analyzed between ages of 6 and 10 months had markedly increased 
numbers of p53
E5-6
-positive cells in the corpus callosum and adjacent areas, indicating a 
continuous expansion of the p53
E5-6
-positive cellular populations during tumor 
development (Figure 9). In all but two of these 14 mutant brains, the p53
E5-6
-positive 
cells were specifically distributed in the forebrain areas that are anatomically 
immediately adjacent to the SVZ-associated areas (Figure 9). Importantly, most, if not 
all, of the continuously expanded p53
E5-6
-positive cells exhibited the similar features of 
glioma precursors identified in younger mutant mice, which include hyperproliferation, 
and expression of Nestin and Olig2, but not GFAP (Figure 9 and data not shown). 
Together, these results suggest that the p53
E5-6
-positive SVZ-C*-like cells in the corpus 
callosum are glioma precursors, whose continuous expansion underlying malignant 
glioma development. These observations also demonstrate that the histologically 
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homogeneous p53
E5-6
-positive SVZ-C*-like glioma precursors can give rise to 
malignant gliomas with a high degree of heterogeneity. 
 
2.3.7 A minor population of adult SVZ cells express mutant p53
ΔE5-6 
proteins 
 
The observations described above raise the possibility that we might be able to identify 
the cell of origin for p53
ΔE5-6
-positive malignant glioma cells by determining which cell 
type in mutant brains first accumulates a detectable level of mutant p53
ΔE5-6
 proteins. To 
test this, we analyzed the brain of 11 2-month-old p53
ΔE5-6 
mice when there was no overt 
abnormality. Immunohistochemical analysis revealed that 1 of these 11 mutant brains 
lacked any p53
ΔE5-6
-positive cells and 5 of them exhibited p53 expression only in one of 
the two brain hemispheres. These results further confirm the notion that accumulation of 
a detectable p53
ΔE5-6 
protein expression is not an inherent property of this mutant allele, 
but rather a tumor-dependent event and hence may be used for identifying incipient 
tumor cells.  
 
In the brains with p53
ΔE5-6 
expression, about 80% of p53
ΔE5-6
- positive cells were 
exclusively identified in the adult SVZ niche, including the anterior (SVZa1 and SVZa2), 
medial (SVZm), and posterior SVZ (Figures 10A and C–F’). Approximately 14% of 
p53
ΔE5-6
-positive cells were found in the RMS (Figures 10B and B’), and a minor 
population was identified in the areas of the corpus callosum just outside the SVZ 
(Figures 10F and 10F’, arrowhead). Similar to the SVZ-B stem cells, all the p53ΔE5-6-
positive cells expressed Nestin and about 90% of those expressed GFAP, but not markers 
for lineage-restricted cells (e.g., PSA-NCAM and Olig2) (Figures 10G–10J’) (Merkle and 
Alvarez-Buylla 2006). A small population of the p53
ΔE5-6
-positive cells in the SVZ were 
GFAP negative, which resemble the transit-amplifying SVZ-C progenitor cells (Figures 
10H and 10H’, arrowhead) (Merkle and Alvarez-Buylla 2006). Together, these results 
suggest that a minor population of the adult SVZ cells, particularly the SVZ-B stem cells 
with the lineage marker expression pattern of Nestin
+
/GFAP
+
/ PSA-NCAM
-
/Olig2
-
/NG2
-
/CD133
-
, are the first and the primary cell types that accumulate a detectable p53
ΔE5-6 
protein expression in the young adult brain. However, it is worth noting that these p53
ΔE5-
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6
-positive cells morphologically were not significantly different from the surrounding 
SVZ cells (Figure 10).  
 
To assess whether these p53
ΔE5-6
-positive SVZ cells manifested other tumor cell 
characteristics, we examined the percentage of proliferating cells in the p53
ΔE5-6
-positive 
and -negative cellular compartments. As revealed by BrdU staining, about 33% of the 
p53
ΔE5-6
-negative stem or progenitor cells were proliferating in the mutant SVZ 
(370/1112, n = 4 brains). Strikingly, nearly 77% of the p53
ΔE5-6
-positive SVZ cells were 
proliferating (36/47; n = 7 brains; p53high versus p53negative; p < 0.0001) (Figures 
10K–L’). Because most of the p53ΔE5-6-positive cells were immunohistochemically 
identified as SVZ-B stem cells that are relatively a quiescent cell population (Merkle and 
Alvarez-Buylla 2006), these results suggest that the expression of mutant p53
ΔE5-6 
proteins may identify a subpopulation of SVZ stem cells as incipient tumor cells in 
otherwise relatively normal brains at this age.  
 
2.3.8 Possible lineage relationship between p53
ΔE5-6
-positive cell populations  
 
The hyperproliferative phenotypes of p53
ΔE5-6
-positive SVZ-B stem cells in the 2-month-
old brain raise the possibility that these cells are the cell of origin for the p53
ΔE5-6
-positive 
SVZ-C*-like glioma precursors identified in the corpus callosum of the older mice. To 
study a possible lineage relationship between these two p53
ΔE5-6
-positive cell populations, 
we quantified the number of p53
ΔE5-6
-positive cells in mutant brains at these two ages. 
Except for the corpus callosum, the number of p53
ΔE5-6
-positive cells in mutant SVZ or 
RMS at 4 months was not significantly increased compared to those at a younger age 
(Figure 11A). However, in contrast to the p53
ΔE5-6
-positive cells that rarely expressed 
Olig2 in the 2-month-old SVZ, over 60% of the p53
ΔE5-6
-positive cells in the SVZ and 
RMS at 4 months acquired Olig2 expression and exhibited the same lineage marker 
expression pattern as that of the p53
ΔE5-6
-positive glioma precursors (Figure 11B). These 
results suggest that similar to normal stem cells, the p53
ΔE5-6
-positive SVZ-B stem cells 
can differentiate into Olig2
+
 SVZ-C* progenitor cells, which may function as an 
intermediate cell type between SVZ-B stem cells and Olig2
+
 SVZ-C*-like glioma 
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precursors. In support of such a transition, most of the proliferating clusters were 
identified in the areas immediately adjacent to the adult SVZ neurogenic niches, some of 
which directly involved the cells in the SVZ (Figures 11C and 11D). More importantly, 
within these proliferating clusters, the p53
ΔE5-6
-positive cells inside and outside the SVZ 
stem cell niche expressed the same lineage markers as the Olig2
+
 SVZ-C* progenitors 
regardless of the positions at the anterior SVZ (Figure 11C) or posterior SVZ (Figure 
11D) (For high magnification view, see Figure 12).  
 
If the p53
ΔE5-6
-positive SVZ-B stem cells give rise to the p53
ΔE5-6
-positive Olig2
+
 SVZ-
C*-like glioma precursors, both should be p53 deficient and thus can be labeled by Cre-
mediated R26R-LacZ expression. To test this, we studied the R26R-LacZ expression in 
the p53
ΔE5-6
 brain. In contrast to most mature astrocytes, all the p53
ΔE5-6
-positive SVZ 
cells expressed -gal in the mutant brains at 2 months, confirming our lineage marker 
analysis that these cells were SVZ stem cells or transit-amplifying progenitors (Figure 
13A). Furthermore, all the p53
ΔE5-6
-positive glioma precursors could also be identified by 
-gal expression within the proliferating clusters located in the corpus callosum of older 
mutant brains (Figures 13B and 13C). These results indicate that both p53
ΔE5-6
-positive 
SVZ-B stem cells and Olig2
+
 SVZ-C*-like glioma precursors are p53 deficient, 
supporting the notion that these neural stem and progenitor-like cells are the precursors 
for p53-deficient malignant glioma cells in this model. Finally, of the mutant brains 
identified with a proliferating cluster, one rare case contained p53
ΔE5-6
-positive glioma 
precursors in the neuronal layers of the OB (Figures 13Da and 13Da’). Despite their 
presence in the migratory destination of neuroblasts, these p53
ΔE5-6
-positive glioma 
precursors expressed the same lineage markers as Olig2
+
 SVZ-C* progenitors (Figures 
13Db–13Dd) and do not express neuronal markers PSA-NCAM, Dcx, or NeuN (data not 
shown).  
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2.4 Discussion 
 
2.4.1 p53 glioma mouse model and clinical implications 
 
This study demonstrates that a single p53 mutation can efficiently induce malignant 
astrocytic glioma formation in mice. Malignant astrocytic gliomas observed in the p53
E5-
6
 model recapitulate genetic, histopathological and molecular features of human GBM 
(Furnari et al., 2007; Louis et al., 2007). In contrast, using the same hGFAP-cre driver as 
described here, we previously showed that the hGFAP-cre+;Nf1
flox/flox
 mice exhibited no 
evidence of tumor formation in the brain, even in the Nf1 heterozygous background, 
despite that Nf1-deficient brain cells had activation of both MAPK and PI3K/Akt 
signaling pathways (Zhu et al., 2005a; Zhu et al., 2005b). In addition, p53 deficiency can 
cooperate with Nf1- or Pten-deficiency to induce malignant astrocytic gliomas in mice 
(Reilly et al., 2000; Zheng et al., 2008; Zhu et al., 2005a). These results reveal a central 
role of p53 deficiency in gliomagenesis.  
 
Compared to existing GEM glioma models that utilize multiple genetic mutations (Reilly 
et al., 2000; Zheng et al., 2008; Zhu et al., 2005a), the uniqueness of our mouse model is 
that we initially only introduce a single p53 mutation in our system, and this allows for 
subsequent stochastic accumulation of additional oncogenic mutations to promote glioma 
formation, which better mimics the “stepwise model” of human tumor development. This 
opens many directions for future studies. For instance, by analyzing glioma cells at 
different stages of glioma development in our p53 model, we could pinpoint the 
sequential activation of oncogenic pathways in an in vivo setting and identify genetic 
pathways that are critical for glioma initiation, progression and maintenance (for detailed 
discussion, see Chapter IV). In addition, since p53
E5-6
 mice provide a sensitive genetic 
background for glioma development, this strain could be used to validate newly identified 
glioma genes and to generate a series of GBM models for preclinical testing of therapies 
that target more specific oncogenic pathways. 
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2.4.2 Possible oncogenic activity of p53
E5-6 
protein 
 
In human cancers, TP53-associated tumors typically contain mis-sense mutations in the 
TP53 gene rather than deletions of TP53. These mutant p53 proteins are highly expressed 
in endstage tumor cells, suggesting possible growth advantage for cells with missense 
mutations. The oncogenic roles of p53 mutants have been examined extensively in cell 
lines. Mouse models that inherit p53 mutations expressed at physiological levels have 
recently been generated to examine the activities of mutant p53 in vivo. Mice with p53 
hotspot point mutations develop tumor spectrums and metastatic phenotypes different 
from those of mice with a p53-null allele. Mechanisms for this gain-of-function potential 
include increased genomic instability, increased cell migration and invasion and 
resistance to proapoptotic signals. Many gain-of-function effects of mutant p53 rely on its 
ability to bind and inactivate the p53 family members p63 and p73 (for review, see 
Moshe Oren and Varda Rotter, 2010).  
 
Although the same p53
ΔE5-6
 mutation is not found in human gliomas, our mouse model 
phenocopies the histological features of human GBM and exhibits high level of p53
 ΔE5-6
 
accumulation in tumor cells.  Previous studies reported no brain tumor formation in p53 
germline knockout mice (Gil-Perotin et al. 2006; Meletis et al. 2006), and p53
-/- 
mice in 
our colony with a similar genetic background to CKO1 and CKO2 mice do not develop 
brain tumors. This raises the question whether p53
 ΔE5-6
 could have oncogenic activities 
similar to p53 missense mutations. The comparison of p53
 ΔE5-6
, p53 hotspot point 
mutation and p53 conditional null allele is an ongoing project in the lab carried out by Dr. 
Yinghua Li. His preliminary data suggest that mutant p53 could facilitate the 
accumulation of DNA damage and promote the survival of cells with DNA damage 
(personal communication).  
 
2.4.3 Cell-of-origin for malignant astrocytic glioma 
 
Murine models have been widely used to study the cell-of-origin of a cancer. Ideally, an 
oncogenic mutation can be targeted into the cells at various developmental stages of a 
specific cell lineage. However, this approach is often limited in the CNS due to a lack of 
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well-defined cell lineage-specific promoters. For example, despite being one of the best 
characterized and the most widely used CNS stem/progenitor cell markers, Nestin is 
expressed not only in multipotent SVZ-B neural stem cells and SVZ-C transit amplifying 
progenitors but also in lineage-restricted SVZ-A neuroblasts in the adult brain (Doetsch 
et al. 1997). Moreover, if a deletion-based mutational strategy (e.g., Cre/loxP system) is 
employed to drive tumor formation, lineage-restricted SVZ-OPC glial progenitors and 
oligodendrocytes, albeit expressing no Nestin, will inherit the same mutations that are 
targeted in Nestin
+
 SVZ-B and C cells (Menn et al. 2006). Thus, with current 
technologies, it is not feasible to specifically target a genetic mutation in the multipotent 
CNS stem/progenitor cells.  
 
Compared to currently available p53-associated glioma models, one feature of our model 
is that mutant p53
ΔE5-6
 proteins are accumulated to a detectable level in all stages of 
glioma cells but not in normal brain cells. Combining proliferation, lineage marker 
expression, and morphological analysis, we used this p53 marker to study glioma 
precursors at the single-cell level during the earliest stages of tumor development. 
Although advanced-stage p53
ΔE5-6
 gliomas are extremely heterogeneous 
histopathologically and molecularly, the p53
ΔE5-6
-positive glioma precursors are 
remarkably homogeneous and exhibit a lineage marker expression pattern reminiscent of 
Olig2
+
 SVZ-C* transitamplifying progenitor cells. Moreover, despite that the p53
ΔE5-6
 
mutation was targeted to diverse CNS cell populations throughout the brain, the p53
ΔE5-6
-
positive glioma precursors were exclusively identified in the two brain areas, corpus 
callosum and OB, which are the migratory destinations of the two differentiated progeny 
of the multipotent SVZ stem cells. Therefore, the lineage marker expression pattern and 
anatomical location of glioma precursors suggest that the p53
ΔE5-6
-positive malignant 
glioma cells may arise from multipotent SVZ stem cells and/or transit-amplifying 
progenitors. Consistently, we demonstrate that the SVZ-B stem cells and SVZ-C 
progenitors are the earliest cell types that accumulate a detectable p53
ΔE5-6
 protein 
expression in the brains of younger mutant mice. Based on these results, we propose a 
model for the role of neural stem cells and transit-amplifying progenitors in p53-mediated 
gliomagenesis: (1) the SVZ-B stem cells are most susceptible to accumulation of 
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oncogenic alterations, as evidenced by high levels of mutant p53
ΔE5-6
 expression; (2) the 
glioma-initiating cells are the Olig2
+
 SVZ-C* progenitor-like cells at the earliest stages of 
tumor development; (Moore et al.) the majority of differentiation-stalled Olig2
+
 SVZ-C* 
progenitor-like cells migrate as SVZ-OPCs to the corpus callosum and a minor 
population migrate as SVZ-A neuroblasts to the RMS and OB; (4) p53
ΔE5-6
-positive SVZ-
C*-like glioma precursors can use diverse cooperative oncogenic alterations to form 
high-grade gliomas with a markedly high degree of heterogeneity (Figure 14).  
 
Although the expression of mutant p53 proteins provides a sensitive tool to monitor 
early-stage glioma cells at the single-cell level, the extremely low number of the p53
ΔE5-6
-
positive cells in mutant brains makes it difficult to establish a definitive lineage 
relationship between the morphologically normal p53
ΔE5-6
-positive neural stem cells and 
glioma precursors. However, we obtain several independent lines of evidence supporting 
a lineage relationship between these two p53
ΔE5-6
-positive cell populations. First, p53
ΔE5-
6
-positive cells in the SVZ are the only cells that exhibit measurable tumor cell 
characteristics, such as hyperproliferation, suggesting that these cells are the incipient 
glioma cells in otherwise normal brains at 2 months. Second, there is an intermediate cell 
type between p53
ΔE5-6
-positive SVZ-B stem cells and Olig2
+
 SVZ-C*-like glioma 
precursors in the 4-month-old mutant brains. These p53
ΔE5-6
-positive intermediate cells 
resemble Olig2
+
 SVZ-C*-like glioma precursors, but are located in the SVZ. 
Consistently, in some proliferating clusters, expansion of the p53
ΔE5-6
-positive SVZ-C*-
like glioma precursors can be found in both the SVZ and corpus callosum. Finally, both 
p53
ΔE5-6
-positive SVZ-B stem cells and Olig2
+
 SVZ-C*-like glioma precursors in the 
corpus callosum can be marked by Cre-mediated R26R-LacZ expression, indicating that 
these two cell populations are genetically p53 deficient.  
  
 47 
 
 
 
Figure 3. Tumorigenesis in CKO1, CKO2 and CKO3 mice. (A) Schematic drawing of the 
genetic configurations of CKO1–3 mice. All the mutant mice analyzed developed brain 
tumors, including those in early stages. The number in parentheses shows the number of 
mutant mice that developed high-grade brain tumors. (B) Survival curves of control and 
CKO1–3 mutant mice. p value was obtained from Kaplan-Meier survival test. (C) The 
percentage of malignant astrocytic gliomas and medulloblastomas observed in the mutant 
mice with high-grade brain tumors. Of note, 1 of 23 CKO1 mice developed both 
malignant glioma and medulloblastoma.  
  
A 
B C 
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Figure 4. The p53
E5-6
 mutant mice develop GBMs (contributed by Yuan Zhu and Jiong 
Yang). 
(A) Serial sections from two representative p53
E5-6
 GBMs (GBM1, 2) were stained with 
H&E (a, a’), anti-GFAP (b, b’), anti-Nestin (c, c’), and anti-Olig2 (d, d’). N, necrosis. 
There are regions of coagulation necrosis (a-d), and pseudopalisades of malignant GBM 
cells adjacent to necrosis (a’-d’). The inset in (a’) shows microvascular proliferation in 
this GBM. (B) High-magnification views of (A) illustrate that both malignant cells and 
nuclei are highly pleomorphic. Many GBM cells have substantial cytoplasm and some 
have eccentric nuclei (a, a’). (C) The p53 E5-6 gliomas exhibit the secondary structures of 
Scherer: accumulation of GFAP-positive tumor cells in the subpial zone of the cerebral 
cortex (a, a’); perivascular satellitosis (arrowheads) (b, b’); and perineuronal satellitosis 
(arrowheads, c, c’). (d, d’) The examples of Olig2+ tumor cells with abnormal mitoses 
(arrowheads). BV, blood vessels. Scale bar, (A, B, Ca-d), 50 m; (Ca’-d’), 25 m. 
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Figure 5. Expression of CD133 in normal brain and malignant astrocytic gliomas.  
(A) Sections of normal brain (a) and three representative gliomas (b, c, d) were stained 
with anti-CD133 (red) and DAPI (blue). (a’ to d’) High magnification views of (a to d) 
illustrates that a subpopulation of glioma cells express CD133 (b, c, d) whereas only 
ependymal cells in normal brain were immunoreactive for CD133 (a). Arrowheads in (b, 
d) point to CD133
+
 malignant glioma cells, many of which were identified around the 
blood vessels (BV, d, d’). The dashed lines in (b) mark the border of the tumor and 
normal brain tissues. Ctx, cerebral cortex; LV or “*”, lateral ventricle; Hp, hippocampus. 
(B) Serial sections from a GBM with focal areas containing a significant number of 
CD133
+
 cells were stained with anti-CD133/anti-p53 (a), anti-CD133/anti-Nestin (b), 
anti-CD133/anti-Olig2 (c), and anti-CD133/anti-CD31 antibodies (d). These sections 
were counterstained with DAPI for labeling tumor nuclei (a’ to d’). Arrows in (d) show 
CD133
+
/CD31
-
 tumor cells and arrowheads point to a minor population of 
CD133
+
/CD31
+
 endothelial cells that surround the blood vessels (*) in the tumor. Scale 
bar, 50 m. 
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Figure 6. Comparison of control and p53
E5-6
 mutant brains at 2 months of age. The 
brains of control and mutant mice at age of 2 months were sagittally sectioned, and 
stained with H&E (A, B and D, E) or anti-BrdU (C, F). Two independent positions (~ 
100  apart) at sagittal planes along the midline to lateral direction were selected to 
compare the size and cellular density of the SVZ between control and mutant brains. (G, 
H, I) and (J, K, L) show the high-magnification views of the SVZ areas in (A, B, C) and 
(D, E, F), respectively. No significant difference in cell density and proliferation was 
identified between control and mutant SVZ. LV, lateral ventricle. Quantification of the 
number of the SVZ cells (M); the density of the SVZ cells (N) that was presented by the 
number of SVZ cells per unit length of the LV; the number of BrdU-positive cells in the 
SVZ and corpus callosum (O); and the density (P) and percentage (Q) of the BrdU-
positive cells in the SVZ between control and mutant brains. Data were presented by 
mean  SEM. P < 0.05 is considered as statistically significant. No detectable 
abnormality was identified in p53
E5-6
 mutant brains at 2 months of age. Scale bar, 100 . 
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Figure 7. p53
ΔE5-6 
brain tumors specifically express a detectable level of mutant p53 
proteins. Representative examples showing p53
ΔE5-6
-positive malignant astrocytic 
gliomas (A and B) and medulloblastomas (D and E). The dashed lines roughly mark the 
border of the tumors and surrounding brain tissues because of the infiltrating nature of 
these tumors (A and D). Arrows in (B) and (E) point to mitotic figures in malignant 
gliomas and nuclear molding in medulloblastomas, respectively. (C) High magnification 
views of a p53
ΔE5-6
-positive multinucleated giant cell (top) and mitotic figure (bottom) in 
a malignant glioma. (F) High magnification views of a p53
ΔE5-6
-positive mitotic figure 
(top) and nuclear molding (bottom) in a medulloblastoma. Ctx, cerebral cortex; Cb, 
cerebellum. (G) Adjacent sections from p53
ΔE5-6
 brain tumors harboring the R26R-LacZ 
transgene were stained with X-gal (a and a’) and anti- -gal/anti-p53 antibodies (b and 
b’). All the p53ΔE5-6-positive tumor cells exhibited -gal expression, indicating p53 
deficiency. (H) A small population of tumor cells expressed little or no -gal, but had 
high levels of GFAP expression (a). Tumor nuclei were counterstained with DAPI (a’). 
Scale bars, 50 . 
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Figure 8. Expression of mutant p53
ΔE5-6 
proteins identifies the earliest-stage glioma cells.  
(A–C) BrdU staining was performed on sections from age-matched control (A) and two 
representative p53
ΔE5-6
 brains that contain proliferation clusters (marked by dashed lines) 
in the corpus callosum adjacent to the anterior SVZ (B and B’ , Mut-1) and to the 
posterior SVZ (C and C’ , Mut-2), respectively. Arrows in (B) through (C’) point to 
abnormal proliferating cells in the SVZ. LV, lateral ventricle. (D) The H&E-stained 
sections from similar areas of control brain (a–c) and the proliferating cluster of Mut-1 
brain (d–f) were imaged and shown at three different magnifications. (E) Adjacent 
sections of the control and Mut-1 brains (D) were stained with anti-Nestin and anti-p53 
antibodies. (F and G) Similar morphological and immunohistochemical analyses of (D 
and E) were performed on control brain and a proliferating cluster of Mut-2 brain. 
Arrows in (D) and (F) point to abnormal cells with atypical nuclei in mutant brains. 
Arrows in (E) and (G) point to Nestin
+
 and p53
+
 cells in mutant brains. Asterisk in (D) to 
(G) denotes the lateral ventricle. The dashed lines in (D) and (E) and in (F) mark the 
border of the SVZ and corpus callosum and the border of the corpus callosum and 
surrounding tissues, respectively. Ctx, cerebral cortex; CC, corpus callosum; Hp, 
hippocampus. (H–K) The sections from the proliferating clusters were stained with anti-
p53/anti-Nestin (H) and DAPI (H’); anti-p53/anti-Olig2 (I) and DAPI (I’); anti-
Nestin/anti-Olig2 (J) and DAPI (J’); anti-p53/ anti-GFAP (K) and DAPI (K’). Arrows in 
(H)–(K) point to p53ΔE5-6-positive cells. Arrowheads in (J) and (J’) point to Nestin-
/Olig2
+
 cells that are most likely normal glial progenitors or oligodendrocytes. 
Arrowheads in (K) and (K’) point to the p53-negative nuclei of GFAP+ cells. The inset in 
(H) shows atypical nuclei of two p53
+
/Nestin
+
 cells (arrowheads). Scale bars, 25 .  
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Figure 9. Continuous expansion of the p53
E5-6
-positive cells underlies tumor 
development (Contributed by Yuan Zhu).  
The images taken at two magnifications (A, B) show p53
E5-6
-positive glioma cells from 
one representative p53
E5-6
 mutant brain in the early stages of tumor development. The 
dashed lines in (A, B) mark the p53
E5-6
-positive early lesions. (C) Adjacent sections of 
the mutant brain with an early lesion (A, B) were stained with anti-p53 (a, e, i), anti-Ki67 
(b, f, j), anti-Nestin (c, g, k), and anti-Olig2 (d, h, l). Arrows in (a to d) mark the length of 
the RMS in these images. RMS, rostral migratory stream; Ctx, cerebral cortex; CC, 
corpus callosum. “*” marks lateral ventricle. (e, i), (f, j), (g, k), and (h, l) are the high-
magnification views of the boxed areas marked in (a), (b), (c), and (d), respectively. Scale 
bar, 100 m. 
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Figure 10. A minor population of SVZ stem and progenitor cells exhibits a detectable 
mutant p53
ΔE5-6 
protein expression in young adult brain.  
(A) Schematic drawing of the sagittal plane of the adult mouse brain. Except for the 
dentate gyrus of the hippocampus, all the Nestin+ cells in the adult brain are restrictively 
located in the SVZ and RMS and colored in gray. Different parts of the RMS and SVZ 
are shown in five designated boxed areas. At 2 months of age, most of the p53
ΔE5-6
-
positive cells (B to F’, arrows) are identified in the adult neurogenic areas, which include 
the RMS (B and B’), the anterior SVZ (C and C’, SVZa1; and D and D’, SVZa2), medial 
SVZ (E and E’ , SVZm), and posterior SVZ (F and F’ , SVZp). The arrowhead in (F) and 
(F’) points to a p53ΔE5-6- positive cell in the adjacent corpus callosum. Sections of the 
anterior SVZ from 2-month-old p53
ΔE5-6
 mice were stained by anti-p53/anti-Nestin (G) 
and DAPI (G’); anti-p53/anti-GFAP (H) and DAPI (H’); anti-p53/anti-PSA-NCAM (I) 
and DAPI (I’); anti-p53/anti-Olig2 (J) and DAPI (J’); and antip53/ anti-BrdU (K and L) 
and DAPI (K’ and L’). Arrows in (G)–(L’) point to the p53ΔE5-6-positive cells in the SVZ. 
An arrowhead in (H) and (H’) points to a p53ΔE5-6-positive/GFAP-negative progenitor 
cell. The insets in (G) and (H) show the high-magnification views of the p53
ΔE5-6
-positive 
cells expressing Nestin and GFAP, respectively. Arrowheads in (L) and (L’) point to a 
p53
ΔE5-6
-positive cells during mitosis. aLV and pLV, anterior and posterior lateral 
ventricle; (*), lateral ventricle. Scale bars, 25 . 
  
 60 
 
 
 61 
 
Figure 11. A possible lineage relationship between p53ΔE5-6-positive SVZ-B stem cells 
and SVZ-C* progenitor-like glioma precursors.  
(A)The quantification of p53
ΔE5-6
-positive cells in brains of mutant mice at 2 and 4 
months. Each dot represents the quantification from each individual brain. ****p < 
0.0001. (B) Sections from a 4-month-old mutant brain were stained with anti-p53/anti-
Olig2 (a) and DAPI (a’) and anti-p53/anti-Nestin (b) and DAPI (b’ ), in which arrows 
point to p53
ΔE5-6
-positive cells in the SVZ. (C) One representative mutant brain has 
proliferating clusters (marked by dashed lines) in the corpus callosum directly associated 
with the anterior SVZ (a and a’). Sections from this proliferating cluster were stained 
with anti-p53/anti-Ki67 (b) and DAPI (b’); anti-p53/anti-Nestin (c) and DAPI (c’); anti-
p53/anti-Olig2 (d) and DAPI (d’); and anti-p53/anti-GFAP (e) and DAPI (e’). Arrows 
and arrowheads in (d) and (d’) point to p53ΔE5-6-positive Olig2+ SVZ-C*-like glioma 
precursors located in the corpus callosum and SVZ, respectively. (D) Adjacent sections 
from one proliferating cluster identified in the posterior SVZ (a) were stained with anti-
p53 (b and b’), anti-Nestin (c), and anti-Olig2 antibodies (d). Arrows in (b) to (d) point to 
p53
ΔE5-6
-positive glioma precursors inside the SVZ. The inset in (a) shows the high-
magnification view of proliferating p53
ΔE5-6
-positive glioma precursors in the SVZ 
(BrdU[green]/p53[red]). aLV and pLV, anterior and posterior lateral ventricle; *, lateral 
ventricle. Scale bars: (Ca, Ca’ , and Da) 100  ; (B, Cb–Ce’ , and Db–Dd) 50 . 
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Figure 12. Lineage marker expression of p53
E5-6
-positive glioma precursors in the 
corpus callosum and SVZ. 
This figure shows the high-magnification views of the images shown in Figure 11C, 
which has a proliferating cluster involving both the corpus callosum and SVZ. Arrows 
and arrowheads in (A to E) point to morphologically similar p53
E5-6
-positive glioma 
precursors in the corpus callosum and SVZ, respectively. These proliferating p53
E5-6
-
positive glioma precursors exhibit the lineage marker expression pattern of 
Nestin
+
/Olig2
+
/GFAP
-
/PSA-NCAM
-
, resembling SVZ-C* transit-amplifying progenitors. 
The dashed lines mark the SVZ. LV, lateral ventricle. Scale bar, 50 . 
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Figure 13. p53
ΔE5-6
-positive SVZ stem cells and glioma precursors express -gal.  
(A) Sections from 2-month-old p53
ΔE5-6
 brains with the R26R-LacZ transgene were 
stained with anti-p53/anti- -gal antibodies (a–c) and were counterstained with DAPI for 
labeling nuclei (a’–c’). All the p53ΔE5-6-positive cells (arrows) at this age express b-gal of 
the R26R-LacZ regardless of their location in the RMS or anterior or medial SVZ (SVZa 
and SVZm). The insets in (a)–(c) show the high-magnification views of p53/ -gal 
double-positive cells. (B) Two representative proliferating clusters identified in the 
corpus callosum adjacent to either the junction of RMS and SVZa (a and a’) or SVZa (b 
and b’) were sectioned and stained with anti-p53/anti- -gal antibodies. Within these 
proliferating clusters, all the p53
ΔE5-6
-positive glioma precursors in the corpus callosum 
(arrows) and SVZ (arrowheads) express -gal of the R26R-LacZ. (C) Adjacent sections 
of a proliferating cluster were stained by BrdU/DAPI staining (a and a’) and X-gal (b and 
c). (b’ and c’) High-magnification views of the boxed areas shown in (b) and (c) reveal a 
group of -gal-positive cells with atypical nuclei (arrows). LV, lateral ventricle. (D) A 
mutant brain contains p53
ΔE5-6
-positive glioma precursors in the OB (a and a’). Sections 
from this proliferating cluster were stained with anti-p53/anti-Nestin (b) and DAPI (b’), 
anti-Nestin/anti-Olig2/DAPI (c), and anti-p53/anti-GFAP/DAPI (d). Arrows in (b) and 
(b’) point to p53ΔE5-6-positive cells.  
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Figure 14. Proposed model for p53-mediated gliomagenesis. 
(A) A model summarizes p53-mediated gliomagenesis (See main text).  
(B) The anatomical location of p53
ΔE5-6
-positive early-stage glioma precursors during 
tumor development. Red dots, p53
ΔE5-6
-positive SVZ-B stem cells; blue dots, p53ΔE5-6-
positive SVZ-C*-like glioma precursors. Scale bars, 50 . 
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Chapter III Nf1 regulates fate-specification of neural progenitor cells in 
developing and adult brain  
 
3.1 Introduction 
 
Von Recklinghausen’s neurofibromatosis type 1 (NF1) is a familiar cancer syndrome that 
afflicts 1 in 3500 individuals worldwide (Friedman and Riccardi 1999). The hallmark 
feature of NF1 is the development of benign peripheral nerve sheath tumors termed 
neurofibromas in the peripheral nervous system (PNS) (Friedman and Riccardi 1999; 
Cichowski and Jacks 2001). In the central nervous system (CNS), NF1 deficiency causes 
tumor-related and non-tumor-related complications. Approximately15% to 20% of NF1 
patients develop low-grade astrocytic tumors (gliomas) predominantly involving the optic 
pathway and the incidence of high-grade malignant astrocytoma development in the brain 
is increased by more than 5 fold compared to the general population (Listernick et al. 
1997; Listernick et al. 1999). In addition, NF1 patient brains exhibit various structural 
defects including astrogliosis, megalencephaly (abnormal enlarged brain) and increased 
white matter (corpus callosum, CC) volume (Moore et al. 2000). The most common 
complication, however, is cognitive deficits and learning disabilities. About 40%-60% of 
NF1 children exhibit varying degrees of cognitive deficits associated with lower IQ 
scores (Hyman et al. 2005). The structural and functional defects in NF1 patients are 
closely related. Enlarged corpus callosum in NF1 children is found to be associated with 
severe forms of cognitive deficits and may serve as an early structural marker for the 
children at risk of learning disabilities (Dubovsky et al. 2001).  
 
The gene responsible for this disease, NF1, encodes the protein neurofibromin, which 
contains a functional domain that shares homology with Ras GTPase activating protein 
(GAP) family members. Like other GAPs, neurofibromin negatively regulates the 
Ras/ERK signaling cascade by activating Ras GTPase and accelerating the 
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transformation of Ras from its active, GTP-bound form to inactive GDP-bound form 
(Ballester et al. 1990). NF1 belongs to a group of related developmental disorders 
collectively termed “neuro-cardio-facial-cutaneous (NCFC) syndromes, all of which are 
linked to the dysregulation of the Ras/ERK signaling pathway (Rodriguez-Viciana et al. 
2006). 
 
Since NF1 patients are heterozygous for Nf1, such broad spectrum of neurological 
deficits could be caused by two possible genetic mechanisms. The first possibility is that 
a single copy of the normal gene does not produce enough proteins to carry out normal 
function compared to two copies of the wildtype gene (haploinsufficiency). Consistently, 
Cui et al. reported that an Nf1 heterozygous null mutation increases GABA release in the 
hippocampus, which in turn impairs hippocampal long-term potentiation (LTP) and 
learning (Cui et al. 2008). Additionally, pharmacological downregulation of ERK 
signaling reverses this phenotype. However, there is no evidence that NF1-associated 
brain abnormalities are solely caused by haploinsufficiency. For instance, brains of Nf1 
heterozygous mice do not exhibit the structural defects found in NF1 patients. The second 
possibility is that a subset of cells stochastically lose the wildtype copy of NF1 through a 
genetic event termed loss of heterozygousity (LOH), and the resultant NF1-deficient cells 
fail to produce neurofibromin. In particular, in the event that LOH occurs in neural 
stem/progenitor cells during development, NF1-deficiency would be passed down to all 
the derivative progeny, potentially causing structural defects due to wide-spread NF1-
deficiency altering mature cell function. Alternatively, NF1-deficiency may also have a 
direct effect on neural stem/progenitor cells in their ability to produce differentiated cells. 
Therefore, investigating the role of NF1 in neural stem/progenitor cells could provide us 
a new angle to understand the disease mechanism, which could lay the foundation for 
developing novel therapies.  
 
Neural stem cells are a unique population of cells in the CNS, characterized by their 
ability to renew themselves via mitotic cell division (self-renewal) and differentiate into 
both neurons and glia (multipotency). In the developing brain, neuroepithelial cells give 
rise to brain lipid binding protein (BLBP)-expressing radial glial cells in the ventricular 
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zone (VZ), which function as the developing neural stem cells (Campbell and Gotz 
2002). Radial glial cells divide asymmetrically to directly generate neurons or indirectly 
produce neurons through neural intermediate progenitor cells (nIPCs). In late stages of 
embryonic development, oligodendrocytes are also derived from radial glial cells through 
intermediate progenitor cells that generate oligodendrocytes (oIPCs). At perinatal stage, 
the majority of radial glial cells transform into astrocytes while the rest of them continue 
to simultaneously generate neurons and oligodendrocytes through respective IPCs 
(Kriegstein and Alvarez-Buylla 2009). In the adult brain, multipotent neural stem and 
progenitor cells are spatially restricted in two stem cell niches: the subventricular zone 
(SVZ) of the lateral ventricle and the subgranular layer (SGL) of the hippocampal dentate 
gyrus (Merkle and Alvarez-Buylla 2006). SVZ NSCs, also called type B cells, are glial 
fibrillary acidic protein (GFAP)-expressing astrocytic cells derived from neonatal radial 
glial cells. Type B cells give rise to transit amplifying intermediate progenitor cells (also 
known as Type C cells), which are highly proliferative and generate neural progenitor 
cells (neuroblasts, Type A Cells) and oligodendrocytes precursor cells (OPCs). 
Neuroblasts migrate tangentially along rostral migratory stream (RMS), a neuronal 
migratory path ensheathed by glial cells, until they reach the olfactory bulb (OB) and 
differentiate into mature interneurons. OPCs, on the other hand, migrate radially into the 
overlying corpus callosum and become oligodendrocytes. Notably, gliogenesis in adult 
brain is significant reduced compared to the developing brain and the majority of SVZ 
progenitor cells (95%-97%) are later committed to the neuronal fate (Hack et al. 2005; 
Menn et al. 2006). Regulation of neuron-glial switch requires the interplay of a number of 
transcription factors. Homeobox transcription factors Dlx1 and Dlx2 have been shown to 
repress OPC production and favor neuronal fate (Petryniak et al. 2007), while basic helix-
loop-helix (bHLH) transcriptional repressor Olig2 plays an essential role in the lineage 
specification of progenitor cells into oligodendrocytes and astrocytes (Marshall et al. 
2005). However, the fate specification of neural progenitor cells remain incompletely 
understood.  
 
A number of studies in murine models have provided significant insights into how Nf1 
could regulate neural stem/progenitor cell function in the developing brain. In Nf1 
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germline knockout mice, Dasgupta et al. found increased proliferation and self-renewal 
of Nf1-deficient embryonic neural stem cells through an in vitro neurosphere assay 
(Dasgupta and Gutmann 2005). In conditional knockout mouse models that target NSCs, 
Zhu et al. used hGFAP-Cre to target Nf1 mutation into radial glial cells during 
development and found global astrogliosis and increased glial progenitor cells in the 
brain (Zhu et al. 2005). This was confirmed by a similar study from Hegedus et al. using 
BLBP-Cre, who also reported an abnormal increase of glial cells in Nf1-deficient 
developing brain, as well as neurite development defects (Hegedus et al. 2007). The 
underlying mechanisms of increased glial cell production, whether this represents glial 
lineage hyperproliferation or neuron-glia fate-specification switch, as well as how these 
developmental abnormalities could lead to the structural and functional defects in adult 
brains remain unclear.  
 
In this study, by utilizing both conditional and inducible knockout mouse models, we 
analyzed the impact of Nf1-deficiency on neural stem/progenitor cells at different time 
points in developing and adult brain. We demonstrated that neurofibromin suppresses 
gliogenesis by inhibiting Olig2 expression specifically in neonatal and adult SVZ transit-
amplifying progenitors in an ERK-dependent manner. The fate switch in these progenitor 
cell population leads to increased gliogenesis at the expense of neurogenesis, which 
contributes to a structural brain defect associated with learning deficits. Importantly, Nf1-
associated developmental defects could be rescued by treatment during neonatal stages 
with a MEK inhibitor which prevents the activation of ERK. Thus, our finding 
establishes the significant role of Nf1 in the regulation of neuron-glial fate specification 
and has clinical implications for the treatment of NF1-associated learning disabilities. 
 
3.2 Material and methods 
 
3.2.1 Control and mutant mice 
 
The control mice used in this study are a pool of phenotypically indistinguishable mice 
with genotypes Nf1
flox/flox
; Nf1
flox/+
; and hGFAP-cre+; Nf1
flox/+
. The mutant Nf1
hGFAP
KO 
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mice include both hGFAP-cre+; Nf1flox/-; and hGFAP-cre+; Nf1
flox/flox
; which have 
similar phenotypes. All mice in this study were cared for according to the guidelines that 
were approved by the Animal Care and Use Committees of the University of Michigan at 
Ann Arbor. 
 
3.2.2 Tissue preparation 
 
Mice were perfused with 4% paraformaldehyde (PFA) and brains were dissected, 
followed by overnight post-fixation in 4% PFA at 4 ºC. Brains were divided into two 
hemispheres along the midline and each hemisphere was processed for either paraffin-
embedded or cryostat sections.  
 
3.2.3 Histological analysis 
 
Serial sections were sagittally prepared at 5 μm for paraffin sections or 10~14 μm for 
cryostat sections. Slides from histologically comparable positions were stained by H&E. 
And adjacent sections were subjected to immunohistochemical or immunofluorescence 
analysis. For adult brains in particular, at least three independent positions (position 1-3) 
that contain SVZ/RMS were selected for quantification. Each plane is approximately 100 
μm apart at sagittal planes along the midline to lateral direction and was determined by 
histological criteria (P1: oval lateral ventricle with intact RMS; P2: triangular lateral 
ventricle with intact RMS; P3: triangular lateral ventricle with non-intact RMS) (Figure 
23). At least three mutants and three controls were used for each analysis.  
 
3.2.4 LacZ/ -gal staining 
 
The R26R-LacZ transgene was used as a reporter to indicate Cre-mediated recombination 
in different mouse strains. Dissected tissues were post-fixed in PFA for 2 hours and 
transferred to 30% sucrose for overnight dehydration. Dehydrated brains were embedded 
in OCT and frozen on dry ice as cryostat blocks. Cryosections were cut at 10-14 μm and 
subjected to X-gal staining for 1 hour to overnight depending on the signal intensity. X-
 76 
 
gal stained sections were then counterstained by nuclear fast red for 5 minutes to 
visualize the nuclei.   
 
LacZ staining solution: 1) Solution A: 5mM potassium ferricyanide crystalline; 5mM 
Potassium ferricyanide trihydrate; 2mM Magnesium Chloride in 1X Phosphate buffered 
saline (PBS) (stored at 4
o
C, protected from light, then warm to 37
o
C prior to using); 2) X-
gal stock solution (40X):40 mg/ml in DMSO (100 mg in 2.5 ml DMSO) (stored at -20
o
C, 
protected from light); 3) permeabilization solution: 10% NP-40; 2.5% sodium 
deoxycholate; 4) final X-gal solution: dilute X-gal stock solution 1:40 in Solution A. Add 
NP-40 (final concentration: 0.02%) and sodium deoxycholate (final concentration: 
0.01%). All reagents were from Sigma. 
 
Co-localization of -gal expressing cells with other lineage markers was obtained by 
double immunofluorescence (See below).  
 
3.2.5 Immunohistochemistry/immunofluorescence 
 
Paraffin sections were deparaffinized through Xylene, 100% ethanol, 95% ethanol, 50% 
ethanol and 30% ethanol and rehydrated in distilled water. Antigen retrieval was 
performed with Retrieve-all antigen retrieval solution from Signet. Cryosections do not 
require deparaffinization or antigen retrieval steps and were directly fixed in 4% PFA for 
15 minutes. Sections were then permeablized by 0.3% Triton-X (Sigma) solution for 20 
minutes and blocked for 1 hour with 1.5% normal goat/horse/donkey serum (Sigma) 
depending on the secondary antibody to be used (e.g. use goat serum for blocking if the 
secondary antibody is from goat). Slides were put in humidified chamber and incubated 
in primary antibodies dissolved in the blocking solution at 4
o
C overnight. The 
visualization of primary antibodies was performed with either a horseradish peroxidase 
system using a diaminobenzidine-based (DAB) peroxidase substrate (Vectastain ABC kit, 
Vector) or immunofluorescence by using Cy2 (or Alexa 488), Cy3 (or Alexa 555) and 
Cy5 (Alexa 647)-conjugated secondary antibodies at 1:200 dilution for 1 hour incubation 
(Cy2/Cy3/Cy5, Jackson Immunoresearch; Alexa 488/555/647, Invitrogen). Slides were 
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washed in between the steps with 1X PBS. The dilutions of primary antibodies were: 
Nestin (1:100, mouse, Chemicon), GFAP (1:2000, mouse, BD Pharmingen), GFAP 
(1:2000, mouse, DAKO),  Ascl1(Mash1, 1:200, mouse, BD Pharmingen), Dlx2 (1:2000, 
guinea pig, a kind gift from Dr. K.Yoshikawa), Dcx (1:2000, rabbit, Abcam), Dcx 
(1:2000, guinea pig, Chemicon), Pax6 (1:500, rabbit, Covance), PSA-NCAM (1:1000, 
mouse, Chemicon), NeuN (1:400, mouse, Chemicon), TH (1:1000, rabbit, Abcam), Olig2 
(1:2000, rabbit, Millipore), Olig2 (1:10000, guinea pig, a kind gift from Dr. B. Novitch), 
NG2 (1:200, mouse, Millipore), MBP (1:500, rat, Chemicon), BrdU (1:1000, rat, 
Abcam), Ki-67 (1:500, mouse, BD Pharmingen), -gal (1:1000, rabbit, 5 prime-3 prime) , 
-gal (1:1000, goat, AbD Serotec), p-ERK (1:100, rabbit, Cell Signaling), p-S6 (1:1000, 
rabbit, Cell Signaling), Cleaved Caspase 3 (1:500, rabbit, Cell signaling). Sections were 
examined under either a light or a fluorescence microscope (Olympus).  
 
3.2.6 BrdU Assay 
 
For BrdU assays, mutant and control littermates were pulsed with BrdU five times a day 
at 2-hour intervals. The dose of BrdU was 50μg/g (gram, body weight). For BrdU 
proliferation assay, mice were perfused with 4% PFA 2 hours after the last pulse. For 
BrdU differentiation assay, mice were sacrificed 30 days after the initial pulse. In both 
cases, brains were dissected and processed for either paraffin-embedded or cryostat 
sections. BrdU is a thymidine (T) analog. The staining for BrdU followed the regular 
immunofluorescence or immunohistochemistry protocol described above, except that 
after the Triton-X permeablization step, sliders were incubated in 2N HCl for 30 minutes 
followed by 0.1 M sodium borate for 20 minutes to denature the DNA.  
When colocalizing BrdU with other protein markers through immunofluorescence 
labeling, sometimes the HCl treatment may have a negative impact on the staining quality 
of the other antigens (i.e. Olig2). To solve this problem, I used a 3-day staining procedure 
to first visualize the protein marker through regular immunofluorescence protocol. The 
stained slides were fixed in 4% PFA for 15 minutes, followed by the HCl/sodium borate 
treatment, and then subjected to anti-BrdU antibody incubation at 4
o
C overnight. BrdU 
was visualized by fluorophore-conjugate secondary antibodies on the third day.  
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3.2.7 Tamoxifen administration in Nestin-Cre
ER
 inducible system 
 
Tamoxifen was dissolved in corned oil and stored at -20
o
C, and the concentration for TM 
stocks is 20mg/ml. Mice carrying the Nestin-Cre
ER 
transgene were administered with 
tamoxifen through intraperitoneal. injection at a dosage of 5mg per 40g body weight. 
Induction at P0.5 or P8 only required a single TM injection, while induction in young 
adult required daily TM injections for 5 constitutive days from P26-P30 (For more 
details, see main text).  
 
3.2.8 MEK inhibitor treatment  
 
MEK inhibitor PD0325901 (Selleck) was formulated in 0.5% hydroxypropyl methyl-
cellulose plus 0.2% Tween 80 (Sigma) and administered by oral gavage and IP injections 
at the dosage of 5 mg/kg body weight every day from P0.5-P18. Mice that receive vehicle 
(0.5% hydroxypropyl methyl-cellulose plus 0.2% Tween 80) treatment were used as 
controls.   
 
3.2.9 Neurosphere Cell culture (adapted from Sean Morrison lab protocol, by Anna 
Molofsky) 
 
SVZ cells were dissected and dissociated from adult brains and was cultured in self-
renewal medium. To dissect SVZ tissue, mouse brains were cut coronally at 3 different 
positions (the underside facing up): one to cut off the olfactory bulb, one just rostral to 
the optic chiasm, and one just before the hypothalamus. Slices were placed in Opti-MEM 
(Gibico), and SVZ was dissected out with fine forceps under the dissecting scope. The 
SVZ is the almost translucent, fine grey unmyelinated material that lines that lateral side 
of the lateral ventricle. Dissected pieces of SVZ were placed in 1 ml fresh Opti-MEM, 
and minced with fine forceps.  The minced tissue was then transferred into a sterile 
conical tube, and dissociated in 3 ml pre-warmed dissociation medium (Solution C) for 
20 min at 37°C. 3 ml of trypsin inhibitor solution plus 30 ul of Solution A (DNase) were 
added to the solution to quench trypsin activity.  The mixture was spinned at 100xg for 
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10 minutes, and the pellet was resuspended in 400-500 μl of staining medium. The 
resultant solution was filtered through a 45 micron nylon mesh to get rid of debris and 
un-dissociated tissue. Cell density was quantified on a cell-counter plate and 2000 
cells/well were plated to 6-well ultra-low binding plates for primary neurosphere culture. 
Each well contains 1.5 ml self-renewal medium. Neurosphere cultures were grown 10 
days before analysis. The number and size of neurospheres were quantified and 
compared. To self-renew neurospheres, single 10-day old neurospheres were picked by 
pipette, centrifuged, and then mechanically dissociated and replated. 10 days into the 
secondary culture, we quantified self-renewal as the number of secondary neurospheres 
generated per primary neurosphere (2°NS/1°NS). Only spheres greater than 40 microns 
should be counted. 
 
Self-renewal medium (100 ml): 1) 54 ml DMEM-low + 32 ml Neurobasal medium 
(Gibco); 2) 10 ml Chick embryo extract (lab preparation); 3)1 ml Penn/Strep (10,000 
U/ml); 4) 1 ml N-2 Supplement (Gibco); 5) 2 ml B-27 Supplement (Gibco); 6) 100 μl of 
50mM 2-mercaptoethanol stock (50uM final concentration; Sigma); 7) 80 ul FGF (25 
ug/ml stock ) (final concentration of 20ng/ml); 8) 80 ul EGF (25 μg/ml stock) (20ng/ml 
final concentration).  
 
Solution C (200mls): 2 ml of 1 M HEPES + 192 μl of 0.5 M EDTA in 200 ml Ca/Mg free 
HBSS (Gibco). Adjust pH to 7.6. Dissolve 50mg Trypsin (Calbiochem) + 2mg DNase 1 
(Boehringer) in above solution. Filter sterilize. Store 10 ml aliquots at -80 C.  
Solution A: 10 mg DNase 1 (Boehringer) in 10 ml HBSS-free (Gibco).  Filter Sterilize, 
store at –20 C in 0.5 ml single-use aliquots. 
 
Trypsin Inhibitor solution: 100 ml of staining medium, with 14mg of trypsin inhibitor 
(Sigma) added, sterile filter. 
 
 
 
 
 80 
 
3.2.10 Quantification and statistical analysis  
 
Anatomically comparable sections from control and mutant brains were visualized under 
40X magnification using an Olympus BX51 microscope. Images were captured and 
subjected to double-blinded counting. Lengths, areas and the number of cells were 
quantified by the NIH software, ImageJ. Control and mutant groups were compared, and 
statistical analysis was carried out using two-tailed Student’s t-test. p < 0.05 was 
considered to be statistically significant. Comparisons among more than two groups (i.e. 
wildtype, heterozygous and mutant) were based on Anova test. To compare the 
proportions of certain types of cells from two independent cell populations (i.e. 
percentage of Olig2
+
 cells in Ascl1
+ 
cells in control and mutant SVZ) and to determine if 
they are statistically different from one another, the number of specific cell types was 
quantified and subjected to Chi-Square test. p < 0.05 was considered to be statistically 
significant.  
 
3.3 Results 
 
3.3.1 Nf1 suppresses Olig2 expression in neonatal SVZ stem and progenitor cells 
 
To investigate the role of Nf1 in neural stem and progenitor cells in the subventricular 
zone (SVZ), we targeted an Nf1 mutation into radial glia at embryonic day 12.5 (E12.5) 
by using a Cre transgenic strain (Zhuo et al. 2001) under the control of the human glial 
fibrillary acidic protein promoter (hGFAP-cre). During embryonic development, radial 
glia are the primary neural stem cell populations, which give rise to neurons, glia as well 
as adult neural stem cells in the SVZ (Merkle and Alvarez-Buylla 2006). Thus, this gene 
targeting strategy permits us to assess the phenotypic consequence of Nf1 inactivation in 
both developing and adult SVZ stem cells and their progeny. To confirm the specificity 
of this transgenic targeting strategy, we crossed hGFAP-cre+ mice to a mouse strain 
carrying Rosa26-LacZ reporter, whose expression indicates the presence of Cre-mediated 
recombination (Soriano 1999). Nearly all the SVZ stem and progenitor cells as well as 
Olig2-expressing progenitors and oligodendrocytes in the corpus callosum of the 
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resulting mice could be readily labeled by -galactosidase ( -gal) expressed from the 
R26R-LacZ (Figures 15A and 15B). Although R26R-LacZ does not efficiently report 
Cre-mediated recombination in most astrocytes in the forebrain (Figure 15B b,b’), all the 
GFAP-expressing astrocyte express hGFAP-cre transgene (Figure 15B c, c’). 
 
For simplicity, Nf1 mutant mice with the genotypes of hGFAP-cre+;Nf1
flox/flox
 and 
hGFAP-cre+; Nf1
flox/- 
were referred to as Nf1
hGFAP
KO (Nf1
-/-
) while age-matched 
littermates with genotypes of hGFAP-cre+;Nf1
flox/+
 (Nf1
+/-
),  hGFAP-cre-;Nf1
flox/+
 (Nf1
+/+
) 
and hGFAP-cre-;Nf1
flox/flox
 (Nf1
+/+
) were used for control groups, as loss of one Nf1 allele 
exhibited no significant in vivo phenotypes in the brain. First, to determine whether Nf1 
inactivation has any phenotypic consequence during embryonic development, we 
performed histological analysis on brains of newborn mice at postnatal day 0.5 (P0.5). 
We measured the size and cell number of the anterior SVZ (SVZa) and more posterior 
SVZ that includes a more significant contribution of stem cells in the ventricular zone 
(referred to as VZ/SVZ). No significant difference was identified in the SVZa and 
VZ/SVZ between control and Nf1
hGFAP
KO neonatal brains (Figure 16Aa, a’, B, C). 
Furthermore, the overall rate of proliferation and apoptosis in the SVZ was not 
significantly altered, evidenced by Ki67 and Cleaved Caspase 3 expression (Figure 16E, 
F, H). These results demonstrate that Nf1 has a dispensable role in overt embryonic SVZ 
development. However, compared to controls, one striking phenotype observed was an 
over 2-fold increase in the number of cells that expressed a basic helix-loop-helix 
(bHLH) transcription factor Olig2 in the Nf1
hGFAP
KO SVZ (Figure 16Ab, b’; Figure 2D). 
No increase in the percentage of Ki67
+
 proliferating cells in the Olig2
+
 lineage was 
observed, indicating that Olig2
+ 
cells were not hyperproliferative in the Nf1
hGFAP
KO SVZ 
(Figure 16E, G). Given that Nf1
hGFAP
KO SVZ had a similar number of cells and 
comparable apoptotic rate to controls, we investigated the possibility of whether Nf1 
inactivation leads to ectopic Olig2 expression in SVZ stem and progenitor cells. Previous 
studies showed that in the embryonic SVZ, Ascl1
+
 progenitor cells selectively express the 
Dlx homeodomain transcription factors and Olig2, which direct neural precursors to 
undergo neuronal versus glial differentiation, respectively (Marshall et al. 2005; 
Petryniak et al. 2007). Thus, we performed Olig2/Dlx2/Ascl1 triple immunofluorescent 
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labeling to determine the lineage specification of Asc11
+ 
progenitors. Although the 
number of Ascl1
+
 cells was comparable in mutant and control SVZ (p = 0.104), the 
percentage of Olig2-expressing cells in Ascl1
+
 progenitors (Olig2
+
/Ascl1
+
) was 
dramatically increased from 16.7% in controls to 38.7% in mutants (p < 0.0001, Figure 
16I, J, K). Accordingly, the Dlx2
+
/Ascl1
+
 progenitor populations were reduced from 
82.5% to 65.3% (p < 0.0001, Figure 16I, J, K). Moreover, the percentage of Ascl1
+
 cells 
that expressed both Olig2 and Dlx2 was increased from 5.5% to 11.7% (p = 0.001, Figure 
16Ib, b’, J, K). Taken together, these observations demonstrate that Nf1 suppresses Olig2 
expression in the neonatal Ascl1
+
 SVZ progenitors, which otherwise would acquire Dlx2 
expression and differentiate into neurons.  
 
Unlike the SVZa, neural stem/progenitor cells and more differentiated cells in the more 
posterior SVZ are anatomically separated in the VZ/SVZ and overlying intermediate 
zone, respectively. Similarly, in the Nf1
hGFAP
KO VZ/SVZ, we observed an over 2-fold 
increase in Olig2 expression whereas the number of Dlx2
+
 cells was not significantly 
changed (Figure 17A, B). We further confirmed that the increased Olig2 expression in 
the VZ/SVZ was also not caused by hyperproliferation (Figure 17C, G), but instead was 
caused by ectopic Olig2 expression in Ascl1
+
 and Dlx2
+
 progenitors (Figure 17A, F, G). 
Of note, Olig2 expression was not expanded in Pax6
+
 VZ and Tbr2
+
 SVZ progenitor cells 
(Figure 17D, E, G). In the IZ, the expression of Olig2 and Dlx2 is almost mutually 
exclusive, suggesting that once cells become more differentiated, they selectively express 
only one of these two transcription factors. Strikingly, Nf1
hGFAP
KO IZ cells exhibited a 
substantial loss of Dlx2 expression with a concomitant increase of Olig2 expression, 
suggesting that ectopic Olig2 expression results in overproduction of Olig2
+
 lineage cells 
at the expense of the Dlx2
+
 lineage (Figure 17A, B).  
 
3.3.2 Nf1 deficiency leads to increased gliogenesis at the expense of neurogenesis 
during neonatal development 
 
To investigate the phenotypic consequence of ectopic Olig2 caused by Nf1 deficiency 
during neonatal development, we analyzed the size of brains of control and Nf1
hGFAP
KO 
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mice at P0.5 and P8. No significant difference was identified, particularly for the size of 
the olfactory bulb (OB) where a large number of neurons are generated from neonatal 
SVZ stem cells (Figure 18). While P0.5 SVZa contains a minimal number of GFAP
+
 
cells, the SVZa at P8 is comprised of a significant number of proliferating GFAP
+
 stem 
cells. Compared to controls, Nf1
hGFAP
KO SVZ GFAP
+
 cells were hyperproliferative 
(Figure 19A, C), which was accompanied by increased number of cells in the enlarged 
mutant SVZ at P8 (Figure 19D). However, the proliferation rate of Olig2
+
 cells was not 
significantly altered in P8 Nf1
hGFAP
KO SVZa (Figure 19B, E). While the percentage of 
Olig2
+
 cells in the Ascl1
+
 progenitors remained comparable between P0.5 and P8 control 
SVZa (16.7% vs. 19.3%, p = 0.269), the percentage of Olig2
+
/Ascl1
+
 cells in Nf1
hGFAP
KO 
SVZa was continuously increased from 38.7% at P0.5 to 46.5% at P8 (p = 0.012, Figure 
19F). These results further support the notion that Nf1 plays a critical role in suppressing 
Olig2 in neonatal SVZ Ascl1
+ 
progenitor cells. 
 
To determine whether the altered expression pattern of Olig2 and Dlx2 lineage markers 
disrupts the balance of glial versus neuronal output of Nf1
hGFAP
KO SVZ stem cells, we 
focused on the SVZa, the largest postnatal germinal zone where multipotent stem and 
progenitor cell populations persist into adulthood. We pulsed control and Nf1
hGFAP
KO 
mice with bromodeoxyuridine (BrdU) at P8, a stage when most of the proliferating cells 
become restricted to the SVZ/RMS in the forebrain. After a 10-day BrdU chase, we 
analyzed the mice at P18 for SVZ-derived neurogenesis in the OB and gliogenesis in the 
corpus callosum (CC), respectively. As shown in Figure 20, the size and neuronal density 
of the Nf1
hGFAP
KO OB were significantly reduced compared to controls (Figure 20A, B, 
C). Notably, neuronal clusters, which could be readily identified in the control OB, were 
largely absent in mutants (Figure 20Ac, c’ and 20Ad, d’). Consistently, SVZ-derived 
newborn neurons labeled by BrdU and NeuN (BrdU
+
/NeuN
+
) were markedly reduced in 
the Nf1
hGFAP
KO OB compared to controls (Figure 20A, D). Neurogenesis in the granular 
cell layer (GCL) and periglomerular cell layer (PGL) was equally reduced in the mutant 
OB (Figure 20D). It is worth noting that the number of BrdU
+
 cells coexpressing a 
neuronal marker Pax6 was not significantly different in the RMS between control and 
Nf1
hGFAP
KO brains (Figure 21A, D), suggesting that reduced neurogenesis was unlikely 
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caused by migratory defects. However, compared to controls, the number of BrdU
+
 cells 
was increased by over 3 folds in the Nf1
hGFAP
KO RMS and CC, where most of the BrdU
+
 
cells expressed glial markers, GFAP and Olig2 (Figure 21B, C, D; Figure 22A, B, C). 
These observations demonstrate that Nf1 inactivation leads to increased gliogenesis at the 
expense of neurogenesis in the neonatal SVZ/RMS/OB/CC system. Interestingly, the 
ratio of newly generated BrdU
+
/GFAP
+
 astrocytes and BrdU
+
/Olig2
+
 oligodendrocytes 
was not significantly different in control and Nf1
hGFAP
KO CC, suggesting that Nf1 
deficiency only promotes overproduction of Olig2
+ 
progenitors, but does not alter their 
potential to differentiate into astrocytes versus oligodendrocytes (Figure 22D).  
 
3.3.3 Nf1-deficient adult brain exhibits enlarged SVZ with increased glial 
differentiation 
 
To determine disease manifestations of the neonatal defects observed in Nf1-deficient 
SVZ cells, we studied adult control and Nf1
hGFAP
KO SVZ at 2 months of age. 
Specifically, we analyzed the SVZ from these mice at three independent positions along 
the midline to lateral hemisphere (Figure 23). At each of these three positions, 
Nf1
hGFAP
KO SVZ exhibited a 2- to 3-fold increase in the size of the SVZ compared to 
controls (Figure 24). To investigate the relative contribution of SVZ stem cells, 
progenitor cells and differentiated cells to the enlarged size, we determined the number of 
individual SVZ cell populations by using lineage markers. Compared to controls, the 
percentage of SVZ cells expressing glial-lineage markers including GFAP, Olig2 and 
NG2 was markedly increased with a concomitant reduction of Doublecortin (Dcx)-
expressing neuroblasts in the Nf1
hGFAP
KO SVZ (Figure 25). To determine whether 
increased GFAP
+
 cells were SVZ stem cells or differentiated astrocytes in mutant brains, 
we double-labeled brains sections with GFAP and Nestin-a stem/progenitor cell marker. 
Similar to controls, Nf1
hGFAP
KO SVZ contained GFAP
+
/Nestin
+
 stem cells that were 
closely associated with the lateral ventricle (Figure 26A). However, mutant SVZ 
accumulated a greater number of GFAP
+
/Nestin
- 
cells that formed a less cellular area in 
the anterior-dorsal parts of the SVZ, which was not observed in the normal SVZ (dotted 
areas in Figure 24, 25A). Furthermore, these GFAP
+
/Nestin
- 
cells exhibited the critical 
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features of differentiated astrocytes: the presence of multiple long cellular processes and 
not in the cell cycle (Figure 25A, 27D). Together, these results demonstrate that Nf1 
deficiency leads to enlarged SVZ with abnormally increased glial differentiation in the 
adult brain. In the adult SVZ, only 9% of multipotent Ascl1
+ 
transit-amplifying 
progenitors expressed Olig2 (Figure 26A-D), which is consistent with the previous 
studies that glial output of adult SVZ stem cells is minor (5% to 10%) (Hack et al. 2005; 
Menn et al. 2006). Remarkably, nearly half of Ascl1
+ 
transit-amplifying progenitors 
expressed Olig2 in the Nf1
hGFAP
KO SVZ (48.3%, Figure 26A-D), which is comparable to 
the percentage of mutant Olig2
+
/Ascl1
+ 
progenitors at P8 (46.5%). Thus, the phenotypic 
alteration in Olig2 expression observed in neonatal Nf1
hGFAP
KO Ascl1
+ 
progenitors 
persists in adult SVZ transit-amplifying progenitors. Moreover, we confirmed that 
ectopic Olig2 expression specifically occurred in the Nf1
hGFAP
KO Ascl1
+
 transit-
amplifying SVZ-C progenitors (irrespective of its expression of Dlx2), but not in GFAP
+
 
SVZ-B stem cells or Dcx
+
  SVZ-A neuroblasts (Figure 26E and data not shown).    
 
3.3.4 Nf1 deficiency provides no significant growth advantage to different SVZ cell 
populations 
 
We next investigated whether as a tumor suppressor gene, Nf1 deficiency altered growth 
properties of Nf1
hGFAP
KO SVZ cells that could also contribute to abnormal enlarged 
SVZ. First, we determined the overall proliferation rate in control and Nf1
hGFAP
KO SVZ 
by using a short-term BrdU pulse assay. Although the absolute number of BrdU
+
 cells 
was increased in the enlarged Nf1
hGFAP
KO SVZ, the percentage of BrdU
+
 cells was 
significantly reduced compared to controls (Figure 27A-C). Moreover, the differences in 
the number and percentage of BrdU
+ 
cells remained relatively unchanged between control 
and Nf1
hGFAP
KO SVZ when these mice became aged (from 2 to 8 months, Figure 27B, 
C). These observations indicate that Nf1-deficient SVZ cells are not hyperproliferative or 
tumorigenic. Second, we measured the percentage of BrdU
+
 cells in individual SVZ cell 
populations. No significant difference in proliferation was observed in Ascl1
+
 SVZ-C 
cells, Olig2
+
/NG2
+
 SVZ-OPCs, as well as neurogenic Dlx2
+ 
progenitors and Dcx+ SVZ-
A neuroblasts between control and Nf1
hGFAP
KO SVZ (Figure 27D-I). Notably, due to the 
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presence of a large number of differentiated astrocytes in mutant SVZ, the percentage of 
BrdU
+
 cells in GFAP
+
 cell populations was significantly reduced (Figure 27D, J). Third, 
by using Cleaved Caspase 3 immunohistochemical staining, we found no significant 
difference in apoptotic rate between control and Nf1
hGFAP
KO SVZ (Figure 27K, L). 
Finally, we performed an in vitro neurosphere assay to compare growth properties of 
multipotent control and Nf1
hGFAP
KO SVZ stem and progenitor cells. No significant 
difference was found in the frequency of neurosphere-forming activity and the size of 
primary neurospheres derived from control and Nf1
hGFAP
KO SVZ (Figure 28A, C, D). 
Surprisingly, the self-renewal capacity of SVZ stem and progenitor cells measured by the 
ratio of the number of secondary neurospheres to primary neurospheres was dramatically 
reduced in Nf1
hGFAP
KO cells compared to controls (Figure 28B, E, F). It is worth noting 
that the self-renewal defect in culture is the only phenotype also observed in Nf1 
heterozygous cells (haploinsufficiency). Taken together, these results demonstrate that 
Nf1 deficiency only leads to a transient increased proliferation in neonatal SVZ stem 
cells, which appears to contribute to the enlarged SVZ phenotype. However, the similar 
growth advantage does not persist into adult SVZ cells. Therefore, alterations in 
proliferation or apoptosis in adult Nf1
hGFAP
KO SVZ unlikely contributes to enlarged SVZ 
with increased glial lineage cells.     
 
3.3.5 Nf1 inactivation leads to enlarged corpus callosum 
 
To determine whether similar to neonatal SVZ, adult Nf1
hGFAP
KO SVZ stem cells 
overproduce glial cells at the expense of neuronal production in the OB, we performed a 
long-term BrdU pulse-chase experiment on control and Nf1
hGFAP
KO mice at 2 months of 
age. Thirty days after BrdU pulses, we analyzed the number and the identity of newly 
generated SVZ-derived cells (labeled by BrdU) in the SVZ/RMS/OB/CC system of these 
BrdU-treated mice (Figure 29A, B). In the Nf1
hGFAP
KO OB, the number of BrdU
+
 cells 
was greatly reduced compared to controls. Most of the BrdU
+
 cells were newly generated 
neurons labeled by NeuN, which were reduced by 50% in mutant OB (Figure 29C, D). 
However, there was no significant difference in the BrdU
+
/NeuN
-
 populations, indicating 
that local gliogenesis was not affected by Nf1 deficiency (Figure 29D). Accordingly, the 
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size and neuronal density of Nf1
hGFAP
KO OB was significantly reduced compared to 
controls (Figure 29 E, F).   
 
In contrast to the OB, the SVZ/RMS/CC system as well as surrounding cerebral cortex 
and striatum of Nf1
hGFAP
KO mice contained significantly more BrdU
+
 cells compared to 
those of controls (Figure 29B). For example, the control RMS contained only a small 
number of BrdU
+ 
cells, all of which expressed Pax6 or Dcx, indicating that they were 
migrating neuroblasts. However, we observed a 9-fold increase in BrdU
+
 cells in 
Nf1
hGFAP
KO RMS, 44%, 15% and 41% of which expressed Olig2, GFAP and Pax6, 
respectively (Figure 30A-C). These results indicate that Nf1 deficiency leads to persistent 
gliogenesis in the RMS, which is not existent in controls. Consistently, there was a 
dramatic increase in the number of RMS cells expressing glial lineage markers including 
Olig2 and NG2 in the absence of Nf1 (Figure 30D). Moreover, Nf1
hGFAP
KO RMS, but not 
controls, expressed myelin basic protein (MBP) indicative of terminal differentiation of 
oligodendrocytes, which altered the structure and organization of the mutant RMS 
(Figure 30E, F).  In both control and Nf1
hGFAP
KO SVZ, CC, cerebral cortex and striatum, 
however, all the BrdU
+
 cells expressed Olig2, but not GFAP, Pax6 or Dcx (Figure 31A 
and data not shown). Together, these observations indicate that similar to neonatal SVZ 
cells, Nf1 deficiency only overproduces Olig2
+
 transit-amplifying progenitors, but does 
not alter the differentiation potentials of these adult SVZ progenitor cells that only 
produce oligodendrocytes, not astrocytes. Consistently, the number of Olig2
+
 cells was 
increased in Nf1
hGFAP
KO CC (Figure 31B, C). The increase in GFAP
+
 cells is most likely 
due to increased gliogenesis during neonatal development (Figure 31B, C; Figure 22A). 
Such increase of glial cells in mutant CC is not due to increased local OPC proliferation, 
since we did not observe any difference in the number of BrdU
+
/Olig2
+
 cells in control 
and Nf1
hGFAP
KO  CC (Figure 31 K,L).  
 
To investigate the phenotypic consequence of the imbalance of glial versus neuronal 
production from adult Nf1
hGFAP
KO SVZ, we measured the size of the CC at 4 different 
planes along the midline to lateral hemisphere. At all three positions that are directly 
associated with lateral ventricle (P1-P3), the thickness and cellular density of the CC is 
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significantly increased in the absence of Nf1 (Figure 31E-G). The enlarged CC phenotype 
is reminiscent of what have been described in a subset of NF1 patients that exhibit severe 
learning disabilities. Interestingly, the size of CC from the midline section (position M, 
Figure 31H), which is not directly associated with the lateral ventricle, showed no 
increase in thickness or cellular density. These observations suggest a critical role of 
SVZ-mediated gliogenesis in the formation of the CC.  
 
3.3.6 Acute inactivation of Nf1 is sufficient to induce fate switch in the adult SVZ 
 
To investigate whether abnormal fate-specification observed in the adult SVZ progenitors 
resulted from a neonatal developmental defect or ongoing requirement of Nf1 in 
adulthood, we employed an inducible system in which Cre recombinase (Nestin-cre
ER
) 
can be activated in Nestin-expressing SVZ stem and progenitor cells by tamoxifen (TM) 
treatment (Figure 32A). As revealed by activation of Cre-mediated Rosa26 LacZ reporter 
(R26
LacZR
), the SVZ/RMS/OB/CC system could be efficiently targeted by TM induction 
at neonatal stages (Figure 32 B). From P0.5 to P8, Nestin
+
 neural stem and progenitor 
cells become restricted to the SVZ/RMS in the forebrain. Accordingly, compared to P0.5 
induction, the Nestin-cre
ER
-targeted cell populations at P8 were greatly restricted to the 
SVZ/RMS/OB/CC system (Figure 32B). These observations reveal the efficacy and 
specificity of this Nestin-cre
ER
 transgene. To target adult SVZ cells, we established a 5-
day TM induction protocol from P26 to P30 (Figure 32C). At P31, one day after the 
completion of TM induction, the cells undergoing Cre-mediated recombination revealed 
by -gal staining are restrictedly distributed in the SVZ and RMS, as well as SGL in the 
hippocampus, but not in any other brain regions (Figure 32C and data not shown), 
consistent with the fact that Nestin
+
 cells are restricted to the SVZ and SGL adult 
germinal zones. At P60, a month after TM induction, the majority of -gal-positive cells 
migrated into the OB and became differentiated neurons whereas a minor population of 
-gal
+
 cells was found in the overlying CC in TM-induced control brains (Figure 33A). 
In contrast, -gal
+
 cells dramatically increased and formed clusters in the CC of TM-
induced mutant brains (Figure 33A). Nearly all the -gal
+
 cells in both control and mutant 
CC expressed Olig2, demonstrating that acute Nf1 inactivation in the adult SVZ increased 
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gliogenesis (Figure 33B, C, G). Despite increased gliogenesis in the CC, there was no 
difference in the number of -gal
+
 cells or the proliferation in the SVZ (Figure 33B, F, J). 
The number of -gal
+
 cells in the RMS, however, was significantly reduced in TM-
induced mutants (Figure 33B, D). Moreover, while -gal
+
 cells in the control RMS are 
Dcx
+
/Olig2
-
 neuroblasts, many -gal
+
 cells expressed Olig2 in the mutant RMS (Figure 
33D, H). These results indicate that Nf1 deficiency not only increases gliogenesis at the 
expense of neurogenesis, but also alters the migratory pattern of some glial progenitor 
cells that abnormally enter into RMS, consistent with our finding that there is continuous 
gliogenesis in the Nf1-deficient RMS (Figure 30A). Furthermore, we found increased 
number of Olig2-expressing cells in the Nf1-deficient cellular compartment (marked by 
-gal expression) in the mutant SVZ compared to controls (Figure 33E, I), providing 
additional evidence that Nf1 deficiency leads to ectopic expression of Olig2. Together, 
these results demonstrate that acute inactivation of Nf1 confers no proliferative advantage 
to adult SVZ cells, but instead alters glial versus neuronal fate-specification by promoting 
Olig2 expression in adult SVZ cells. 
 
3.3.7 Nf1 regulates SVZ progenitor cell fate specification in an ERK-dependent 
manner 
 
We next investigated the molecular mechanism underlying the glial versus neuronal fate 
switch in Nf1
hGFAP
KO SVZ progenitors. Since Nf1 functions as a negative regulator of 
Ras-mediated signaling pathways, we analyzed three major downstream effectors of Ras 
signaling pathways: ERK/MAPK, PI3K/AKT and mTORC1. Specifically, we used 
phospho-specific antibodies of ERK (pERK), AKT (pAKT) and S6 (pS6) kinases to 
evaluate the activation status of these pathways in control and Nf1
hGFAP
KO brains. In 
paraffin-embedded sections, pAKT antibody failed to detect specific signals in either 
control or Nf1
hGFAP
KO brains (data not shown). However, both pERK and pS6 antibodies 
readily detected positive cells on these brain sections, though only pERK-positive 
(pERK
+
) cells were significantly increased in both neonatal and adult Nf1
hGFAP
KO brains 
(Figure 34A-E and data not shown). Under this relatively stringent condition (paraffin 
sections), the majority of pERK
 
robust staining was identified in the SVZ of both control 
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and Nf1
hGFAP
KO brains at neonatal (Figure 34A, B) and adult stages (Figure 34C-E). 
Consistent with the finding that Nf1 inactivation causes ectopic Olig2 expression 
specifically in Ascl1
+
 transit-amplifying progenitors, pERK expression was restricted to 
Ascl1
+  
and/or Olig2
+
 cells in the SVZ of both P0.5 (Figure 34A, B) and adult 
Nf1
hGFAP
KO brains (Figure 26C, D). Over 80% and 90% of pERK
+
 cells expressed Ascl 
and Olig2, respectively. This observation indicates that a large proportion of pERK
+
 cells 
expressed both Ascl and Olig2 (Figure 26C, D). Consistently, in the Nf1
hGFAP
KO, the 
majority of neurogenic Dlx2
+
 cells did not express pERK, and no pERK expression was 
found in GFAP
+
 cells (Figure 34F, G). Together, these results are most consistent with 
the model that Nf1-mediated negative regulation of ERK signaling suppresses Olig2 
expression in neurogenic Ascl1
+
 transit-amplifying progenitors.  
 
To directly test this hypothesis, we treated the mice from P0.5-P18 with a potent MEK 
inhibitor (MEKi), PD0325901 (Barrett et al. 2008). The level of ERK activation in 
MEKi-treated Nf1
hGFAP
KO mice at P18 was reduced to the level of control SVZ, and 
more importantly, the number of Olig2
+
 cells in the mutant SVZ was now comparable to 
vehicle-treated control (Figure 35A, D). Furthermore, in the Ascl1
+ 
progenitors, the 
percentage of Olig2
+
 cells in MEKi-treated mutants was also reduced to the control level 
(Figure 35A, E). We further analyzed the glial and neuronal production of SVZ 
progenitor cells. In the CC, the density of Olig2
+ 
cells in MEKi-treated Nf1
hGFAP
KO 
brains was rescued to the level of vehicle-treated controls; the density of GFAP
+
 cells, 
albeit not completely rescued, was significantly reduced compared to that of vehicle-
treated mutants (Figure 35B, F). In the OB, neuronal density was significantly increased 
after MEKi treatment (Figure 35C, F).  Finally, the size defects of CC and OB were also 
partially rescued. These MEKi treatment experiments demonstrate a potential therapeutic 
window for treating NF1-associated brain structural defects. 
 
3.4 Discussion 
 
By analyzing two Nf1 mouse models driven by different Cre transgenes, my study 
demonstrated the pivotal role of Nf1 in the regulation of SVZ progenitor fate 
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specification both during neonatal development and in adulthood. Moreover, these 
observations provide a potential mechanism underlying the neurocognitive defects 
observed in NF1 patients.  
 
3.4.1 Nf1 specifically regulates fate specification of SVZ Asc11
 +
 cells through 
Ras/ERK signaling 
 
Previous studies have reported an abnormal increase of glial cells in Nf1-deficient mouse 
brain, yet the cellular and molecular mechanism has not been fully revealed (Dasgupta 
and Gutmann 2005; Zhu et al. 2005; Hegedus et al. 2007). One possibility is that Nf1-
deficiency leads to overproliferation of glial progenitor cells. However, in their BLBP-
Cre conditional knockout mice, Hegedus et al. found no increase in the proliferation rate 
of glial progenitor cells in the neonatal brain (Hegedus et al. 2007), which is consistent 
with our quantification in P0 and P8 SVZ. We further confirmed that glial progenitor 
cells do not overproliferate in adult SVZ and CC. These findings rule out 
overproliferation of glial progenitor cells as a major underlying mechanism for 
overabundance of glia. Alternatively, overproduction of glial cells could be attributed to 
fate specification alteration in neuroglial progenitor cells. Indeed, we found ectopic 
expression of Olig2 in neonatal and adult SVZ Ascl1
+
 cells. Olig2 expression has been 
demonstrated both necessary and sufficient to act as a master regulator in directing SVZ 
progenitors toward glial fates, while preventing neuronal differentiation, in neonatal and 
adult brain (Marshall et al. 2005; Menn et al. 2006). Consequently, in Nf1-deficient 
brains more Ascl1
+
 cells are specified to the glial lineages at the expense of neuronal 
lineage specification, leading to increased gliogenesis in the SVZ/RMS/CC system and 
reduced neurogenesis in the OB. This alteration of fate specification is very specific to 
SVZ Ascl1
+
 progenitors (type C cells in adult SVZ). Despite our genetic targeting 
strategy of introducing Nf1 mutation to all cell types in the brain, no ectopic Olig2 
expression was found in SVZ-B cells (neural stem cells), SVZ-A cells (neuroblasts) or 
differentiated neurons. Thus, Nf1 appears to function as a negative regulator of Olig2 
specifically in SVZ Ascl1
 +
 cells to repress glial fate determination.  
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There are several signaling pathways known to regulate Olig2 expression in the CNS. 
BMP/Smad signaling plays a crucial role in establishing dorsal neural identity and its 
inhibition is sufficient to generate OPCs both in vitro and in vivo (Bilican et al. 2008). 
Sonic hedgehog (Shh), which opposes BMP signaling in ventral neural tube, can promote 
Olig2 expression in neocortical progenitor cells and induce oligodendrocyte progenitor 
production (Lu et al. 2002; Zhou and Anderson 2002). Kessaris et al. demonstrated that 
Shh activity is dependent on ERK signaling (Kessaris et al. 2004). In cultured dorsal 
spinal cord cells, fibroblast growth factor 2 (FGF2) could induce Olig2 expression, which 
can be inhibited by a MEK inhibitor (Bilican et al. 2008). This observation suggests that 
FGF2-induced Olig2 expression depends on Ras/ERKsignaling pathway. In the forebrain, 
overexpression of growth factors (i.e. epidermal growth factor EGF, platelet-derived 
growth factor PDGF) can lead to overproduction of Olig2
+
 cells in SVZ and CC 
(Chandran et al. 2003; Jackson et al. 2006; Ivkovic et al. 2008). However, the specific 
cell type(s) that are responsive to EGF/PDGF overexpression are yet to be determined. In 
addition, these studies did not provide conclusive mechanism whether the increase of 
Olig2-expressing cells is due to hyperproliferation or fate specification alterations. Our 
study demonstrates that Nf1 regulates Olig2 expression in SVZ Ascl1
+
 cells through 
Ras/ERK signaling, which plays an important role in SVZ progenitor fate specification 
and regulates the overall output of neurogenesis and gliogenesis.  Consistently, we found 
that in control brains, activation of Ras/ERK signaling corresponds to the dynamic 
change of gliogenesis. While pERK level is very low in adult brain where there is 
minimal gliogenesis in adult, we found a number of pERK
+
 cells colocalizing with Olig2 
in the SVZ at neonatal stages (the peak of gliogenesis in the brain), indicating the 
involvement of Ras/ERK signaling in normal gliogenesis process. In addition, MEK 
inhibitor treatment on Nf1-deficient mice not only repressed Olig2 expression in SVZ 
progenitors, but also rescued the neuron-glial output in the brain, suggesting that Nf1 
indeed inhibits Olig2 expression by inactivating Ras/ERK signaling. Based on these 
findings we propose a model for the fate specification of SVZ Ascl1
+
 cells. Ascl1
+
 cells 
are bipotent and can undergo specification to acquire a neuronal or glial fate. Upon 
commitment to glial intermediate progenitors (gIPCs), Ascl1
+
 cells downregulate Nf1 and 
activate Ras/ERK signaling to promote Olig2 expression, while neuronal committed 
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progenitors (nIPCs) maintain high level of Nf1 to inhibit Ras/ERK signaling and prevent 
misexpression of Olig2. In Nf1
hGFAP
KO brains, Ras/ERK signaling transduction activity 
is dysregulated in Ascl1
+
 cells and nIPCs due to the loss of its negative regulator, Nf1. 
Overactive Ras/ERK activity leads to expression of Olig2 in these cells, ultimately 
resulting in fate switch from the neuronal lineage to the glial linage (Figure 36). 
 
This new model, while addresses important questions concerning neural progenitor fate 
specification, opens up many directions for follow-up studies. First, the relationship 
between Ras/ERK signaling and increased Olig2 expression in Ascl1
+ 
cells has yet to be 
defined. A recent publication by Bilican et al. demonstrated that in dorsal spinal cord, 
FGF-induced ERK signaling could counteract with BMP signaling by deactivating 
Smad1, the major effecter in the BMP signaling pathway. ERK signaling phosphorylates 
the linker region of Smad1 and prevents its nuclear translocation, which inhibits Smad1 
transcriptional activity (Bilican et al. 2008). It is possible that this is a conserved 
mechanism for different types of progenitors in the CNS. Second, the upstream signal 
that activates Ras/ERK signaling cascade in SVZ cells is yet to be determined. As 
aforementioned, Shh signaling, as well as activation of RTK signaling through growth 
factors FGF/EGF/PDGF could all be likely candidates. Finally, how Ras/ERK activity is 
dynamically regulated in neuronal committed nIPCs and glial committed gIPCs still 
remains to be uncovered. One possible mechanism could be that these two cell 
populations have different neurofibromin level. This could be achieved through 
differential transcriptional or post-transcriptional regulation of Nf1 gene expression. 
Alternatively, the level of neurofibromin could be regulated by protein degradation. One 
candidate molecule that regulates neurofibromin degradation is FBW7 (F-box and WD 
repeat domain-containing 7). FBW7 is a substrate-recognition component of the SCF 
complex (SKP1, CUL1 and F-box), an E3 ubiquitin ligase. Dr. Yi Sun at the University 
of Michigan has recently identified that FBW7 recognizes neurofibromin and mediates 
neurofibromin degradation through ubiquitination (personal communication). In addition, 
Dr. Huarui Zheng from our lab found reduced Olig2
+
 cells in FBW7 knockout mice 
(personal communication). These findings lead to an intriguing possibility that FBW7 
specifically degrades neurofibromin in gIPCs to maintain high level of Ras/ERK 
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signaling in these cells. Assessment of the protein level of FBW7 and neurofibromin in 
different progenitor cells will be the key to test this hypothesis. These possible directions 
will be further explored in Chapter IV.  
 
3.4.2 Clinical implications for NF1-associated learning disabilities  
 
One unique feature of our mouse model is that Nf1
hGFAP
KO mice exhibit enlarged corpus 
callosum that recapitulates the structural abnormalities in the brains of a subset of NF1 
patients. Enlarged corpus callosum in NF1 children is associated with severe cognitive 
deficits and may serve as an early structural marker for the children at risk of learning 
disabilities. A recent publication compared the IQ score and white matter enlargement 
index among NF1 children with varying degree of cognitive deficits. Their results 
indicate  that NF1 children with larger white matter volume tend to suffer from more 
severe learning disabilities (Pride et al. 2010). My study demonstrates that bi-allelic 
inactivation of Nf1 in SVZ stem/progenitor cells is sufficient to induce excessive 
gliogenesis in the corpus callosum and increase corpus callosum size, providing the 
cellular basis for such structural defects. Since NF1 patients are heterozygous for NF1, 
enlarged corpus callosum is most likely due to loss of heterzygosity in a subset of neural 
stem/progenitor cells, and the number of cells that undergo LOH determines the degree of 
corpus callosum enlargement and the severity of cognitive impairment. Our mouse model 
could therefore serve as a valuable tool to study the structure-function relationship in 
NF1-associated learning disabilities. Importantly, the MEK inhibitor treatment studies 
have reversed the corpus callosum defect, suggesting that targeting Ras/ERK pathway 
during neonatal development could potentially be used as a therapy in NF1 patients to 
alleviate associated neurocognitive defects. In addition, these observations might have a 
broader clinical implication in NCFC syndromes caused by germline mutations in the 
oncogenic Ras/ERK signaling pathway, which all share a variable degree of cognitive 
impairment (Rodriguez-Viciana et al. 2006). 
 
The remaining questions include why enlarged corpus callosum leads to learning 
disabilities and whether rescuing the structural defect could rescue the cognitive deficits. 
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Since Nf1
hGFAP
KO
 
mice are paralyzed due to the widespread genetic recombination in 
CNS and PNS, we were not able to carry out behavioral analysis on these mice. The 
optimal model for future studies will be the Nestin-Cre
ER
 inducible model, which only 
targets a small number of cells and could avoid defects caused by Nf1-deficiency during 
embryonic development. By inducing around P0.5, we could very likely induce the 
corpus callosum phenotype without paralyzing the mice. This will allow us to analyze the 
electrophysiological and behavioral alterations in Nf1 mutant mice and treatment studies 
on these mice will provide the appropriate platform for future clinical trials. This 
possibility will be explored further in Chapter IV.  
 
 
 
 
 
 96 
 
 
  
 97 
 
Figure 15. hGFAP-cre-mediated genetic recombination in the developing and neonatal 
brain. (A) Brain sections from hGFAP-cre+; R26R-LacZ transgenic mice at ages of 
neonatal day 0.5 (P0.5, upper panels) and P21 (lower panels) were stained with X-gal and 
imaged at three different magnifications. (B) Brain sections from adult hGFAP-
cre+;R26R-LacZ double transgenic mice were stained with anti- -gal/anti-Olig2 (a, a’), 
anti- -gal/anti-GFAP (b, b’), anti- -gal/anti-Cre (c, c’). Arrows mark the co-localizing 
cells. Ctx, cerebral cortex; OB, olfactory bulb; Hp, hippocampus; LV and “*”, lateral 
ventricle. Scale bar, 100 .  
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Figure 16. Loss of Nf1 leads to misexpression of Olig2 in neural stem/progenitor cells in 
the neonatal SVZa.  
(A)-(D) P0.5 brains from control and Nf1
hGFAP
KO mice were sectioned and stained for 
H&E (A, left column) and Olig2 immunofluorescence labeling (A, right column). The 
numebr of cells in SVZa and VZ/SVZ was quantified in (B) and (C), respectively.  The 
percentage of Olig2+ cells among SVZa cells was quantified in (D). While SVZ size and 
cell number are comparable at this stage, the absolute number and percentage of Olig2
+ 
cells were dramatically increased in Nf1
hGFAP
KO
 
SVZa. 
(E)-(G) Olig2 and Ki67 double immunofluorescence (E) revealed no difference in the 
total number of Ki67+ cells that were in the cell cycle (F), or the percentage of Olig2+ 
cells that colocalized with Ki67 (G). Arrowheads point to the colocalizing cells and 
arrows indicate the non-colocalizng Olig2
+ 
cells.  
(H) The number of cleaved caspase 3
+
 cells that underwent apoptosis was quantified and 
compared. No difference was identified between control and mutants. 
(I) Olig2, Ascl1 and Dlx2 triple immunofluorescence labeling to analyze the cellular 
composition of SVZa Ascl1+ cells. Arrowheads point to the triple-labeled cells and 
arrows indicate the non-colocalizng Ascl1
+
/Dlx2
+
/Olig2
-
 cells.  
(J) and (K) The quantification for the percentage of different types of cells in SVZa 
Ascl1
+
 cell compartment from 3 controls and 3 mutants. 39% of mutant Ascl1
+
 cells were 
Olig2
+
, compared to 17% in controls.   
Dashed lines roughly demarcate the SVZa or VZ/SVZ regions. LV, *, lateral ventricle. 
Scale bars, 50 . 
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Figure 17. Characterization of Olig2
+
 cells in P0.5 VZ/SVZ/IZ.  
(A) Olig2, Dlx2 doublelabeling for cells in VZ/SVZ/IZ. Note that Dlx2
+
 cells were 
almost depleted in the mutant IZ with a significant increase of Olig2
+
 cells.  
(B) The quantification for these two cell populations in VZ/SVZ and IZ.  
(C)-(F) Characterization of Olig2
+
 cells through doublelabeling with different markers.  
(G) and (H) are the quantifications for colocalization. The ratio of Olig2
+
 cells 
colocalizng with Ki67 was comparable in mutant and controls (C), and Olig2 expression 
was not expanded in Tbr2
+
 SVZ and Pax6
+
 VZ progenitor cells (D, E). Instead, ectopic 
expression of Olig2 was found in Ascl1
+
 (F) and Dlx2
+
 cells (See G, H).  
Dashed lines roughly demarcate the VZ/SVZ. LV, *, lateral ventricle. Scale bars, 50 . 
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Figure 18. Whole mount analysis for P0.5 and P8 brains.   
Whole mount brains from control and Nf1
hGFAP
KO mice were dissected, fixed in 4% PFA 
and imaged under the dissection microscope.  Olfactory bulb size from P0.5 (panel A) 
and P8 (panel B) brains were measured and compared from dorsal view (A, B upper 
panels) and  lateral view (A, B lower panels) in (C). There was no obvious difference in 
olfactory bulb size in P0.5 and P8 brains. Scale bars, 1 mm 
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Figure 19. Nf1 deficiency results in a transient increase of GFAP
+
 cells at P8. 
(A) GFAP
+
 cells in Nf1
hGFAP
KO SVZ exhibit increased proliferation as demonstrated by 
GFAP/BrdU doublelabeling, which was quantified in (C).  
(B) Ki67/Olig2 double-labeling demonstrating that Olig2
+
 cells did not overproliferate in 
P8 Nf1
hGFAP
KO
 
SVZ. (E): the quantification for Ki67
+
/Olig2
+ 
cells among total SVZ 
Olig2
+
 cell population.  
(D) The total cell number was increased in P8 Nf1
hGFAP
KO
 
SVZ.  
(F)  Quantification and characterization of Ascl1
+
 cells in P8 SVZa based on their 
colocalization with Dlx2 and Olig2. 
Dashed lines roughly demarcate the SVZa and RMS in (B). *, lateral ventricle. Scale 
bars, 50 .   
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Figure 20. Nf1 deficiency leads to reduced neurogenesis during neonatal development.  
Control and Nf1
hGFAP
KO
 
mice were pulsed with BrdU at P8 and analyzed at P18 after a 
10-day BrdU chase to quantitatively analyze SVZ-derived neurogenesis in the OB and 
gliogenesis in the corpus callosum.  
(A) SVZ-derived newborn neurons labeled by BrdU and neuronal marker NeuN 
(BrdU
+
/NeuN
+
) were markedly reduced in the Nf1
hGFAP
KO OB compared to controls. 
(a,b) Low magnification view for the distribution of BrdU
+
 cells. (c-d’) High 
magnification view of NeuN/BrdU colocalizing cells, some of which are marked by 
arrowheads. Dashed lines mark the neuronal clusters in control OB which were largely 
absent in mutants.  
(B) and (C): The size (B) and neuronal density (C) of control and Nf1
hGFAP
KO OB were 
measured and compared. Nf1
hGFAP
KO OB exhibited significant reduction. 
(D) Quantification of BrdU
+
/NeuN
+
 cells in the granular cell layer (GCL) and 
periglomerular cell layer (PGL). Neurogenesis was reduced in both regions in mutant 
OB.  
Scale bars, 50 . 
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Figure 21. Nf1
hGFAP
KO mice exhibit ectopic gliogenesis in the RMS during neonatal 
development.  
In the P8-P18 BrdU differentiation assay, BrdU
+ 
cells in the
 
RMS were characterize by 
colocalization with neuronal/glial markers.  
(A) The number of BrdU
+
 cells coexpressing neuronal marker Pax6 was not significantly 
different between control and Nf1
hGFAP
KO brains. 
(B) and (C) Gliogenesis is significantly increased compared to controls, marked by 
BrdU
+
/GFAP
+
 (B) and BrdU
+
/Olig2
+
 (C).  
(D) Quantification of the number of BrdU
+
 cells that colocalize with Pax6, GFAP and 
Olig2.  
Arrowheads point to colocalizing cells and arrows label the non-colocalizing cells. 
Dashed lines roughly demarcate the RMS. Scale bars, 50 .  
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Figure 22. Nf1
hGFAP
KO mice exhibit increased gliogenesis in the CC during neonatal 
development.  
(A)-(C) In the P8-P18 BrdU differentiation assay, BrdU
+ 
cells in the
 
CC were colocalized 
with glial markers GFAP (panel A) and Olig2 (panel B). The number of newly generated 
astrocytes (BrdU
+
/GFAP
+
) and oligodendrocytes (BrdU
+
/Olig2
+
)
 
was quantified and 
compared in (C).  
(D) The relative ratio of astrogenesis versus oligodendrogenesis (BrdU
+
/GFAP
+
 versus 
BrdU
+
/Olig2
+
)
 
was unchanged.   
Arrowheads in point to colocalizing cells and arrows label the non-colocalizing cells. *, 
lateral ventricle. Scale bars, 50 .   
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Figure 23. Schematic demonstration of different histological planes used for adult 
analysis.  
For adult brains in particular, at least three independent positions (position 1-3) that 
contain SVZ/RMS were selected for quantification. Each plane is approximately 100μ 
apart at sagittal planes along the midline to lateral direction (A) and was determined by 
the following histological criteria:  P1: oval lateral ventricle with intact RMS (C); P2: 
triangular lateral ventricle with intact RMS (D); P3: triangular lateral ventricle with non-
intact RMS) (E). For CC analysis, we also compared the midline position as 
demonstrated in (A) and (B).   
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Figure 24. Enlarged SVZ in adult Nf1hGFAPKO mice at all three histological positions.  
(A)-(R) H&E staining of 2 month old control and mutant SVZ at different 
magnifications. Position 1: (A)-(F); Position 2: (G)-(L); Position 3: (M)-(R); Mutant SVZ 
was significantly enlarged. Dashed lines demarcate the less cellular area uniquely 
identified in mutant SVZ. 
(S) Quantification of the absolute cell number in wildtype, heterozygous and mutant 
SVZ.  
(T) Normalized quantification of the number of cells per unit length of LV (number of 
cells divided by the length of LV).  Wildtype and heterozygous mice were combined as 
controls.  
Scale bars, 50 .  
  
 111 
 
 
 
Figure 25. Nf1
hGFAP
KO SVZ has disproportionally increased glial differentiation. 
Sections from 2 month old control and mutant brains were stained for SVZ lineage 
markers. In mutant SVZ, the percentage of cells that expressed glial lineage markers 
GFAP (panel A), Olig2, and NG2 (panel B) was significantly increased, while the 
percentage of DCX
+ 
neuroblasts is reduced (panel C).  The less cellular area marked by 
dashed lines in mutant SVZ was largely composed of differentiated astrocytes that are 
Nestin
-
/GFAP
+
.   
(D) Quantification of the cellular composition of SVZ. The percentage of cells expressing 
GFAP, Olig2, Olig2/NG2 and DCX was quantified and compared.  
*, lateral ventricle. Scale bars, 50 .  
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Figure 26. Nf1 deficiency specifically alters fate specification of SVZ Ascl1
+
 cells.  
(A)–(D) Lineage distribution of SVZ Ascl1+ transit amplifying cells. (A) and (B) 
Olig2/Dlx2/Ascl1 triple labeling in ventral (A) and dorsal anterior (B) regions of control 
and mutant SVZ. Arrows label Olig2
+
/Dlx2
+
/Ascl1
+
 triple positive cells; Arrowheads 
point to Olig2
+
/ Ascl1
+
 double-positive cells. Of note, Olig2
+
/Dlx2
+
/Ascl1
+
 triple positive 
cells were not found in the dorsal anterior area of control SVZ (Ba) and the arrows point 
to Dlx2
+
/Ascl1
+
 double-positive cells. (E) The specificity of ectopic Olig2 expression in 
SVZ progenitors. Olig2 misexpression was not found in GFAP
+
 SVZ B cells or mature 
astrocytes based on GFAP/Olig2 double-immunofluorescence. Scale bars, 50 .   
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Figure 27. Nf1 deficiency provides no significant growth advantage to different SVZ 
progenitors.  
(A)-(C) BrdU proliferation assay on 2 month old mouse brains. Although the absolute 
number of BrdU
+
 cells was increased in the enlarged Nf1
hGFAP
KO SVZ, the percentage of 
BrdU
+
 cells was significantly reduced compared to controls. Such difference in the 
number and percentage of BrdU
+ 
cells was also identified in aged control and mutant 
SVZ.  
(D, E) Prolfieration marker BrdU was colocalized with different lineage markers to 
determine the proliferation ratio in different SVZ progenitor populations. No difference 
was found in Ascl1
+
 SVZ-C cells (E), Olig2
+
/NG2
+
 SVZ-OPCs (F,G), as well as 
neurogenic Dlx2
+ 
progenitors  (H) and DCX
+
 SVZ-A neuroblasts (I). Proliferation in 
GFAP
+
 cells was significantly in reduced Nf1
hGFAP
KO
 
SVZ
 
due to the presence of a large 
number of differentiated astrocytes (D). Arrowheads point to the colocalizing cells and 
arrows indicate the non-colocalizing cells. The colocalization was quantified and 
summarized in (J). 
(K)-(L) No difference in apoptosis was detected through Cleaved Caspase 3 IHC.  
Arrowheads represent cleaved caspase 3
+
 cells.  
Scale bars, 50 .  
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Figure 28. Nf1 deficient neural stem/progenitor cells have reduced self-renewal capacity 
in vitro.   
(A) in vitro neurosphere culture compared the primary neurosphere (NS) forming 
capacity between Nf1 wildtype, heterozygous and Nf1
hGFAP
KO neural progenitors, and no 
significant difference was found in the frequency and size of primary neurospheres (C, 
D). Scale bars, 500 . 
(B) Primary neurospheres derived from Nf1 wildtype, heterozygous and Nf1
hGFAP
KO 
progenitors were further passaged to assess the secondary sphere forming capacity. The 
frequency of secondary spheres was drastically reduced in Nf1 heterozygous and 
Nf1
hGFAP
KO neural progenitors (F). Of note, these Nf1 heterozygous and Nf1
hGFAP
KO 
cells
 
could still form cell clusters in culture (E), but the size of these clusters was too 
small to be considered as secondary neurospheres. Scale bars, 200 . 
 
 116 
 
 
 117 
 
Figure 29. Reduced neurogenesis in adult Nf1
hGFAP
KO brain. 
BrdU pulse-chase assay from P60-P90 was performed to label newly generated neurons 
and glia. (A) Low magnification view of the overall distribution of BrdU
+
 cells in P90 
brains. Arrows point to BrdU
+
 cells in the CC and arrowheads mark the abnormal 
increase of BrdU
+ 
cells in the mutant RMS. Dashed line roughly compares OB size in 
control and mutants.  
(B) Quantification of the BrdU
+
 cells demonstrated a significant increase of BrdU
+
 cells 
in the mutant SVZ/RMS/CC/CTX system.  
(C) and (D) Neurogenesis in mutant OB is reduced by 50% evidenced by the 
quantification of BrdU
+
/NeuN
+
 cells (pointed by arrows). Of note, there was no 
significant difference in the BrdU
+
/NeuN
- 
populations.  
(E) and (F) Whole mount analysis revealed that reduced neurogenesis in mutant results in 
reduced OB size. 
Scale bars, 1 mm for (E) and 50  for others.  
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Figure 30. Persistent glial differentiation in the RMS of adult Nf1
hGFAP
KO brains. 
(A)-(C) In the P60-P90 BrdU differentiation assay, there was a 9-fold increase of BrdU
+
 
cells in the mutant RMS. Characterization of these BrdU
+
 cells was performed through 
double/triple-labeling with Pax6, DCX, GFAP and Olig2 (panel A). The number of 
BrdU
+
 cells that coexpressed Pax6, DCX, GFAP and Olig2 was quantified in (B). Unlike 
control RMS which only had a small number of BrdU
+
 cells that expressed Pax6, in the 
mutant RMS,  44%, 15% and 41% of BrdU
+
 cells expressed Olig2, GFAP and Pax6, 
respectively.  
(D) Olig2/NG2
 
double-labeling
 
revealed the presence of a large number of Olig2
+
/NG2
+ 
(labeled by arrowheads)
 
in Nf1
hGFAP
KO
 
RMS.  
(E) Mutant RMS exhibited high level of MBP, a marker for mature oligodendrocyte. 
(F) Comparison between 2 month and 8 month old control and mutant RMS (H&E) 
demonstrated that over the time course Nf1
hGFAP
KO RMS became a collection of loosely 
packed cells in contrast to the tightly packed neuroblast migratory chain in control RMS.  
Dashed lines mark the border of RMS. Arrowheads label colocalizing cells and arrows 
represent noncolocalizing cells. Scale bars, 50 . 
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Figure 31. Increased gliogenesis leads to structural defects in the CC of Nf1
hGFAP
KO 
brains. 
(A) In the P60-P90 BrdU differentiation assay, increased oligodendrogenesis, marked by 
Brdu/Olig2, was found in mutant CC. Arrows label Brdu
+
/Olig2
+
 cells.  
(B) and (C) Number and density of GFAP
+
 astrocytes and Olig2
+
 oligodendrocytes were 
dramatically increased in mutant CC. Of note, cells expressing both GFAP and Olig2 
were also increased (D). Dashed lines roughly delineate the border of SVZ and LV. 
Arrowheads label colocalizing cells and arrows represent noncolocalizing cells. 
(E)-(H) H&E–stained paraffin sections from 4 different histological planes. The thickness 
and cell density of CC were quantified and compared in (I) and (J). Aside from the 
midline position, enlargement of CC was found in Position 1-Position 3 sections. Arrows 
highlight cells that were clustered in the CC. Dashed lines roughly delineate the dorsal 
border of CC.  
(K) and (L) 2 month BrdU proliferation assay. Local proliferation of Olig2
+
 cells was not 
increased in mutant CC based on the quantification (panel L) of BrdU/Olig2 double 
positive cells.  
Scale bars, 50 . 
 
 122 
 
 
 123 
 
Figure 32.  Characterization of the Nestin-Cre
ER
 strain.  
(A) Genetic configuration of the inducible mouse model and how tamoxifen (TM) 
induction leads to conditional inactivation of Nf1 (see text for details).  
(B) Control mice were induced at P0 or P8 and analyzed at P21. LacZ staining was 
performed on brain sections to label targeted cells. While P0.5 induction targeted a large 
number of cells in the brain, P8-induced recombinant cells were more restricted in 
SVZ/RMS/CC/OB system. Hippocampus area also exhibited robust recombination.  
(C) Young adult mice were induced from P26-P30 and analyzed at P31, one day after the 
completion of TM induction. The cells undergoing Cre-mediated recombination revealed 
by LacZ staining were restrictedly distributed in the SVZ (upper panel) and RMS (lower 
panel), as well as SGL in the hippocampus, but not in any other brain regions.  
Scale bars, 50 . 
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Figure 33. Acute inactivation of Nf1 is sufficient to induce fate switch in the adult SVZ.  
(A) LacZ staining of TM-induced control and mutant brains at P60, a month after P26-
P30 TM induction. In control brains, only a small population of LacZ
 +
 cells was found in 
the overlying CC (Left panel). In contrast, LacZ
 +
 cells dramatically increased and formed 
clusters (marked by dashed lines) in the CC of TM-induced mutant brains (Right panel).  
(B) Quantification of -gal
+
 cells in SVZ/RMS/ CC.  
(C) The majority of -gal
+
 cells were Olig2
+
 in both control and mutant CC. Arrows 
point to the colocalizing cells. Panel (G) is the quantification for the number of -gal
+
 
/Olig2
+ 
cells in the CC.  
(D) The number of -gal
+
 cells was reduced in mutant RMS, and many of the -gal
+
 cells 
ectopically expressed Olig2 instead of neuroblast marker Dcx (inset). Panel (H) is the 
quantification for the number of -gal
+
 /Olig2
+ 
cells in the RMS.  
(E) The ratio of Olig2-expressing cells in the -gal
+
 cell compartment was increased in 
mutant SVZ. Panel (I) is the quantification.  
(F) The proliferation rate of -gal
+
 cells marked by BrdU/ -gal in the SVZ was 
comparable between mutant and controls, quantified in (J). 
Arrows label the non-colocalizing cells and arrowheads point to colocalizing cells. 
Dashed lines delineate the SVZ and/or RMS region. *, lateral ventricle. Scale bars, 50 . 
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Figure 34. Nf1-deficiency leads to specific ERK activation in SVZ progenitors. 
(A)-(B) Activation of ERK signaling was found in both control and mutant SVZ at P0.5 
through p-ERK immunofluorescence. Mutant SVZ already contained more p-ERK
+
 cells, 
and many of them were expressing Ascl1 and/or Olig2.  
(C)-(E) In 2 month old brains, p-ERK staining was barely detected in control SVZ, while 
in mutants, p-ERK
+ 
cells persisted and were restricted to Ascl1
+
 and/or Olig2
+
 cells.  
(F) and (G) The majority of Dlx2
+
 cells did not express pERK, and no pERK expression 
was found in GFAP
+
 cells.  
Arrows label the non-colocalizing cells and arrowheads point to colocalizing cells. *, 
lateral ventricle. Scale bars, 50 . 
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Figure 35. MEK inhibitor treatment rescues the CC and OB phenotypes in Nf1
hGFAP
KO 
mice through inhibition of ERK in SVZ progenitors. 
Nf1
hGFAP
KO mice were treated with MEK inhibitor PD0325901 from P0.5-P18, and 
compared to vehicle-treated control mice and Nf1
hGFAP
KO mice.  
(A) Triple labeling of p-ERK/Ascl1/Olig2 demonstrated that MEK inhibitor treatment 
inhibits ERK signaling in SVZ Olig2
+
/Ascl1
+
 cells (quantified in D). Such inhibition of 
ERK signaling restored Olig2 expression to control level (quantified in E).  
(B) After treatment, in the CC, the density of Olig2
+
 cells in MEKi-treated Nf1
hGFAP
KO 
brains was rescued to the level of vehicle-treated controls; the density of GFAP
+ 
cells, 
albeit not completely rescued, was significantly reduced compared to that of vehicle-
treated mutants. Dashed lines mark the dorsal border of CC.  
(C) In the OB, neuronal density was significantly increased after MEKi treatment. 
(D) Quantification of GFAP
+
 and Olig2
+
 cells in the CC and NeuN
+
 cells in the OB. 
Statistical comparison was performed by Anova test.  
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Figure 36. Proposed model of how neurofibromin regulates SVZ C cell fate specification 
in adult.  
(A) In Nf1 wildtype mice, the Ascl1
+
 cells are bipotent intermediate progenitors and have 
the potential to acquire a neuronal or glial fate. Upon commitment to glial intermediate 
progenitors (gIPCs), Ascl1
+
 cells downregulate Nf1 and activate Ras/ERK signaling to 
promote Olig2 expression, while neuronal committed progenitors (nIPCs) maintain high 
level of Nf1 to inhibit Ras/ERK signaling and prevent misexpression of Olig2.  
(B) In Nf1
hGFAP
KO brains, Ras/ERK signaling is dysregulated in Ascl1
+
 cells and nIPCs 
due to the loss of Nf1. Overactive Ras/ERK activity leads to expression of Olig2 in these 
cells and ultimately specify these cells to the glial linage.  
Red arrows indicate the Ras/ERK signaling activation, red represents the neuronal 
lineage and blue represents the glial lineage.  
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Chapter IV Discussion 
 
4.1 p53 and Nf1 in glioma development 
 
4.1.1 The sequential order and respective contribution of p53 and Nf1 loss in glioma 
development  
 
The objective of my thesis project is to understand the role of the tumor suppressors p53 
and Nf1 in neural stem cells and how loss of these tumor suppressors could independently 
and cooperatively transform neural stem cells into cancer cells. Our p53 glioma mouse 
models demonstrate that a p53-deficiency alone can efficiently induce malignant glioma 
formation in mice. Furthermore, in all instances in which Nf1 is lost either simultaneously 
or subsequent to loss of p53 (Mut1, Mut3 and CKO3 in Table 1) (Mut1: hGFAPCre+; 
p53 KO/KO; Nf1 flox/flox; Mut3: hGFAPCre+; p53 KO/+; Nf1 flox/+; CKO3: 
hGFAPCre+; p53 flox/flox; Nf1 KO/+), the rate of glioma formation was greatly 
enhanced (Zhu et al. 2005; Wang et al. 2009). This suggests that Nf1-deficiency 
cooperates with p53-deficiency to promote tumorigenesis. However, Nf1 deficiency alone 
is insufficient for malignant transformation; Nf1
hGFAP
KO mice could live up to a year 
without brain tumor development. More strikingly, as Zhu et al. demonstrated in their 
2005 paper, when Nf1-deficiency is induced prior to loss of p53 glioma rarely arose 
(Mut2 on Table 1) (Mut2: hGFAPCre+; p53 KO/+; Nf1 flox/flox) (Zhu et al. 2005). 
Together, these observations suggest that in order to efficiently promote gliomagenesis, 
p53 must be inactivated prior to or simultaneously with Nf1. The order of genetic 
mutations and tumor penetrance in different mouse models are summarized in Table 1. 
Such sequential order of p53 and Nf1 inactivation is supported by Attolini et al. in 2010 
who employed mathematic modeling to deduce the temporal sequence of genetic 
mutations based on genomic data of human glioblastoma (Attolini et al. 2010). These 
findings are consistent with the clinical observation that p53 mutations are among the 
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earliest genetic lesions in human gliomas (Maher et al. 2001; Ohgaki et al. 2004; Furnari 
et al. 2007). However, two central questions remain unaddressed: 1) in a p53 wildtype or 
heterozygous background, how Nf1-deficient cells are resistant to malignant 
transformation and 2) in a p53-deficient background, how Nf1-deficiency promotes 
gliomagenesis. 
 
One potential explanation for why Nf1-deficient cells do not progress to malignancy is 
that additional oncogenic mutations are required for glioma transformation, and only p53 
deficiency could provide a permissive environment for these cells to accumulate such 
mutations. However, this alone does not explain the stark contrast between models where 
Nf1 is lost prior to p53 (Mut2) and simultaneous Nf1 and p53 loss (Mut3) in terms of 
glioma penetrance. As shown in Figure 37A, via co-LOH, both Mut2 and Mut3 require 
only one genetic event to become p53/Nf1 double deficient. Mut2 mice also have the 
additional option of acquiring loss of function mutations at the p53 locus. If the 
accumulation of additional oncogenic mutations in p53-deficient cells is the rate-limiting 
step for gliomagenesis, we would expect Mut2 and Mut3 to develop gliomas at a similar 
rate. In fact, while the tumor penetrance in Mut3 mice is 100%, only 1 out of 18 Mut2 
mice develop brain tumors (Zhu et al. 2005). The huge difference in glioma incidence 
between Mut2 and Mut3 leads us to propose that in cells that have undergone loss of Nf1 
in the presence of wildtype p53, Nf1-deficiency must trigger a p53-mediated response(s) 
to eliminate the oncogenic potential of Nf1
-/-
 cells (Mut2). Such p53-mediated response(s) 
are absent in cells that have undergone simultaneous loss of Nf1 and p53 (Mut3). This 
model of cellular events makes the reasonable assumptions that Nf1 heterozygosity does 
not elicit this p53 response and that the loss of the wildtype Nf1 allele accompanied by 
the loss of p53 precludes any p53-mediated response. This can potentially resolve how 
Nf1-deficient cells are resistant to malignant transformation in the context of functional 
p53.  
 
It has been well documented that p53 is activated in response to stress signals including 
DNA damage, oxidative stress and oncogenic mutations. The activation of p53 and its 
downstream transcriptional targets could result in one of three cellular responses: 
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transient cell-cycle arrest, permanent cell-cycle arrest (senescence) and apoptosis 
(Vogelstein et al. 2000; Junttila and Evan 2009; Kruse and Gu 2009; Vousden and Prives 
2009). When cells suffer from low level stress or DNA damage, p53 induces transient 
cell-cycle arrest and activates DNA repair proteins to fix the damage. If DNA damage is 
severe or irreparable, p53 initiates senescence or apoptosis to remove these damaged 
cells. In Nf1-deficient brains, we did not observe any change in the incidence of apoptosis 
either during neonatal development or adulthood. Apoptosis is therefore unlikely to be 
the mechanism that protects Nf1-deficient SVZ cells from malignant transformation. A 
recent study in human glioma cell lines demonstrated that Nf1 inactivation can induce a 
p53-dependent senescence response (McGillicuddy et al. 2009). However, our in vivo 
analysis demonstrated that Nf1-deficiency does not alter the proliferation rate of SVZ 
cells nor prevent differentiation, suggesting that a large number of Nf1
-/-
 SVZ progenitors 
remain in the cell cycle and do not undergo cellular senescence. Our in vitro neurosphere 
assay also suggests that Nf1-/- SVZ progenitors normally proliferate and form primary 
neurospheres comparable to their WT counterparts. Alternatively, p53 may induce 
transient cell cycle arrest and restrict the number or length of cell cycles in Nf1-deficient 
progenitors, which would ultimately differentiate and become resistant to malignant 
transformation. In support of this hypothesis, we identified that the most dramatic 
difference between Nf1
-/-
 and Nf1
+/+
 SVZ progenitors is their ability to form secondary 
neurospheres. The ratio of the number of secondary neurospheres to primary 
neurospheres was dramatically reduced in Nf1
hGFAP
KO cells compared to controls, which 
indicates that under culture conditions, Nf1
-/-
 progenitors have reduced self-renewal 
capacity and can only undergo limited number of cell cycles. Consistently, p53 has been 
shown to be a negative regulator of neural stem cell self-renewal in neurosphere assays 
(Meletis et al. 2006). Based on these observations, we hypothesize that p53 eliminates the 
oncogenic potential of Nf1-/- progenitors by suppressing their self-renewal capacity 
through restriction of the number/length of cell cycles. We can directly test this 
hypothesis in vivo by comparing the number/length of cell cycles of Nf1
-/-
 progenitors 
with Nf1
+/+
 progenitors using a short-term BrdU pulse-chase experiment. Mice will be 
pulsed with BrdU once and analyzed 24 hours later. By using Ki67 as a marker for cells 
that remain in cell cycle, we could identify cells that exit the cell cycle after 24h as 
 137 
 
BrdU
+
/Ki67
-
, and the cells that remain in or re-enter the cell cycle will be marked as 
BrdU
+
/Ki67
+
. The ratio of BrdU
+
/Ki67
-
 vs. BrdU
+
/Ki67
+
 represent a “cell cycle exit 
index (CCEI)” and reflects the relative fraction of cells that exit the cell cycle and begin 
to differentiate versus cells that remain in the cell cycle (Chenn and Walsh 2002). Based 
on our hypothesis, we predict that Nf1
-/-
 progenitors are more likely to exit the cell cycle 
and have a higher CCEI value. In addition, if Nf1-deficiency leads to reduced self-
renewal in vivo, we would expect to see a gradual depletion of SVZ neural progenitor 
cells in Nf1-deficient brains. The ideal system to test this is the Nestin-Cre
ER 
inducible 
model. By introducing Nf1 mutation into a subset of adult neural stem/progenitor cells 
through tamoxifen-induced Cre activation, we could monitor the long-term fate of these 
Nf1
-/-
 progenitors with the R26
LacZ 
reporter and determine whether they are more likely to 
be eliminated in the SVZ compared to Nf1 heterozygous or wild type cells. To further 
determine whether reduced self-renewal of Nf1
-/-
 progenitors is dependent on p53, we 
could analyze the Mut1 brains, which are p53/Nf1 double-deficient, and investigate 
whether p53-deficiency could rescue the in vivo and in vitro self-renewal defects of Nf1
-/-
 
progenitors. More specifically, we could compare the CCEI of p53/Nf1 double-deficient 
SVZ progenitors with Nf1
-/-
 progenitors, and test their secondary-sphere-forming capacity 
in neurosphere assays.  The proposed model is summarized in Figure 37B.  
 
The second question to address is how loss of Nf1, in the context of p53-deficiency, 
accelerates glioma development. In the p53 model, we demonstrated that Olig2-
expressing SVZ-C-like cells are the cell-of-origin for gliomas, and Ligon et al have 
demonstrated that Olig2 plays a critical role in promoting the proliferation of neural stem 
cells and malignant glioma cells through its inhibition of  tumor suppressor p21 (Ligon et 
al. 2007). Our finding that Nf1 regulates Olig2 expression specifically in SVZ-C cells 
leads us to hypothesize that ectopic activation of Olig2 could be the underlying 
mechanism for Nf1-deficiency to promote gliomagenesis. However, while Nf1-deficiency 
significantly expands the number of Olig2
 +
 cells in the brain, many of these cells are 
well-differentiated oligodendrocytes, and Olig2
+
 glial progenitors do not overproliferate. 
One possible explanation for this is the phosphorylation status of Olig2 in Nf1-deficient 
cells. Recent studies have identified that the proliferative function of Olig2 in glioma 
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cells is dependent on the phosphorylation of Olig2 triple-serine motif (Sun et al. 2011), 
and Nf1-deficiency may not promote phosphorylation of Olig2 at this specific site. One 
intriguing possibility is that in the p53-deficient background, either through blockade of 
p53-mediated response, or through accumulation of additional oncogenic mutations, 
Olig2 becomes phosphorylated at this triple-serine motif. Under such circumstances, Nf1-
deficiency may provide a much larger pool of target cells available for malignant 
transformation by activating Olig2 overexpression in SVZ progenitors. This model of 
how Nf1 may promote gliomagenesis can be tested using an antibody that specifically 
recognizes the phosphorylated form of Olig2 at this triple-serine motif.  
 
In summary, my study on p53 and Nf1 mouse models underscores the significance of the 
sequential order of genetic mutations in tumor development. This set of data opens up 
many directions toward the understanding of how these two tumor suppressors interact 
and synergistically promote gliomagenesis. 
 
4.1.2 The uniqueness of our p53
 ΔE5-6
 glioma mouse model and its clinical 
implications 
 
Our p53
 ΔE5-6
 mouse model is unique because, as opposed to existing GEM glioma mouse 
models that inactivate multiple tumor suppressors (Reilly et al. 2000; Zhu et al. 2005; 
Zheng et al. 2008), we introduce only the initiating mutation, allowing stochastic 
accumulation of additional oncogenic mutations. This model therefore more closely 
recapitulates the stepwise accumulation of oncogenic mutations in human tumor 
development (Maher et al. 2001). Another unique feature of our p53
 ΔE5-6
 model is that 
the expression of mutant p53 can be used as a marker to identify early glioma cells. 
Although advanced-stage p53
ΔE5-6
 gliomas are extremely heterogeneous 
histopathologically and molecularly, the p53
ΔE5-6
-positive glioma precursors are 
remarkably homogeneous in terms of lineage marker expression and are likely driven by 
the activation of limited number of signaling pathways. Further characterization of these 
early glioma cells at different stages of glioma development would allow us to pinpoint 
the sequential order of the activation of oncogenic pathways in an in vivo setting and 
identify genetic pathways that are critical for the glioma initiation, progression and 
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maintenance. For instance, our preliminary data demonstrate that p53
ΔE5-6
-expressing 
cells in the CC of 4.5-5 month old mice already have high level of ERK activation based 
on pERK immunofluorescence, suggesting that the activation of Ras/ERK signaling 
could be among the early genetic events that drive the initial expansion of glioma 
precursor cells (unpublished observation). Targeting these signaling pathways could be 
used as therapies to treat individuals who are genetically predisposed to glioma 
development and eliminate the tumor initiating cells in their brains. Finally, since p53
ΔE5-
6
 mice provide a sensitive genetic background and can cooperate with oncogenic 
mutations (such as Nf1) to promote glioma development, this strain could be used to 
validate newly identified glioma genes and investigate their respective role in 
gliomagenesis. In addition, compound mutants may also generate a series of fast-growing 
GBM models that can be used for preclinical testing of therapies that target more specific 
oncogenic pathways. 
 
4.1.3 Potential oncogenic activity of p53
E5-6 
protein 
 
In human cancers, TP53-associated tumors typically contain missense mutations in the 
TP53 gene rather than deletions of TP53 (Olivier et al. 2002). These mutant p53 proteins 
are highly expressed in endstage tumor cells, suggesting possible growth advantage for 
cells with missense mutations (Sigal and Rotter 2000). The oncogenic roles of mutant 
p53 alleles have been examined extensively in cell lines (Iwamoto et al. 1996; Gualberto 
et al. 1998; Li et al. 1998; Blandino et al. 1999; Murphy et al. 2000; Dong et al. 2007). 
Mouse models that inherit p53 mutations expressed at physiological levels have recently 
been generated to examine the activities of mutant p53 in vivo (Duan et al. 2002; Lang et 
al. 2004; Olive et al. 2004; Heinlein et al. 2008; Adorno et al. 2009). In these models, 
mice with p53 hotspot point mutations develop tumor spectrums and metastatic 
phenotypes different from those of mice with a p53-null allele. Mechanisms for this gain-
of-function potential include increased genomic instability, increased cell migration and 
invasion and resistance to proapoptotic signals (Oren and Rotter 2010). Many gain-of-
function effects of mutant p53 rely on its ability to bind and inactivate the p53 family 
members p63 and p73 (Gaiddon et al. 2001; Oren and Rotter 2010). 
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Although the same p53
ΔE5-6
 mutation is not found in human gliomas (Olivier et al. 2002), 
our mouse model phenocopies the histological features of human GBM and exhibits high 
level of p53
ΔE5-6
 accumulation in tumor cells.  Previous studies reported no brain tumor 
formation in p53 germline knockout mice (Gil-Perotin et al. 2006; Meletis et al. 2006), 
and p53
-/- 
mice in our colony with a similar genetic background to CKO1 and CKO2 
mice do not develop brain tumors. This raises the question whether p53
ΔE5-6
 could have 
oncogenic activities similar to p53 missense mutations. The comparison of p53
ΔE5-6
, p53 
hotspot point mutation (R172H) and p53 conditional null allele is an ongoing project in 
the lab carried out by Dr. Yinghua Li. His preliminary data suggest that mutant p53, 
compared to p53 conditional null, does increase the genetic instability and promote the 
survival of cells after irradiation. However, p53
ΔE5-6
, p53 R172H and p53 conditional null 
mice develop glioma at a similar rate and penetrance (personal communication). This 
could be due to the fact that our genetic targeting strategy using hGFAP-Cre is targeting 
too many cells in the brain, which masked the difference between mutant p53 and p53 
conditional null in their tumorigenic capacity. Whether mutant p53 has oncogenic activity 
in gliomagenesis could be better tested in the Nestin-Cre
ER
 inducible system, which 
targets much fewer cells in adult brain and allows for the assessment of whether 
increased genetic instability/survival in a relatively minor population of cells could 
contribute to increased glioma penetrance.  
 
4.2. Nf1 in neural progenitor fate specification and cognitive deficits 
 
4.2.1 Potential mechanism for the regulation of Olig2 expression by Neurofibromin 
 
Multiple lines of evidence suggest that neurofibromin may inhibit Olig2 expression via 
negative regulation of receptor tyrosine kinases, specifically by suppressing the Ras/ERK 
signaling pathway. Ras acts as a major second messenger for receptor tyrosine kinases. 
Neurofibromin contains GTPase Activating Protein (GAP) related domain, which 
converts active Ras-GTP to inactive Ras-GDP. Erk/MAPK is an effector pathway of Ras, 
therefore inhibition of Ras by neurofibromin will also result in suppression of the 
Erk/MAPK pathway. There have been numerous studies that have linked Ras/ERK 
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activity to Olig2 expression. BMP/Smad signaling plays a crucial role in establishing 
dorsal neural identity and its inhibition is sufficient to generate OPCs both in vitro and in 
vivo (Mekki-Dauriac et al. 2002; Munoz-Sanjuan and Brivanlou 2002; Vallstedt et al. 
2005; Bilican et al. 2008). Activation of the Sonic hedgehog (Shh) pathway, which 
opposes BMP signaling in ventral neural tube, can promote Olig2 expression in 
neocortical progenitor cells and induce oligodendrocyte progenitor production (Lu et al. 
2002; Zhou and Anderson 2002). Kessaris et al. demonstrated that Shh activity is 
dependent on ERK signaling (Kessaris et al. 2004). In cultured dorsal spinal cord cells, 
fibroblast growth factor 2 (FGF2) induces Olig2 expression, which can be inhibited by a 
MEK inhibitor (Bilican et al. 2008). This observation suggests that FGF2-induced Olig2 
expression depends on the Ras/ERK signaling pathway. In the forebrain, overexpression 
of growth factors, i.e. epidermal growth factor (EGF) or platelet-derived growth factor 
(PDGF), can lead to overproduction of Olig2
+
 cells in SVZ and CC (Chandran et al. 
2003; Jackson et al. 2006; Ivkovic et al. 2008). However, the specific cell type(s) that are 
responsive to EGF/PDGF overexpression have not yet been determined. In addition, 
these studies did not offer data to support any mechanisms that could account for the 
expansion of Olig2-expressing cells. 
 
Our study demonstrates that Nf1 regulates Olig2 expression in SVZ Ascl1
+
 cells through 
Ras/ERK signaling, which plays an important role in SVZ progenitor fate specification 
and regulates the overall output of neurogenesis and gliogenesis. Consistently, we found 
that in control brains, the level of Ras/ERK signaling activation corresponds to the level 
of gliogenesis. Phosphorylated ERK levels, a readout for active Erk/MAPK activity, are 
very low in the adult brain where there is minimal gliogenesis in adult. In contrast, we 
found a number of pERK
+
 cells colocalizing with Olig2 in the SVZ at early postnatal 
stages, the peak period of gliogenesis in the brain, suggesting a role for Ras/ERK 
signaling during the normal gliogenesis process. In addition, MEK inhibitor treatment of 
Nf1-deficient mice not only repressed Olig2 expression in SVZ progenitors, but also 
rescued the neuron-glial output in the brain, suggesting that Nf1-deficient phenotype is 
indeed caused by overactivation of Ras/ERK signaling. Based on these findings we 
propose the following model for the fate specification of Ascl1
+ 
SVZ cells: Ascl1
+
 cells 
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are bipotent and can undergo specification to acquire either a neuronal or glial fate. Upon 
commitment to glial intermediate progenitors (gIPCs), Ascl1
+
 cells downregulate Nf1 and 
activate Ras/ERK signaling to promote Olig2 expression, while neuronal committed 
progenitors (nIPCs) maintain high level of Nf1 to inhibit Ras/ERK signaling and prevent 
misexpression of Olig2. In Nf1
hGFAP
KO brains, Ras/ERK signaling transduction activity 
is dysregulated in Ascl1
+
 cells and nIPCs due to the loss of its negative regulator, Nf1. 
Overactive Ras/ERK activity leads to expression of Olig2 in these cells, ultimately 
resulting in a fate switch from the neuronal lineage to the glial lineage. 
 
This model of how neurofibromin regulates the expression of Olig2 not only addresses 
important questions concerning neural progenitor fate specification, but also opens up 
many directions for follow-up studies. First, the relationship between Ras/ERK signaling 
and increased Olig2 expression in Ascl1
+ 
cells has yet to be defined. A recent publication 
by Bilican et al. demonstrated that in dorsal spinal cord, FGF-induced ERK signaling 
counteracts BMP signaling by deactivating Smad1, the major effecter in the BMP 
signaling pathway. Upon activation, ERK phosphorylates the linker region of Smad1, 
preventing nuclear translocation and thus inhibits Smad1 transcriptional activity (Bilican 
et al. 2008). It is possible that this is a conserved mechanism for different types of 
progenitors in the CNS. Second, the upstream signal that activates Ras/ERK signaling 
cascade in SVZ cells is yet to be determined. As aforementioned, Shh signaling, as well 
as activation of RTK signaling through growth factors FGF/EGF/PDGF could all be 
likely candidates. Finally, how Ras/ERK activity is dynamically regulated in neuronal 
committed nIPCs and glial committed gIPCs still remains to be uncovered. One possible 
mechanism could be that these two cell populations have different neurofibromin levels. 
This could be achieved through differential transcriptional or post-transcriptional 
regulation of Nf1 gene expression. However, based on the Alan Brain Atlas which 
provides the in situ hybridization data for Nf1, at mRNA level there is no evidence that 
different SVZ cells have different Nf1 transcription (Lein et al. 2007). Alternatively, the 
level of neurofibromin could be regulated by protein degradation. One candidate 
molecule that regulates neurofibromin degradation is F-box and WD repeat domain-
containing 7 (FBW7). FBW7 is a substrate-recognition component of the SKP1, CUL1 
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and F-box (SCF) complex, an E3 ubiquitin ligase. Dr. Yi Sun at the University of 
Michigan has recently provided in vitro evidence that FBW7 recognizes neurofibromin 
and targets neurofibromin for degradation through ubiquitination (personal 
communication). In addition, my colleague from the Zhu Lab, Dr. Huarui Zheng, found 
reduced number of Olig2
+
 cells in FBW7 conditional knockout mice accompanied by 
increased Nf1 expression (personal communication). These findings lead to the intriguing 
possibility that FBW7 specifically degrades neurofibromin in gIPCs to maintain high 
level of Ras/ERK signaling in these cells. Assessment of the protein level of FBW7 and 
neurofibromin in different progenitor cells will be key experiments to test this hypothesis. 
To perform cell-type specific analysis, it is necessary to introduce transgenic reporters to 
facilitate effective sorting of different population of SVZ cells. Previously published 
strains that carry Ascl1-GFP and Olig2-GFP reporters could be very useful in these 
experiments (Marshall et al. 2005; Parras et al. 2007).   
 
4.2.2 Corpus callosum defect and NF1-associated learning disabilities  
 
One unique feature of our mouse model is that Nf1
hGFAP
KO mice exhibit an enlarged 
corpus callosum, a common structural abnormality found in the brains of a subset of NF1 
patients with severe cognitive deficits. Importantly, as MEK inhibition rescued the 
enlarged corpus collusum and glial specification phenotype found in Nf1
hGFAP
KO mice, a 
similar treatment during neonatal development might serve as a therapeutic strategy in 
NF1 patients to alleviate associated neurocognitive defects. These results may have a 
broader clinical implication in NCFC syndromes caused by germline mutations in the 
oncogenic Ras/ERK signaling pathway, which all have cognitive impairment as a 
common symptom (Rodriguez-Viciana et al. 2006). 
 
The remaining questions include how an enlarged corpus callosum is related to learning 
disabilities and whether rescuing the structural defect could rescue the cognitive deficits. 
To address these questions, we need to first confirm that Nf1-deficient mice exhibit 
learning disabilities as seen in NF1 patients. However, Nf1
hGFAP
KO
 
mice are not the ideal 
model for behavioral analysis because they have hindlimb paralysis and thus cannot be 
subjected to behavioral analysis. The exact cause of such hindlimb paralysis is yet to be 
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determined. One notable observation is that in our Nestin-Cre
ER
 inducible model, when 
Nf1-deficiency is introduced into a restricted number of SVZ Nestin-expressing cells at 
P26-P30, we did not observe any hindlimb defects, suggesting that it is most likely a 
developmental phenotype caused by the widespread genetic recombination in CNS and 
PNS induced by hGFAP-Cre (Zhuo et al. 2001). Although we did find an increase of 
oligodendrocytes in the CC in these mice, the number of targeted cells is too small to 
recapitulate the enlarged CC phenotype in Nf1
hGFAP
KO
 
mice. Yet this opens up a 
possibility that there may exist a time point earlier than P26-P30 to induce differentiation, 
which targets a sufficient amount of cells in the brain to recapitulate the CC phenotype 
without causing hindlimb paralysis. This would allow us to analyze the behavioral 
alterations in Nf1 mutant mice and determine whether they have learning disabilities. If 
so, we could treat these mice with MEK inhibitors and assess cognitive impairment with 
or without treatment.    
 
Besides behavior studies, it is important to understand how an enlarged corpus callosum 
can lead to cognitive deficits. The corpus callosum is a thick band of neural fibers that 
connects the left and right cerebral hemispheres and facilitates interhemispheric 
communication by transferring motor, sensory, and cognitive information between the 
brain hemispheres (Raybaud 2010). To establish a structure-function relationship 
between enlarged corpus callosum and cognitive deficits, we need to determine whether 
the Nf1
hGFAP
KO corpus callosum is structurally compromised for interhemispheric 
communication. We will first perform EM analysis on control and Nf1
hGFAP
KO corpus 
callosum and specifically compare the number of axons and their myelination status. In 
the CNS, a single oligodendrocyte can ensheath and myelinate multiple axons. 
Myelination is critical for the quick and accurate transmission of electrical current from 
one nerve cell to the next, and demyelination could lead to a number of clinical 
symptoms including cognitive disruption such as speech impairment and memory loss 
(Jessen and Mirsky 2008). However, since Nf1
hGFAP
KO corpus callosum has increased 
number of oligodendrocytes which can normally produce myelin (based on myelin basic 
protein MBP immunostaining), it is unlikely that cognitive defect in Nf1
hGFAP
KO mice is 
due to demyelination. Rather, we would expect increased myelination in Nf1
hGFAP
KO 
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corpus callosum and one possibility is that excessive myelination interferes with the 
integration and processing of information, ultimately resulting in diminished cognitive 
performance. Alternatively, it is equally possible that while Nf1-deficient 
oligodendrocytes could produce myelin, they could not properly entheath axons. This 
could be readily tested in EM ultrastructural analysis. Further, we will perform 
electrophysiological analysis to directly compare the signal transmission capacity of 
axons in wildtype and Nf1
hGFAP
KO corpus callosum. 
 
4.3. Summary  
 
In this thesis, I used genetically engineered mouse models to investigate the role of the 
tumor suppressor genes Nf1 and p53 in the regulation of neural stem/progenitor cell 
function. My study has made significant insights into basic developmental biology and 
glioma development. These mouse models could provide valuable tools for future studies 
to explore the mechanism underlying gliomagenesis and NF1-associated learning deficits 
and could be used for preclinical trials to treat these diseases.  
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Table 1. Summary of p53/Nf1 glioma models  
Mouse 
models 
Genetic configuration 
Sequential order of 
genetic mutations 
Glioma 
penetrance 
Tumorigenesis 
rate  
Mut1  
hGFAPCre+; p53 
KO/KO; Nf1 flox/flox 
Loss of p53 in germline 
first, followed by tissue 
specific inactivation of 
Nf1 
high fast 
CKO3 
hGFAPCre+; p53 
flox/flox; Nf1 KO/+ 
Tissue specific 
inactivation of p53 first 
in a Nf1 HET 
background, then loss of 
the Nf1 WT allele 
through LOH 
high fast 
Mut3 
hGFAPCre+; p53 KO/+; 
Nf1 flox/+ 
Loss of the WT 
chromosome through 
Co-LOH; concurrent 
loss of p53 and Nf1 
high slow 
Mut2 
hGFAPCre+; p53 KO/+; 
Nf1 flox/flox 
Tissue specific 
inactivation of Nf1 first 
in a p53 HET 
background, then loss of 
the p53 WT allele 
through Co-LOH 
extremely 
low 
slow 
CKO1 and 
CKO2 
hGFAPCre+; p53 
KO/flox or flox/flox 
Tissue specific 
inactivation of p53 in a 
Nf1 WT background 
high slow 
Nf1hGFAPCKO 
hGFAPCre+; Nf1 
flox/flox 
Tissue specific 
inactivation of Nf1 in a 
p53 WT background 
none none 
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Figure 37. Proposed model for genetic events that occur during glioma development in 
different mouse models. (A) Illustration why Mut2 and Mut3 mice have equal chance to 
develop gliomas if accumulation of additional mutations is the rate-limiting step of 
gliomagenesis. (B)  Proposed model for the tumor prevention machinery in Mut2 and 
Nf1
hGFAP
CKO mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 149 
 
4.4 References 
 
Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse 
S, Rondina MB, Guzzardo V et al. 2009. A Mutant-p53/Smad complex opposes 
p63 to empower TGFbeta-induced metastasis. Cell 137: 87-98. 
Attolini CS, Cheng YK, Beroukhim R, Getz G, Abdel-Wahab O, Levine RL, Mellinghoff 
IK, Michor F. 2010. A mathematical framework to determine the temporal 
sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A 107: 
17604-17609. 
Bilican B, Fiore-Heriche C, Compston A, Allen ND, Chandran S. 2008. Induction of 
Olig2 precursors by FGF involves BMP signalling blockade at the Smad level. 
PLoS One 3: e2863. 
Blandino G, Levine AJ, Oren M. 1999. Mutant p53 gain of function: differential effects 
of different p53 mutants on resistance of cultured cells to chemotherapy. 
Oncogene 18: 477-485. 
Chandran S, Kato H, Gerreli D, Compston A, Svendsen CN, Allen ND. 2003. FGF-
dependent generation of oligodendrocytes by a hedgehog-independent pathway. 
Development 130: 6599-6609. 
Chenn A, Walsh CA. 2002. Regulation of cerebral cortical size by control of cell cycle 
exit in neural precursors. Science 297: 365-369. 
Dong P, Tada M, Hamada J, Nakamura A, Moriuchi T, Sakuragi N. 2007. p53 dominant-
negative mutant R273H promotes invasion and migration of human endometrial 
cancer HHUA cells. Clin Exp Metastasis 24: 471-483. 
Duan W, Ding H, Subler MA, Zhu WG, Zhang H, Stoner GD, Windle JJ, Otterson GA, 
Villalona-Calero MA. 2002. Lung-specific expression of human mutant p53-273H 
is associated with a high frequency of lung adenocarcinoma in transgenic mice. 
Oncogene 21: 7831-7838. 
Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon 
KL, Louis DN, Brennan C et al. 2007. Malignant astrocytic glioma: genetics, 
biology, and paths to treatment. Genes Dev 21: 2683-2710. 
Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. 2001. A subset of tumor-derived 
mutant forms of p53 down-regulate p63 and p73 through a direct interaction with 
the p53 core domain. Mol Cell Biol 21: 1874-1887. 
Gil-Perotin S, Marin-Husstege M, Li J, Soriano-Navarro M, Zindy F, Roussel MF, 
Garcia-Verdugo JM, Casaccia-Bonnefil P. 2006. Loss of p53 induces changes in 
the behavior of subventricular zone cells: implication for the genesis of glial 
tumors. J Neurosci 26: 1107-1116. 
Gualberto A, Aldape K, Kozakiewicz K, Tlsty TD. 1998. An oncogenic form of p53 
confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint 
control. Proc Natl Acad Sci U S A 95: 5166-5171. 
Heinlein C, Krepulat F, Lohler J, Speidel D, Deppert W, Tolstonog GV. 2008. Mutant 
p53(R270H) gain of function phenotype in a mouse model for oncogene-induced 
mammary carcinogenesis. Int J Cancer 122: 1701-1709. 
Ivkovic S, Canoll P, Goldman JE. 2008. Constitutive EGFR signaling in oligodendrocyte 
progenitors leads to diffuse hyperplasia in postnatal white matter. J Neurosci 28: 
914-922. 
 150 
 
Iwamoto KS, Mizuno T, Ito T, Tsuyama N, Kyoizumi S, Seyama T. 1996. Gain-of-
function p53 mutations enhance alteration of the T-cell receptor following X-
irradiation, independently of the cell cycle and cell survival. Cancer Res 56: 
3862-3865. 
Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, Roy M, Quinones-Hinojosa A, 
VandenBerg S, Alvarez-Buylla A. 2006. PDGFR alpha-positive B cells are neural 
stem cells in the adult SVZ that form glioma-like growths in response to increased 
PDGF signaling. Neuron 51: 187-199. 
Jessen KR, Mirsky R. 2008. Negative regulation of myelination: relevance for 
development, injury, and demyelinating disease. Glia 56: 1552-1565. 
Junttila MR, Evan GI. 2009. p53--a Jack of all trades but master of none. Nat Rev Cancer 
9: 821-829. 
Kessaris N, Jamen F, Rubin LL, Richardson WD. 2004. Cooperation between sonic 
hedgehog and fibroblast growth factor/MAPK signalling pathways in neocortical 
precursors. Development 131: 1289-1298. 
Kruse JP, Gu W. 2009. Modes of p53 regulation. Cell 137: 609-622. 
Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, 
Caldwell LC, Strong LC et al. 2004. Gain of function of a p53 hot spot mutation 
in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872. 
Lein ES Hawrylycz MJ Ao N Ayres M Bensinger A Bernard A Boe AF Boguski MS 
Brockway KS Byrnes EJ et al. 2007. Genome-wide atlas of gene expression in the 
adult mouse brain. Nature 445: 168-176. 
Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, 
Prokocimer M, Rotter V. 1998. Mutant p53 protein expression interferes with 
p53-independent apoptotic pathways. Oncogene 16: 3269-3277. 
Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M, Louis 
DN, Depinho RA et al. 2007. Olig2-regulated lineage-restricted pathway controls 
replication competence in neural stem cells and malignant glioma. Neuron 53: 
503-517. 
Lu QR, Sun T, Zhu Z, Ma N, Garcia M, Stiles CD, Rowitch DH. 2002. Common 
developmental requirement for Olig function indicates a motor 
neuron/oligodendrocyte connection. Cell 109: 75-86. 
Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho 
RA. 2001. Malignant glioma: genetics and biology of a grave matter. Genes Dev 
15: 1311-1333. 
Marshall CA, Novitch BG, Goldman JE. 2005. Olig2 directs astrocyte and 
oligodendrocyte formation in postnatal subventricular zone cells. J Neurosci 25: 
7289-7298. 
McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson 
BW, Williams SM, Nghiemphu P, Liau LM et al. 2009. Proteasomal and genetic 
inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 16: 44-
54. 
Mekki-Dauriac S, Agius E, Kan P, Cochard P. 2002. Bone morphogenetic proteins 
negatively control oligodendrocyte precursor specification in the chick spinal 
cord. Development 129: 5117-5130. 
 151 
 
Meletis K, Wirta V, Hede SM, Nister M, Lundeberg J, Frisen J. 2006. p53 suppresses the 
self-renewal of adult neural stem cells. Development 133: 363-369. 
Munoz-Sanjuan I, Brivanlou AH. 2002. Neural induction, the default model and 
embryonic stem cells. Nat Rev Neurosci 3: 271-280. 
Murphy KL, Dennis AP, Rosen JM. 2000. A gain of function p53 mutant promotes both 
genomic instability and cell survival in a novel p53-null mammary epithelial cell 
model. FASEB J 14: 2291-2302. 
Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, 
Schuler D, Probst-Hensch NM, Maiorka PC et al. 2004. Genetic pathways to 
glioblastoma: a population-based study. Cancer Res 64: 6892-6899. 
Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 
2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni 
syndrome. Cell 119: 847-860. 
Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. 2002. The IARC TP53 
database: new online mutation analysis and recommendations to users. Hum 
Mutat 19: 607-614. 
Oren M, Rotter V. 2010. Mutant p53 gain-of-function in cancer. Cold Spring Harb 
Perspect Biol 2: a001107. 
Parras CM, Hunt C, Sugimori M, Nakafuku M, Rowitch D, Guillemot F. 2007. The 
proneural gene Mash1 specifies an early population of telencephalic 
oligodendrocytes. J Neurosci 27: 4233-4242. 
Raybaud C. 2010. The corpus callosum, the other great forebrain commissures, and the 
septum pellucidum: anatomy, development, and malformation. Neuroradiology 
52: 447-477. 
Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. 2000. Nf1;Trp53 mutant 
mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 26: 
109-113. 
Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, 
McCormick F, Rauen KA. 2006. Germline mutations in genes within the MAPK 
pathway cause cardio-facio-cutaneous syndrome. Science (New York, NY 311: 
1287-1290. 
Sigal A, Rotter V. 2000. Oncogenic mutations of the p53 tumor suppressor: the demons of 
the guardian of the genome. Cancer Res 60: 6788-6793. 
Sun Y, Meijer DH, Alberta JA, Mehta S, Kane MF, Tien AC, Fu H, Petryniak MA, Potter 
GB, Liu Z et al. 2011. Phosphorylation state of Olig2 regulates proliferation of 
neural progenitors. Neuron 69: 906-917. 
Vallstedt A, Klos JM, Ericson J. 2005. Multiple dorsoventral origins of oligodendrocyte 
generation in the spinal cord and hindbrain. Neuron 45: 55-67. 
Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408: 307-310. 
Vousden KH, Prives C. 2009. Blinded by the Light: The Growing Complexity of p53. 
Cell 137: 413-431. 
Wang Y, Yang J, Zheng H, Tomasek GJ, Zhang P, McKeever PE, Lee EY, Zhu Y. 2009. 
Expression of mutant p53 proteins implicates a lineage relationship between 
neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell 
15: 514-526. 
 152 
 
Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu 
GC, Ding Z et al. 2008. p53 and Pten control neural and glioma stem/progenitor 
cell renewal and differentiation. Nature 455: 1129-1133. 
Zhou Q, Anderson DJ. 2002. The bHLH transcription factors OLIG2 and OLIG1 couple 
neuronal and glial subtype specification. Cell 109: 61-73. 
Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, Messing A, Parada LF. 2005. 
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss 
induces malignant astrocytoma. Cancer Cell 8: 119-130. 
Zhuo L, Theis M, Alvarez-Maya I, Brenner M, Willecke K, Messing A. 2001. hGFAP-cre 
transgenic mice for manipulation of glial and neuronal function in vivo. Genesis 
31: 85-94. 
